# ESC Guidelines: ACS NSTE (2020)

**Source**: `2020_ACS_NSTE.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 79

---

## Table of Contents

- [tblfn1](#tblfn1) *(p. 13)*
- [tblfn2](#tblfn2) *(p. 13)*
- [tblfn3](#tblfn3) *(p. 13)*
- [tblfn4](#tblfn4) *(p. 13)*
- [tblfn5](#tblfn5) *(p. 15)*
- [tblfn6](#tblfn6) *(p. 15)*
- [tblfn7](#tblfn7) *(p. 18)*
- [tblfn8](#tblfn8) *(p. 18)*
- [tblfn17](#tblfn17) *(p. 19)*
- [tblfn18](#tblfn18) *(p. 19)*
- [tblfn19](#tblfn19) *(p. 19)*
- [tblfn20](#tblfn20) *(p. 19)*
- [tblfn21](#tblfn21) *(p. 19)*
- [tblfn22](#tblfn22) *(p. 19)*
- [tblfn23](#tblfn23) *(p. 19)*
- [tblfn9](#tblfn9) *(p. 20)*
- [tblfn10](#tblfn10) *(p. 20)*
- [tblfn11](#tblfn11) *(p. 20)*
- [tblfn12](#tblfn12) *(p. 21)*
- [tblfn13](#tblfn13) *(p. 21)*
- [tblfn14](#tblfn14) *(p. 21)*
- [tblfn15](#tblfn15) *(p. 21)*
- [tblfn16](#tblfn16) *(p. 21)*
- [tblfn26](#tblfn26) *(p. 23)*
- [tblfn27](#tblfn27) *(p. 23)*
- [tblfn28](#tblfn28) *(p. 23)*
- [tblfn24](#tblfn24) *(p. 24)*
- [tblfn25](#tblfn25) *(p. 24)*
- [tblfn39](#tblfn39) *(p. 26)*
- [tblfn40](#tblfn40) *(p. 26)*
- [tblfn41](#tblfn41) *(p. 26)*
- [tblfn42](#tblfn42) *(p. 28)*
- [tblfn43](#tblfn43) *(p. 28)*
- [tblfn47](#tblfn47) *(p. 28)*
- [tblfn48](#tblfn48) *(p. 28)*
- [tblfn44](#tblfn44) *(p. 29)*
- [tblfn45](#tblfn45) *(p. 29)*
- [tblfn46](#tblfn46) *(p. 29)*
- [tblfn49](#tblfn49) *(p. 30)*
- [tblfn50](#tblfn50) *(p. 30)*
- [tblfn51](#tblfn51) *(p. 30)*
- [tblfn29](#tblfn29) *(p. 31)*
- [tblfn103](#tblfn103) *(p. 31)*
- [tblfn30](#tblfn30) *(p. 33)*
- [tblfn31](#tblfn31) *(p. 33)*
- [tblfn32](#tblfn32) *(p. 33)*
- [tblfn33](#tblfn33) *(p. 34)*
- [tblfn34](#tblfn34) *(p. 34)*
- [tblfn35](#tblfn35) *(p. 34)*
- [tblfn36](#tblfn36) *(p. 41)*
- [tblfn37](#tblfn37) *(p. 41)*
- [tblfn38](#tblfn38) *(p. 41)*
- [tblfn104](#tblfn104) *(p. 42)*
- [tblfn105](#tblfn105) *(p. 42)*
- [tblfn106](#tblfn106) *(p. 43)*
- [tblfn107](#tblfn107) *(p. 43)*
- [tblfn108](#tblfn108) *(p. 43)*
- [tblfn109](#tblfn109) *(p. 44)*
- [tblfn110](#tblfn110) *(p. 44)*
- [tblfn111](#tblfn111) *(p. 44)*
- [tblfn112](#tblfn112) *(p. 45)*
- [tblfn113](#tblfn113) *(p. 45)*
- [tblfn114](#tblfn114) *(p. 45)*
- [tblfn115](#tblfn115) *(p. 45)*
- [tblfn116](#tblfn116) *(p. 45)*
- [tblfn117](#tblfn117) *(p. 45)*
- [tblfn118](#tblfn118) *(p. 46)*
- [tblfn119](#tblfn119) *(p. 46)*
- [tblfn120](#tblfn120) *(p. 47)*
- [tblfn121](#tblfn121) *(p. 47)*
- [tblfn122](#tblfn122) *(p. 47)*
- [tblfn123](#tblfn123) *(p. 48)*
- [tblfn124](#tblfn124) *(p. 48)*
- [tblfn125](#tblfn125) *(p. 48)*
- [tblfn126](#tblfn126) *(p. 48)*
- [tblfn52](#tblfn52) *(p. 51)*
- [tblfn53](#tblfn53) *(p. 51)*
- [tblfn54](#tblfn54) *(p. 51)*
- [tblfn55](#tblfn55) *(p. 51)*
- [tblfn56](#tblfn56) *(p. 55)*
- [tblfn99](#tblfn99) *(p. 59)*
- [tblfn100](#tblfn100) *(p. 59)*
- [tblfn101](#tblfn101) *(p. 59)*
- [tblfn1102](#tblfn1102) *(p. 59)*
- [tblfn1103](#tblfn1103) *(p. 59)*
- [tblfn1104](#tblfn1104) *(p. 59)*
- [tblfn1105](#tblfn1105) *(p. 59)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
Authors/Task Force Members: Jean-Philippe Collet
* (Chairperson) (France),
Holger Thiele
* (Chairperson) (Germany), Emanuele Barbato (Italy),
Olivier Barthe´le´my (France), Johann Bauersachs (Germany), Deepak L. Bhatt
(United States of America), Paul Dendale (Belgium), Maria Dorobantu (Romania),
Thor Edvardsen (Norway), Thierry Folliguet (France), Chris P. Gale
(United Kingdom), Martine Gilard (France), Alexander Jobs (Germany),
Peter Ju¨ni (Canada), Ekaterini Lambrinou (Cyprus), Basil S. Lewis (Israel),
Julinda Mehilli (Germany), Emanuele Meliga (Italy), Be´la Merkely (Hungary),
Christian Mueller (Switzerland), Marco Roffi (Switzerland), Frans H. Rutten
(Netherlands), Dirk Sibbing (Germany), George C.M. Siontis (Switzerland)
* Corresponding authors: Jean-Philippe Collet, Sorbonne Universite´, ACTION Study Group, INSERM UMRS 1166, Institut de Cardiologie, Hoˆpital Pitie´-Salp^etrie`re (Assistance
Publique- Hoˆpitaux de Paris) (AP-HP), 83, boulevard de l’Hoˆpital, 75013 Paris, France. Tel þ 33 01 42 16 29 62, E-mail: jean-philippe.collet@aphp.fr
Holger Thiele, Department of Internal Medicine/Cardiology, Heart Center Leipzig at University of Leipzig, Stru¨mpellstr. 39, 04289 Leipzig, Germany. Tel: þ49 341 865 1428, Fax:
þ49 341 865 1461, E-mail: holger.thiele@medizin.uni-leipzig.de
ESC Committee for Practice Guidelines (CPG) and National Cardiac Societies document reviewers, and Author/Task Force Member afﬁliations: listed in the Appendix.
ESC entities having participated in the development of this document:
Associations: Association for Acute CardioVascular Care (ACVC), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of
Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European
Heart Rhythm Association (EHRA), Heart Failure Association (HFA).
Councils: Council for Cardiology Practice.
Working Groups: Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Coronary Pathophysiology and Microcirculation, Thrombosis.
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to
Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientiﬁc and medical knowledge, and the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other ofﬁcial recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from taking into full and careful consideration the relevant ofﬁcial updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientiﬁcally accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.
V
C The European Society of Cardiology 2020. All rights reserved. For permissions, please email: journals.permissions@oup.com.
ESC GUIDELINES
doi:10.1093/eurheartj/ehaa575


<!-- PAGE 2 -->

### Page 2

.......................................................................
Document Reviewers: Adnan Kastrati (CPG Review Coordinator) (Germany), Mamas A. Mamas (CPG
Review Coordinator) (United Kingdom), Victor Aboyans (France), Dominick J. Angiolillo (United States of
America), Hector Bueno (Spain), Raffaele Bugiardini (Italy), Robert A. Byrne (Ireland), Silvia Castelletti
(Italy), Alaide Chieffo (Italy), Veronique Cornelissen (Belgium), Filippo Crea (Italy), Victoria Delgado
(Netherlands), Heinz Drexel (Austria), Marek Gierlotka (Poland), Sigrun Halvorsen (Norway), Kristina
Hermann Haugaa (Norway), Ewa A. Jankowska (Poland), Hugo A. Katus (Germany), Tim Kinnaird (United
Kingdom), Jolanda Kluin (Netherlands), Vijay Kunadian (United Kingdom), Ulf Landmesser (Germany),
Christophe Leclercq (France), Maddalena Lettino (Italy), Leena Meinila (Finland), Darren Mylotte
(Ireland), Gjin Ndrepepa (Germany), Elmir Omerovic (Sweden), Roberto F. E. Pedretti (Italy), Steffen E.
Petersen (United Kingdom), Anna Sonia Petronio (Italy), Gianluca Pontone (Italy), Bogdan A. Popescu
(Romania), Tatjana Potpara (Serbia), Kausik K. Ray (United Kingdom), Flavio Luciano Ribichini (Italy),
Dimitrios J. Richter (Greece), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (United Kingdom),
Miguel Sousa-Uva (Portugal), Robert F. Storey (United Kingdom), Rhian M. Touyz (United Kingdom),
Marco Valgimigli (Switzerland), Pascal Vranckx (Belgium), Robert W. Yeh (United States of America)
The disclosure forms of all experts involved in the development of these guidelines are available on the
ESC website www.escardio.org/guidelines
For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the Guidelines see European Heart Journal online.
...................................................................................................................................................................................................
Keywords
Guidelines • acute cardiac care • acute coronary syndrome • angioplasty • anticoagulation • antiplatelet
• apixaban • aspirin • atherothrombosis • betablockers • bleedings • bivalirudin • bypass surgery • cangrelor • chest pain unit • clopidogrel • dabigatran • diabetes • dual antithrombotic therapy • early invasive strategy • edoxaban • enoxaparin • European Society of Cardiology • fondaparinux • glycoprotein IIb/
IIIa inhibitors • heparin • high-sensitivity troponin • minoca • myocardial ischaemia • myocardial infarction
• nitrates • non-ST-elevation myocardial infarction • platelet inhibition • prasugrel • recommendations •
revascularization • rhythm monitoring • rivaroxaban • stent • ticagrelor • triple therapy • unstable angina
Table of contents
Abbreviations and acronyms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1293
1 Preamble . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1295
2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1296
2.1 Definitions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1296
2.1.1 Universal definition of myocardial infarction . . . . . . . . . . . . 1296
2.1.1.1 Type 1 myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . 1296
2.1.1.2 Type 2 myocardial infarction . . . . . . . . . . . . . . . . . . . . . . . 1297
2.1.1.3 Types 35 myocardial infarction . . . . . . . . . . . . . . . . . . 1297
2.1.2 Unstable angina in the era of high-sensitivity cardiac troponin assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1297
2.2 Epidemiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1297
2.3 What is new? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1297
2.4 Number and breakdown of classes of recommendations (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . 1298
3 Diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1298
3.1 Clinical presentation (Supplementary Data) . . . . . . . . . . . . . . . . 1298
3.2 Physical examination (Supplementary Data) . . . . . . . . . . . . . . . . 1298
3.3 Diagnostic tools . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1298
3.3.1 Electrocardiogram . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1298
3.3.2 Biomarkers: high-sensitivity cardiac troponin . . . . . . . . . . . 1299
3.3.2.1 Central laboratory vs. point-of-care . . . . . . . . . . . . . . . . 1300
3.3.2.2 Other biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1301
3.3.3 Rapid ‘rule-in’ and ‘rule-out’ algorithms . . . . . . . . . . . . . . . . . 1301
3.3.4 Observe . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1303
3.3.4.1 Caveats of using rapid algorithms . . . . . . . . . . . . . . . . . . 1303
3.3.4.2 Confounders of cardiac troponin concentration . . . . 1303
3.3.4.3 Practical guidance on how to implement the
European Society of Cardiology 0 h/1 h algorithm . . . . . . . . . 1304
3.3.4.4 Avoiding misunderstandings: time to decision
= time of blood drawrn-around time . . . . . . . . . . . . . . . . . . . . . 1304
3.3.5 Non-invasive imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1305
3.3.5.1 Functional evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1305
3.3.5.2 Anatomical evaluation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1305
3.4 Differential diagnosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1305
4 Risk assessment and outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1307
4.1 Electrocardiogram indicators (Supplementary Data) . . . . . . . . 1307
4.2 Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1307
4.3 Clinical scores for risk assessment (Supplementary Data) . . . . 1307
4.4 Bleeding risk assessment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1308
4.5 Integrating ischaemic and bleeding risks . . . . . . . . . . . . . . . . . . . . . 1309
5 Pharmacological treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1309
5.1 Antithrombotic treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1309
5.1.1 Antiplatelet drugs and pre-treatment . . . . . . . . . . . . . . . . . . . 1311
5.1.1.1 Antiplatelet drugs and dual antiplatelet therapy . . . . . 1311


<!-- PAGE 3 -->

### Page 3

.............................................................................................................................................................................
5.1.1.2 Pre-treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1312
5.1.2 Peri-interventional anticoagulant treatment . . . . . . . . . . . . . 1314
5.1.3 Peri-interventional antiplatelet treatment . . . . . . . . . . . . . . . 1315
5.1.4 Post-interventional and maintenance treatment . . . . . . . . 1315
5.2 Pharmacological treatment of ischaemia
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1318
5.2.1 Supportive pharmacological treatment
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1318
5.2.2 Nitrates and beta-blockers (Supplementary Data) . . . . . . 1318
5.3 Managing oral antiplatelet agents in patients requiring long-termoral anticoagulants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1318
5.3.1 Patients with atrial fibrillation without mechanical prosthetic heart valves or moderate-to-severe mitral stenosis undergoing percutaneous coronary intervention or managed medically (Supplementary Data) . . . . . . . . . . . . . . . . 1318
5.3.2 Patients requiring vitamin K antagonists or undergoing coronary artery bypass surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1320
5.4 Management of acute bleeding events
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.1 General supportivemeasures
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.2 Bleeding events on antiplatelet agents
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.3 Bleeding events on vitamin K antagonists
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.4 Bleeding events on non-vitamin K antagonist oral anticoagulants (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.5 Non-access-related bleeding events
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.6 Bleeding events related to percutaneous coronary intervention (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.7 Bleeding events related to coronary artery bypass surgery (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
5.4.8 Transfusion therapy (Supplementary Data) . . . . . . . . . . . . . 1322
5.4.9 Recommendations for bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients . . . . . . . . . . . . . 1322
6 Invasive treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
6.1 Invasive coronary angiography and revascularization . . . . . . . . 1322
6.1.1 Routine invasive vs. selective invasive approach (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
6.1.2 Timing of invasive strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1323
6.1.2.1 Immediate invasive strategy (<2 h) . . . . . . . . . . . . . . . . . 1323
6.1.2.2 Early invasive strategy (<24 h) . . . . . . . . . . . . . . . . . . . . . 1323
6.1.2.3 Selective invasive strategy . . . . . . . . . . . . . . . . . . . . . . . . . 1324
6.1.3 Pattern of coronary artery disease in non-ST-segment elevation acute coronary syndrome (Supplementary Data) . . . 1325
6.1.4 How to identify the culprit lesion? (Supplementary
Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1325
6.1.5 Spontaneous coronary artery dissection . . . . . . . . . . . . . . . . 1325
6.1.6 Fractional flow reserve, instantaneous wave-free ratio, and other resting indices (Supplementary Data) . . . . . . . . 1326
6.1.6.1 Fractional flow reserve . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.1.6.2 Instantaneous wave-free ratio and other resting indices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.1.7 Intracoronary imaging . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.2 Conservative treatment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.2.1 Patients who are not candidates for invasive coronary angiography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.2.2 Patients with coronary artery disease not amenable to revascularization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1326
6.3 Technical aspects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
6.3.1 Technical aspects and challenges . . . . . . . . . . . . . . . . . . . . . . . 1327
6.3.2 Vascular access . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
6.3.3 Revascularization strategies . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
6.4 Coronary artery bypass grafting . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
6.5 Percutaneous coronary intervention vs. coronary artery bypass surgery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1327
6.6 Specific situations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1328
6.6.1 Management of patients with ongoing myocardial ischaemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1328
6.6.2 Management of patients with cardiac arrest . . . . . . . . . . . . . 1328
6.7 Recommendations for coronary revascularization . . . . . . . . . . 1328
7 Myocardial infarction with non-obstructive coronary arteries and alternative diagnoses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1329
8 Special populations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1331
8.1 Heart failure and cardiogenic shock . . . . . . . . . . . . . . . . . . . . . . . . 1331
8.2 Diabetes mellitus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1332
8.3 Chronic kidney disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1333
8.4 Anaemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
8.5 Thrombocytopenia (Supplementary Data) . . . . . . . . . . . . . . . . . . 1334
8.5.1 Thrombocytopenia related to glycoprotein IIb/IIIa inhibitors (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
8.5.2 Heparin-induced thrombocytopenia
(Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
8.6 The older person . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
8.7 Frailty . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
8.8 Sex disparities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
9 Long-term management of non-ST-segment elevation acute coronary syndrome (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335
9.1 Lifestyle management (Supplementary Data) . . . . . . . . . . . . . . . 1335
9.1.1 Smoking (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . 1335
9.1.2 Diet and alcohol (Supplementary Data) . . . . . . . . . . . . . . . . 1335
9.1.3 Weight management (Supplementary Data) . . . . . . . . . . . . 1335
9.1.3 Physical activity (Supplementary Data) . . . . . . . . . . . . . . . . . 1335
9.1.4 Cardiac rehabilitation (Supplementary Data) . . . . . . . . . . . 1335
9.1.5 Psychosocial factors (Supplementary Data) . . . . . . . . . . . . . 1335
9.1.6 Environmental factors (Supplementary Data) . . . . . . . . . . . 1335
9.1.7 Sexual activity (Supplementary Data) . . . . . . . . . . . . . . . . . . . 1335
9.1.8 Adherence and sustainability (Supplementary Data) . . . . . 1335
9.1.9 Influenza vaccination (Supplementary Data) . . . . . . . . . . . . 1335
9.2 Pharmacological management (Supplementary Data) . . . . . . . 1335
9.2.1 Anti-ischaemic drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335
9.2.1.1 Beta-blockers (Supplementary Data) . . . . . . . . . . . . . . . 1335
9.2.2 Antithrombotic treatments . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335
9.2.3 Proton pump inhibitors (Supplementary Data) . . . . . . . . . . 1335
9.2.4 Statins and other lipid-lowering agents . . . . . . . . . . . . . . . . . 1335
9.2.5 Glucose-lowering therapy in patients with diabetes . . . . . 1336
9.2.6 Renin-angiotensin-aldosterone system blockers (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1336
9.2.7 Mineralocorticoid receptor antagonist therapy (Supplementary Data) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1336
9.2.8 Antihypertensive therapy (Supplementary Data) . . . . . . . . 1336
9.2.9 Hormone replacement therapy (Supplementary Data) . . 1336
ESC Guidelines
1291


<!-- PAGE 4 -->

### Page 4

........................................................................................................................................................................
10 Quality indicators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1337
11 Management strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1340
12 Key messages . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1341
13 Gaps in evidence for non-ST-segment elevation acute coronary syndrome care and future research . . . . . . . . . . . . . . . . . . . . . 1342
14 ‘What to do’ and ‘what not to do’messages . . . . . . . . . . . . . . . . . . . . 1343
15 Supplementary data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1347
16 Appendix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1347
Tables of Recommendations
Recommendations for diagnosis, risk stratification, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1306
Recommendations on biomarker measurements for prognostic stratification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1308
Recommendations for antithrombotic treatment in non-STsegment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention . . . . . . . . . . . . . . . . . . 1314
Recommendations for post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1317
Recommendations for anti-ischaemic drugs in the acute phase of non-ST-segment elevation acute coronary syndrome . . . . . . . . . . . 1318
Recommendations for combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation . . . . . . . . . . 1321
Recommendations for bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1322
Recommendations for coronary revascularization . . . . . . . . . . . . . . . . 1328
Recommendations for myocardial infarction with non-obstructive coronary arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1331
Recommendations for non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock . . . . . . . . . 1332
Recommendations for diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients . . . . . . . . . . . . . . . . . . . . . . 1333
Recommendations for patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome . . . . . . . . . 1333
Recommendations for older persons with non-ST-segment elevation acute coronary syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1334
Recommendations for lifestyle managements after non-STsegment elevation acute coronary syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1335
Recommendations for pharmacological long-term management after non-ST-segment elevation acute coronary syndrome
(excluding antithrombotic treatments) . . . . . . . . . . . . . . . . . . . . . . . . . . . 1336
List of tables
Table 1 Classes of recommendations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1295
Table 2 Levels of evidence . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1296
Table 3 Clinical implications of high-sensitivity cardiac troponin assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1301
Table 4 Conditions other than acute type 1 myocardial infarction associated with cardiomyocyte injury (= cardiac troponin elevation) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1301
Table 5 Assay specific cut-off levels in ng/l within the 0 h/1 h and 0 h/2 h algorithms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1303
Table 6 Differential diagnoses of acute coronary syndromes in the setting of acute chest pain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1306
Table 7 Major and minor criteria for high bleeding risk according to the Academic Research Consortium for High
Bleeding Risk at the time of percutaneous coronary intervention
(bleeding risk is high if at least one major or two minor criteria aremet) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1309
Table 8 Dose regimen of antiplatelet and anticoagulant drugs in non-ST-segment elevation acute coronary syndrome patients . . . . . 1311
Table 9 P2Y12 receptor inhibitors for use in non-ST-segment elevation acute coronary syndrome patients . . . . . . . . . . . . . . . . . . . . . . 1312
Table 10 Treatment options for extended dual antithrombotic or antiplatelet therapies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1316
Table 11 Risk criteria for extended treatment with a second antithrombotic agent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1316
Table 12 Suggested strategies to reduce bleeding risk related to percutaneous coronary intervention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1319
Table 13 Randomized controlled trials including patients with non-ST-segment elevation acute coronary syndrome requiring anticoagulation and antiplatelet therapy . . . . . . . . . . . . . . . . . . . . . . . . . . 1319
Table 14 Diagnostic criteria of myocardial infarction with non-obstructive coronary arteries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1330
Table 15 Quality indicators in non-ST-segment elevation acute coronary syndrome care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1337
List of figures
Figure 1 Diagnostic algorithm and triage in acute coronary syndrome. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1299
Figure 2 Value of high-sensitivity cardiac troponin. . . . . . . . . . . . . . . . . . 1300
Figure 3 0 h/1 h rule-out and rule-in algorithm using high-sensitivity cardiac troponin assays in haemodynamically stable patients presenting with suspected non-ST-segment elevation acute coronary syndrome to the emergency department. . . . . . . . . . . . . . . . 1302
Figure 4 Timing of the blood draws and clinical decisions when using the European Society of Cardiology 0 h/1 h algorithm. . . . . . . . 1304
Figure 5 Determinants of antithrombotic treatment in coronary artery disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1310
Figure 6 Antithrombotic treatments in non-ST-segment elevation acute coronary syndrome patients: pharmacological targets. . . . . . . . 1310
Figure 7 Algorithm for antithrombotic therapy in non-ST-segment elevation acute coronary syndrome patients without atrial fibrillation undergoing percutaneous coronary intervention . . . . . . . . . . . . . . . . . . . . . . . . 1313
Figure 8 Algorithm for antithrombotic therapy in non-ST-segment elevation acute coronary syndrome patients with atrial fibrillation undergoing percutaneous coronary intervention or medical management . . . . . 1320
Figure 9 Selection of non-ST-segment elevation acute coronary syndrome treatment strategy and timing according to initial risk stratification. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1323


<!-- PAGE 5 -->

### Page 5

.......................................................................................................................................................................
Figure 10 Time to coronary angiography in the early/immediate invasive and delayed invasive groups of included trials. . . . . . . . . . . . . . 1324
Figure 11 Diagnosis and treatment of patients with non-ST-segment elevation acute coronary syndrome related to spontaneous coronary artery dissection. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1325
Figure 12 Diagnostic algorithm for myocardial infarction with non-obstructive coronary arteries using a traffic light scheme. . . . . . 1331
Figure 13 Central illustration. Management strategy for non-ST-segment elevation acute coronary syndrome patients. . . . . . 1340
Abbreviations and acronyms
ACCOAST
Comparison of Prasugrel at the Time of
Percutaneous Coronary Intervention or as
Pretreatment at the Time of Diagnosis in
Patients with Non-ST Elevation Myocardial
Infarction
ACE
Angiotensin-converting enzyme
ACS
Acute coronary syndromes
ACUITY
Acute Catheterization and Urgent
Intervention Triage strategY
ACVC
Association for Acute Cardiovascular Care
ADP
Adenosine diphosphate
AF
Atrial ﬁbrillation
AGRIS
Australian GRACE Risk score Intervention
Study
AHA
American Heart Association
AMI
Acute myocardial infarction
ARB
Angiotensin receptor blocker
ARC-HBR
Academic Research Consortium for High
Bleeding Risk
ATLAS ACS 2
TIMI 51
Anti-Xa Therapy to Lower Cardiovascular
Events in Addition to Standard Therapy in
Subjects with Acute Coronary
SyndromeThrombolysis In Myocardial
Infarction 51
AUGUSTUS
Antithrombotic Therapy after Acute
Coronary Syndrome or PCI in Atrial
Fibrillation
BARC
Bleeding Academic Research Consortium
BEST
Randomized Comparison of Coronary
Artery Bypass Surgery and EverolimusEluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery
Disease b.i.d
.
Bis in die (twice a day)
BNP
B-type natriuretic peptide
CABG
Coronary artery bypass graft(ing)
CAD
Coronary artery disease
CCS
Chronic coronary syndromes
CCTA
Coronary computed tomography angiography
CCU
Coronary care unit
CFR
Coronary ﬂow reserve
CHA2DS2-VASc
Congestive heart failure, Hypertension, Age
>_75 years (2 points), Diabetes, Stroke (2
points)Vascular disease, Age 6574, Sex category (female)
CHAMPION
Cangrelor versus Standard Therapy to
Achieve Optimal Management of Platelet
Inhibition
CI
Conﬁdence interval
CK
Creatine kinase
CKD
Chronic kidney disease
CK-MB
Creatine kinase myocardial band
CMR
Cardiac magnetic resonance
COACT
Coronary Angiography after Cardiac Arrest
COMPASS
Cardiovascular OutcoMes for People using
Anticoagulation StrategieS
CPG
Clinical practice guidelines
CPR
Cardiopulmonary resuscitation
CrCl
Creatinine clearance
CRUSADE
Can Rapid risk stratiﬁcation of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA
guidelines
CS
Cardiogenic shock
CT
Computed tomography
CULPRITSHOCK
Culprit Lesion Only PCI versus Multivessel
PCI in Cardiogenic Shock
CVD
Cardiovascular disease
CYP
Cytochrome P450
DAPT
Dual antiplatelet therapy
DAT
Dual antithrombotic therapy
DES
Drug-eluting stent
EACTS
European Association for Cardio-Thoracic
Surgery
ECG
Electrocardiogram/electrocardiography
Echo
Echocardiogram eGFR
Estimated glomerular ﬁltration rate
ELISA
Early or Late Intervention in unStable Angina
ENTRUSTAF PCI
EdoxabaN TRreatment versUS VKA in paTients with AF undergoing PCI
ESC
European Society of Cardiology
FAMOUSNSTEMI
Fractional ﬂow reserve versus angiography in guiding management to optimize outcomes in non-ST-elevation myocardial infarction
FFR
Fractional ﬂow reserve
FFR-CT
Fractional ﬂow reserve-computed tomography
GDF-15
Growth differentiation factor 15
GP
Glycoprotein
GRACE
Global Registry of Acute Coronary Events
HAS-BLED
Hypertension, abnormal renal and liver function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly
(>65 years), drugs and alcohol (1 point each)
HBR
High bleeding risk h-FABP
Heart-type fatty acid-binding protein
ESC Guidelines
1293


<!-- PAGE 6 -->

### Page 6

........................................................................................................................................................................
HIT
Heparin-induced thrombocytopenia
HR
Hazard ratio hs-cTn
High-sensitivity cardiac troponin
IABP
Intra-aortic balloon pump
IABP-SHOCK II
Intraaortic Balloon Pump in cardiogenic shock II
ICA
Invasive coronary angiography iFR
Instantaneous wave-free ratio
IMR
Index of microcirculatory resistance
INR
International normalized ratio
ISAR-REACT
Intracoronary stenting and Antithrombotic regimenRapid Early Action for Coronary
Treatment
ISAR-TRIPLE
Triple Therapy in Patients on Oral
Anticoagulation After Drug Eluting Stent
Implantation i.v.
Intravenous
IVUS
Intravascular ultrasound
LBBB
Left bundle branch block
LD
Loading dose
LDL-C
Low-density lipoprotein cholesterol
LIPSIA-NSTEMI
Leipzig Immediate versus early and late
PercutaneouS coronary Intervention triAl in
NSTEMI
LMWH
Low-molecular-weight heparin
LV
Left ventricular
LVEF
Left ventricular ejection fraction
MACE
Major adverse cardiovascular events
MATRIX
Minimizing Adverse Haemorrhagic Events by
TRansradial Access Site and Systemic
Implementation of angioX
MD
Maintenance dose
MDCT
Multidetector computed tomography
MI
Myocardial infarction
MINOCA
Myocardial infarction with non-obstructive coronary arteries
MRA
Mineralocorticoid receptor antagonist
NOAC
Non-vitamin K antagonist oral anticoagulant
NPV
Negative predictive value
NSTE-ACS
Non-ST-segment elevation acute coronary syndrome
NSTEMI
Non-ST-segment elevation myocardial infarction
NT-proBNP
N-terminal pro-B-type natriuretic peptide
OAC
Oral anticoagulation/anticoagulant
OASIS-5
Fifth Organization to Assess Strategies in
Acute Ischemic Syndromes
OCT
Optical coherence tomography o.d.
Once daily
OR
Odds ratio
P
Prasugrel
PAD
Peripheral artery disease
PCI
Percutaneous coronary intervention
PCSK9
Proprotein convertase subtilisin kexin 9
Pd/Pa
Distal coronary to aortic pressure ratio
PEGASUS-TIMI 54
Prevention of Cardiovascular Events in
Patients with Prior Heart Attack Using
Ticagrelor Compared to Placebo on a
Background of Aspirin-Thrombolysis in
Myocardial Infarction 54
PLATO
PLATelet inhibition and patient Outcomes
POCT
Point-of-care test
PPV
Positive predictive value
PRECISE-DAPT
PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy
PRECOMBAT
Premier of Randomized Comparison of
Bypass Surgery versus Angioplasty Using
Sirolimus-Eluting Stent in Patients with Left
Main Coronary Artery Disease
PROMs
Patient-reported outcome measures
QI
Quality indicator
RBBB
Right bundle branch block
RCT
Randomized controlled trial
RE-DUAL PCI
Randomized Evaluation of Dual
Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in
Patients with Nonvalvular Atrial Fibrillation
Undergoing Percutaneous Coronary
Intervention
REDUCE-IT
Reduction of Cardiovascular Events with
Icosapent EthylIntervention Trial
RFR
Resting full-cycle ratio
RIDDLE-NSTEMI
Randomized Study of Immediate Versus
Delayed Invasive Intervention in Patients
With Non-ST-Segment Elevation Myocardial
Infarction
RIVAL
RadIal Vs femorAL access for coronary intervention
RR
Relative risk
SAPT
Single antiplatelet therapy
SCAAR
Swedish Coronary Angiography and
Angioplasty Registry
SCAD
Spontaneous coronary artery dissection
SISCA
Comparison of Two Treatment Strategies in
Patients With an Acute Coronary Syndrome
Without ST Elevation
SMILE
Impact of Different Treatment in Multivessel
Non ST Elevation Myocardial Infarction
Patients: One Stage Versus Multistaged
Percutaneous Coronary Intervention
SPECT
Single-photon-emission tomography
STEMI
ST-segment elevation myocardial infarction
STS
Society of Thoracic Surgeons
SYNTAX
Synergy between PCI with Taxus and cardiac surgery
TAT
Triple antithrombotic therapy
TIMACS
Timing of Intervention in Patients with Acute
Coronary Syndromes
TIMI
Thrombolysis In Myocardial Infarction


<!-- PAGE 7 -->

### Page 7

.................................................................................................
TRITON-TIMI 38
TRial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet InhibitioN
with PrasugrelThrombolysis In Myocardial
Infarction 38
TROPICAL-ACS
Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute
Coronary Syndromes
TWILIGHT
Ticagrelor With Aspirin or Alone in HighRisk Patients After Coronary Intervention
UFH
Unfractionated heparin
UKGRIS
UK GRACE Risk Score Intervention Study
ULTIMATE
Intravascular Ultrasound Guided Drug Eluting
Stents Implantation in “All-Comers”
Coronary Lesions
VALIDATESWEDEHEART
Swedish Web-system for Enhancement and
Development of Evidence-based care in
Heart disease Evaluated According to
Recommended Therapies
VERDICT
Very EaRly vs Deferred Invasive evaluation using Computerized Tomography
VKA
Vitamin K antagonist
WOEST
What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing
1 Preamble
Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.
A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC), as well as by other societies and organizations. Because of their impact on clinical practice,
quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines/
Clinical-Practice-Guidelines/Guidelines-development/Writing-ESCGuidelines). The ESC Guidelines represent the official position of the
ESC on a given topic and are regularly updated.
In addition to the publication of Clinical Practice Guidelines, the
ESC carries out the EurObservational Research Programme of international registries of cardiovascular diseases and interventions which are essential to assess, diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on high-quality data collected during routine clinical practice.
Furthermore, the ESC has developed and embedded in this document a set of quality indicators (QIs), which are tools to evaluate the level of implementation of the Guidelines and may be used by the
ESC, hospitals, healthcare providers and professionals to measure clinical practice as well as used in educational programmes, alongside the key messages from the guidelines, to improve quality of care and clinical outcomes.
The Members of this Task Force were selected by the ESC, including representation from its relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field undertook a
Table 1
Classes of recommendations
Classes of recommendations
Class I 
Evidence and/or general agreement 
that a given treatment or procedure is 
Is recommended or is indicated
Wording to use
Class III 
Evidence or general agreement that the 
given treatment or procedure is not 
useful/effective, and in some cases 
may be harmful.
Is not recommended
     Class IIb established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in 
Should be considered
Class II 
©ESC 2020
ESC Guidelines
1295


<!-- PAGE 8 -->

### Page 8

..........................................................................................................
comprehensive review of the published evidence for management of a given condition according to ESC Committee for Practice
Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the riskbenefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined scales, as outlined below.
2 Introduction
2.1 Definitions
The clinical presentation of acute coronary syndromes (ACS) is broad. It ranges from cardiac arrest, electrical or haemodynamic instability with cardiogenic shock (CS) due to ongoing ischaemia or mechanical complications such as severe mitral regurgitation, to patients who are already pain free again at the time of presentation.1
The leading symptom initiating the diagnostic and therapeutic cascade in patients with suspected ACS is acute chest discomfort described as pain, pressure, tightness, and burning. Chest pain-equivalent symptoms may include dyspnoea, epigastric pain, and pain in the left arm.
Based on the electrocardiogram (ECG), two groups of patients should be differentiated:
• Patients with acute chest pain and persistent (>20 min)
ST-segment elevation. This condition is termed ST-segment elevation ACS and generally reflects an acute total or subtotal coronary occlusion. Most patients will ultimately develop ST-segment elevation myocardial infarction (STEMI). The mainstay of treatment in these patients is immediate reperfusion by primary percutaneous coronary intervention (PCI) or, if not available in a timely manner, by fibrinolytic therapy.2
• Patients with acute chest discomfort but no persistent
ST-segment elevation [non-ST-segment elevation ACS (NSTEACS)]
exhibit
ECG
changes that may include transient
ST-segment elevation, persistent or transient ST-segment depression, T-wave inversion, flat T waves, or pseudonormalization of T waves; or the ECG may be normal.
The pathological correlate at the myocardial level is cardiomyocyte necrosis [non-ST-segment elevation myocardial infarction
(NSTEMI)] or, less frequently, myocardial ischaemia without cell damage (unstable angina). A small proportion of patients may present with ongoing myocardial ischaemia, characterized by one or more of the following: recurrent or ongoing chest pain, marked ST-segment depression on 12-lead ECG, heart failure, and haemodynamic or electrical instability.1 Due to the amount of myocardium in jeopardy and the risk of developing CS and/or malignant ventricular arrhythmias, immediate coronary angiography and, if appropriate, revascularization are indicated (see section 6).
2.1.1 Universal definition of myocardial infarction
Acute myocardial infarction (AMI) defines cardiomyocyte necrosis in a clinical setting consistent with acute myocardial ischaemia.1,3 A
combination of criteria is required to meet the diagnosis of AMI,
namely the detection of an increase and/or decrease of a cardiac biomarker, preferably high-sensitivity cardiac troponin (hs-cTn) T or I,
with at least one value above the 99th percentile of the upper reference limit and at least one of the following:
(1)
Symptoms of myocardial ischaemia.
(2)
New ischaemic ECG changes.
(3)
Development of pathological Q waves on ECG.
(4)
Imaging evidence of loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic aetiology.
(5)
Intracoronary thrombus detected on angiography or autopsy.
2.1.1.1 Type 1 myocardial infarction
Type 1 myocardial infarction (MI) is characterized by atherosclerotic plaque rupture, ulceration, fissure, or erosion with resulting
Table 2
Levels of evidence
Level of 
evidence A
Data derived from multiple randomized clinical trials 
or meta-analyses. 
Level of 
evidence B
Data derived from a single randomized clinical trial or large non-randomized studies. 
Level of 
evidence C
Consensus of opinion of the experts and/or small studies, 
retrospective studies, registries.
©ESC 2020


<!-- PAGE 9 -->

### Page 9

.............................................................................................................................................................................
intraluminal thrombus in one or more coronary arteries leading to decreased myocardial blood flow and/or distal embolization and subsequent myocardial necrosis. The patient may have underlying severe coronary artery disease (CAD) but, on occasion
(510% of cases), there may be non-obstructive coronary atherosclerosis or no angiographic evidence of CAD, particularly in women.1,35
2.1.1.2 Type 2 myocardial infarction
Type 2 MI is myocardial necrosis in which a condition other than coronary plaque instability causes an imbalance between myocardial oxygen supply and demand.3 Mechanisms include hypotension,
hypertension, tachyarrhythmias, bradyarrhythmias, anaemia, hypoxaemia, but also by definition, coronary artery spasm, spontaneous coronary artery dissection (SCAD), coronary embolism, and coronary microvascular dysfunction.68
2.1.1.3 Types 35 myocardial infarction
The universal definition of MI also includes type 3 MI (MI resulting in death when biomarkers are not available) and types 4 and 5 MI
[related to PCI and coronary artery bypass grafting (CABG),
respectively].3
2.1.2 Unstable angina in the era of high-sensitivity cardiac troponin assays
Unstable angina is defined as myocardial ischaemia at rest or on minimal exertion in the absence of acute cardiomyocyte injury/necrosis.
Among unselected patients presenting to the emergency department with suspected NSTE-ACS, the introduction of hs-cTn measurements in place of standard troponin assays resulted in an increase in the detection of MI (4% absolute and 20% relative increases) and a reciprocal decrease in the diagnosis of unstable angina.913
Compared with NSTEMI patients, individuals with unstable angina do not experience acute cardiomyocyte injury/necrosis, have a substantially lower risk of death, and appear to derive less benefit from intensified antiplatelet therapy, as well as an invasive strategy within
72 h.1,35,919 Pathophysiology and epidemiology are discussed in detail elsewhere.1
2.2 Epidemiology
The proportion of patients with NSTEMI in MI surveys increased from one third in 1995 to more than half in 2015, mainly accounted for by a refinement in the operational diagnosis of NSTEMI20. As opposed to STEMI, no significant changes are observed in the baseline characteristics of the NSTEMI population with respect to age and smoking, while diabetes, hypertension, and obesity increased substantially. The use of early angiography (<_72 h from admission)
increased from 9% in 1995 to 60% in 2015 [adjusted odds ratio (OR)
16.4, 95% confidence interval (CI) 12.022.4, P<0.001] and PCI during the initial hospital stay increased from 12.5% to 67%. The main consequences of these changes are a reduction in 6-month mortality from 17.2% to 6.3% and the adjusted hazard ratio (HR) decreased to
0.40 (95% CI 0.300.54) in 2010, remaining stable at 0.40
(0.300.52) in 2015.20
2.3 What is new?
New key recommendations 
Diagnosis
As an alternative to the ESC 0 h/1 h algorithm, it is recommended to use the ESC 0 h/2 h algorithm with blood sampling at 0 h and 2 h, if an hs-cTn test with a validated 0 h/2 h algorithm is available.
For diagnostic purposes, it is not recommended to routinely measure additional biomarkers such 
as CK, CK-MB, h-FABP, or copeptin, in addition to hs-cTn. 
Risk stratification
Measuring BNP or NT-proBNP plasma concentrations should be considered to gain prognostic 
information.
Antithrombotic treatment
In patients with NSTE-ACS who cannot undergo an early invasive strategy, pre-treatment with 
a P2Y12 receptor inhibitor may be considered depending on bleeding risk.
De-escalation of P2Y12 inhibitor treatment (e.g. with a switch from prasugrel or ticagrelor to 
clopidogrel) may be considered as an alternative DAPT strategy, especially for ACS patients 
deemed unsuitable for potent platelet inhibition. De-escalation may be done unguided based on 
clinical judgment, or guided by platelet function testing, or CYP2C19 genotyping depending 
on the patient’s risk profile and availability of respective assays.
It is not recommended to administer routine pre-treatment with a P2Y12 receptor inhibitor to 
patients in whom the coronary anatomy is not known and early invasive management is 
planned.
Prasugrel should be considered in preference to ticagrelor for NSTE-ACS patients who proceed to PCI.
In patients with AF (CHA2DS2-VASc score ≥1 in men and ≥2 in women), after a short period 
of TAT (up to 1 week from the acute event), DAT is recommended as the default strategy using 
a NOAC at the recommended dose for stroke prevention and single oral antiplatelet agent 
(preferably clopidogrel).
Discontinuation of antiplatelet treatment in patients treated with OACs is recommended after 12 
months.
DAT with an OAC and either ticagrelor or prasugrel may be considered as an alternative to 
TAT with an OAC, aspirin, and clopidogrel in patients with a moderate or high risk of stent 
thrombosis, irrespective of the type of stent used.
Invasive treatment
An early invasive strategy within 24 h is recommended in patients with any of the following 
high-risk criteria: 
•
Diagnosis of NSTEMI.  
•
Dynamic or presumably new contiguous ST/T-segment changes suggesting ongoing 
ischaemia. 
•
Transient ST-segment elevation. 
•
GRACE risk score >140. 
A selective invasive strategy after appropriate ischaemia testing or detection of obstructive 
CAD by CCTA is recommended in patients considered at low risk.
Delayed, as opposed to immediate, angiography should be considered in haemodynamically 
stable patients without ST-segment elevation successfully resuscitated after an out-of-hospital 
cardiac arrest.
Complete revascularization should be considered in NSTE-ACS patients without cardiogenic 
shock and with multivessel CAD.
Complete revascularization during index PCI may be considered in NSTE-ACS patients with 
multivessel disease.
FFR-guided revascularization of non-culprit NSTE-ACS lesions may be used during index 
PCI.
Continued
ESC Guidelines
1297


<!-- PAGE 10 -->

### Page 10

.............................................................................................................................................................................
Major changes in recommendations 
0
2
0
2
5
1
0
2
Diagnosis
A rapid rule-out protocol at 0 h and 3 h is 
recommended if hs-cTn tests are available.
A rapid rule-out and rule-in protocol with 
blood sampling at 0 h and 3 h should be 
considered if an hs-cTn test with a validated 
0 h/3 h algorithm is available.
MDCT coronary angiography should be 
considered as an alternative to invasive 
angiography to exclude ACS when there is 
a low-to-intermediate likelihood of CAD 
and when cardiac troponin and/or ECG are 
inconclusive.
CCTA is recommended as an alternative to 
invasive angiography to exclude ACS 
when there is a low-to-intermediate 
likelihood of CAD and when cardiac 
troponin and/or ECG are normal or 
inconclusive. 
Rhythm monitoring up to 24 h or PCI 
(whichever comes first) should be 
considered in NSTEMI patients at low risk 
for cardiac arrhythmias.
Rhythm monitoring up to 24 h or to PCI 
(whichever comes first) is recommended in 
NSTEMI patients at low risk for cardiac 
arrhythmias.
Rhythm monitoring for >24 h should be 
considered in NSTEMI patients at 
intermediate-to-high risk for cardiac 
arrhythmias.
Rhythm monitoring for >24 h is 
recommended in NSTEMI patients at 
increased risk for cardiac arrhythmias.
Risk assessment
It is recommended to use established risk 
scores for prognosis estimation.
GRACE risk score models should be 
considered for estimating prognosis.
Pharmacological treatments
Bivalirudin (0.75 mg/kg i.v. bolus, 
followed by 1.75 mg/kg/h for up to 4 h 
after the procedure) is recommended as an 
alternative to UFH plus GP IIb/IIIa 
inhibitors during PCI.
Bivalirudin may be considered as an 
alternative to UFH.
P2Y12 inhibitor administration in addition 
to aspirin beyond 1 year may be 
considered after careful assessment of the 
ischaemic and bleeding risks of the 
patient. 
Adding a second antithrombotic agent to 
aspirin for extended long-term secondary 
prevention should be considered in 
patients at high risk of ischaemic events 
and without increased risk of major or 
life-threatening bleeding.
Class I 
Class IIa
Class IIb
New sections
•
MINOCA 
•
SCAD 
•
QIs in NSTE-ACS treatment 
New/revised concepts 
•
Rapid rule-in and rule-out algorithms 
•
Risk stratification for an early invasive approach 
•
Definition of high bleeding risk 
•
Definitions of very high and high ischaemic risk 
•
The gap in evidence and corresponding RCTs to be performed 
©ESC 2020
ACS = acute coronary syndromes; AF = atrial fibrillation; BNP = Btype natriuretic peptide; CAD = coronary artery disease; CCTA =
coronary computed tomography angiography; CHA2DS2-VASc =
Congestive heart failure, Hypertension, Age >_75 years (2 points),
Diabetes, Stroke (2 points)Vascular disease, Age 6574, Sex category (female); CK = creatine kinase; CK-MB = creatine kinase myocardial band; DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy; ECG = electrocardiogram/electrocardiography; ESC = European Society of Cardiology; FFR = fractional flow reserve; GP = glycoprotein; GRACE = Global Registry of Acute
Coronary Events; h-FABP = heart-type fatty acid-binding protein;
hs-cTn = high-sensitivity cardiac troponin; MDCT = multidetector computed tomography; MINOCA = myocardial infarction with nonobstructive coronary arteries; NOAC = non-vitamin K antagonist oral anticoagulant; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; NSTEMI = non-ST-segment elevation myocardial infarction; NT-proBNP = N-terminal pro-B-type natriuretic peptide; OAC = oral anticoagulation/anticoagulant; PCI = percutaneous coronary intervention; QI = quality indicator; RCT = randomized controlled trial; SCAD = spontaneous coronary artery dissection;
TAT = triple antithrombotic therapy; UFH = unfractionated heparin.
2.4 Number and breakdown of classes of recommendations (Supplementary Data)
The total number of recommendations is 131. The breakdown of the recommendations according to ESC classes of recommendations and levels of evidence are summarized in Supplementary Figure 1.
3 Diagnosis
3.1 Clinical presentation (Supplementary
Data)
3.2 Physical examination (Supplementary
Data)
3.3 Diagnostic tools
3.3.1 Electrocardiogram
The resting 12-lead ECG is the first-line diagnostic tool in the assessment of patients with suspected ACS (Figure 1). It is recommended to perform it within 10 min of the patient’s arrival in the emergency room or, ideally, at first contact with the emergency medical services in the pre-hospital setting and to have it immediately interpreted by a qualified physician.21 While the ECG in the setting of NSTE-ACS may be normal in more than 30% of patients, characteristic abnormalities include ST-segment depression, transient ST-segment elevation, and
T-wave changes.68,1013,22
If the standard leads are inconclusive and the patient has signs or symptoms suggestive of ongoing myocardial ischaemia, additional leads should be recorded; left circumflex artery occlusion may be detected only in V7V9 or right ventricular MI only in V3R and
V4R.3 In patients with suggestive signs and symptoms, the finding of persistent ST-segment elevation indicates STEMI, which mandates immediate reperfusion.2 Comparison with previous tracings is valuable, particularly in patients with pre-existing ECG abnormalities. It is recommended to obtain additional 12-lead ECGs in case of persistent or recurrent symptoms or diagnostic uncertainty. In patients with left bundle branch block (LBBB), specific ECG criteria
(Sgarbossa’s criteria) may help in the detection of candidates for immediate coronary angiography.23,24 Patients with a high clinical suspicion of ongoing myocardial ischaemia and LBBB should be managed in a way similar to STEMI patients, regardless of whether the LBBB is


<!-- PAGE 11 -->

### Page 11

................................................
previously known.2 In contrast, haemodynamically stable patients presenting with chest pain and LBBB only have a slightly higher risk of having MI compared to patients without LBBB. Therefore, the result of the hs-cTn T/I measurement at presentation should be integrated into the decision regarding immediate coronary angiography.24
In patients with right bundle brunch block (RBBB), ST-elevation is indicative of STEMI while ST-segment depression in lead I, aVL, and
V56 is indicative of NSTE-ACS.25 In patients with paced ventricular beats, the ECG is often of no help for the diagnosis of NSTE-ACS.
Novel ECG algorithms using digital ECG data are in development.2628 In general, it is advisable to perform ECG interpretation using remote technologies at the pre-hospital stage.
It is important to highlight that more than 50% of patients presenting with acute chest pain and LBBB to the emergency department or chest pain unit will ultimately be found to have a diagnosis other than MI.24 Similarly, more than 50% of patients presenting with acute chest pain and RBBB to the emergency department will ultimately be found to have a diagnosis other than MI and should,
therefore, also await the result of the hs-cTn T/I measurement at presentation.25
3.3.2 Biomarkers: high-sensitivity cardiac troponin
Biomarkers complement clinical assessment and 12-lead ECG in the diagnosis, risk stratification, and treatment of patients with suspected
NSTE-ACS. Measurement of a biomarker of cardiomyocyte injury,
preferably hs-cTn, is mandatory in all patients with suspected NSTEACS.1,3,1013 Cardiac troponins are more sensitive and specific markers of cardiomyocyte injury than creatine kinase (CK), its myocardial band isoenzyme (CK-MB), and myoglobin.1,3,4,1013,29,30 If the clinical presentation is compatible with myocardial ischaemia, then a dynamic elevation of cardiac troponin above the 99th percentile of healthy individuals indicates MI. In patients with MI, levels of cardiac
©ESC 2020
Figure 1 Diagnostic algorithm and triage in acute coronary syndrome. The initial assessment is based on the integration of low likelihood and/or high likelihood features derived from the clinical setting (i.e. symptoms, vital signs), the 12-lead ECG, and the cardiac troponin concentration determined at presentation to the emergency department and serially thereafter. ‘Other cardiac’ includes  among others  myocarditis, Takotsubo syndrome, or congestive heart failure. ‘Noncardiac’ refers to thoracic diseases such as pneumonia or pneumothorax. Cardiac troponin and its change during serial sampling should be interpreted as a quantitative marker: the higher the 0 h level or the absolute change during serial sampling, the higher the likelihood for the presence of MI. In patients presenting with cardiac arrest or haemodynamic instability of presumed cardiovascular origin, echocardiography should be performed/interpreted by trained physicians immediately following a 12-lead ECG. If the initial evaluation suggests aortic dissection or pulmonary embolism, D-dimers and CCTA are recommended according to dedicated algorithms.1,2933 CPR = cardiopulmonary resuscitation; ECG = electrocardiogram/electrocardiography; MI = myocardial infarction; NSTEMI = nonST-segment elevation myocardial infarction; STEMI = ST-segment elevation myocardial infarction. Listen to the audio guide of this figure online.
ESC Guidelines
1299


<!-- PAGE 12 -->

### Page 12

............................................................................
troponin rise rapidly (i.e. usually within 1 h from symptom onset if using high-sensitivity assays) after symptom onset and remain elevated for a
variable period of time
(usually several days).1,3,4,1013,29,30 Advances in technology have led to a refinement in cardiac troponin assays and have improved the ability to detect and quantify cardiomyocyte injury.1,3,4,68,1013,29,30,3436 Data from large multicentre studies have consistently shown that hs-cTn assays increase diagnostic accuracy for MI at the time of presentation as compared with conventional assays (Figure 2), especially in patients presenting early after chest pain onset, and allow for a more rapid
‘rule-in’
and
‘rule-out’
of
MI
(see section
3.3.3
and
Table 3).1,3,4,68,1013,29,30,35,36 Overall, hs-cTn T and hs-cTn I assays seem to provide comparable diagnostic accuracy in the early diagnosis of MI.3740
3.3.2.1 Central laboratory vs. point-of-care
The vast majority of cardiac troponin assays that are run on automated platforms in the central laboratory are sensitive (i.e. allow for detection of cardiac troponin in 2050% of healthy individuals) or high-sensitivity (detection in 5095% of healthy individuals) assays.
High-sensitivity assays are recommended over less sensitive ones, as they provide higher diagnostic accuracy at identical low cost.1,3,4,68,1013,29,30,33,35,36
The majority of currently used point-of-care tests (POCTs) cannot be considered sensitive or high-sensitivity assays41. Therefore, the obvious advantage of POCTs, namely the shorter turn-around time,
is counterbalanced by lower sensitivity, lower diagnostic accuracy,
and lower negative predictive value (NPV). Overall, automated assays have been more thoroughly evaluated than POCTs and seem to be preferable at this point in time.1,3,4,68,1013,29,30,33,35,36
As these techniques continue to improve, and performance characteristics are both assay and hospital dependent, it is important to re-evaluate this preference once extensively validated high-sensitivity
POCTs become clinically available.42 The first hs-cTn I POCTs have recently been shown to provide comparable performance characteristics to that of central laboratory hs-cTn I/T assays.43,44
Many cardiac pathologies other than MI also result in cardiomyocyte injury and, therefore, cardiac troponin elevations (Table 4).
Tachyarrhythmias, heart failure, hypertensive emergencies, critical illness, myocarditis, Takotsubo syndrome, and valvular heart disease are the most frequent ones. Most often in elderly patients with renal dysfunction, elevations in cardiac troponin should not be primarily attributed to impaired clearance and considered harmless, as cardiac conditions such as chronic coronary syndromes (CCS) or hypertensive heart disease seem to be the most important contributor to cardiac troponin elevation in this setting.35,45 Other life-threatening conditions presenting with chest pain, such as aortic dissection and pulmonary embolism, may also result in elevated cardiac troponin concentrations and should be considered as differential diagnoses
(Table 4).
©ESC 2020
Figure 2 Value of high-sensitivity cardiac troponin. hs-cTn assays (right) are reported in ng/L and provide identical information as conventional assays
(left, reported in lg/L) if the concentration is substantially elevated, e.g. above 100 ng/L. In contrast, only hs-cTn allows a precise differentiation between
‘normal’ and mildly elevated. Therefore, hs-cTn detects a relevant proportion of patients with previously undetectable cardiac troponin concentrations with the conventional assay who have hs-cTn concentrations above the 99th percentile possibly related to AMI. ??? = unknown due to the inability of the assay to measure in the normal range;68,1013,2931 AMI = acute myocardial infarction; CoV = coefficient of variation; hs-cTn = high-sensitivity cardiac troponin; POCT = point-of-care test. aThe limit of detection varies among the different hs-cTn assays between 1 ng/L and 5 ng/L. Similarly, the 99th percentile varies among the different hs-cTn assays, mainly being between 10 ng/L and 20 ng/L. Listen to the audio guide of this figure online.


<!-- PAGE 13 -->

### Page 13

......................................................................................................................
3.3.2.2 Other biomarkers
Among the multitude of additional biomarkers evaluated for the diagnosis of NSTE-ACS, only CK-MB, myosin-binding protein C,46 and copeptin4758 may have clinical relevance in specific clinical settings when used in combination with cardiac troponin T/I. Compared with cardiac troponin, CK-MB shows a more rapid decline after MI and may provide added value for the timing of myocardial injury and the detection of early reinfarction.1 However, it is important to highlight that little is known on how to best diagnose early reinfarction. Detailed clinical assessment including chest pain characteristics (same characteristics as index event), 12-lead ECG for the detection of new STsegment changes or T-wave inversion, as well as serial measurement of cardiac troponin T/I and CK/CK-MB is recommended. Myosin-binding protein C is more abundant than cardiac troponin and may therefore provide value as an alternative to, or in combination with, cardiac troponin.46 Assessment of copeptin, the C-terminal part of the vasopressin prohormone, may quantify the endogenous stress level in multiple medical conditions including MI. As the level of endogenous stress appears to be high at the onset of MI in most patients, the added value of copeptin to conventional (less sensitive) cardiac troponin assays is substantial.49,50,53 Therefore, the routine use of copeptin as an additional biomarker for the early rule-out of MI should be considered in the increasingly uncommon setting where hs-cTn assays are not available. However, copeptin does not have relevant added value for institutions using one of the well-validated hs-cTn-based rapid protocols in the early diagnosis of MI.47,48,51,52,5458 Other widely available laboratory variables, such as estimated glomerular filtration rate (eGFR), glucose, and B-type natriuretic peptide (BNP) provide incremental prognostic information and may therefore help in risk stratification.59
The determination of D-dimer is recommended in outpatients/emergency department patients with low or intermediate clinical probability, or those that are unlikely to have pulmonary embolism, to reduce the need for unnecessary imaging and irradiation. D-dimers are key diagnostic elements whenever pulmonary embolism is suspected.32,60
3.3.3 Rapid ‘rule-in’ and ‘rule-out’ algorithms
Due to the higher sensitivity and diagnostic accuracy for the detection of MI at presentation, the time interval to the second cardiac troponin assessment can be shortened with the use of hs-cTn assays.
This seems to substantially reduce the delay to diagnosis, translating into shorter stays in the emergency department and lower costs.11,56,6166 It is recommended to use the 0 h/1 h algorithm (best option, blood draw at 0 h and 1 h) or the 0 h/2 h algorithm (secondbest option, blood draw at 0 h and 2 h) (Figure 3). These have been
Table 3
Clinical implications of high-sensitivity cardiac troponin assays
Compared with standard cardiac troponin assays, hs-cTn assays:
• Have higher NPV for AMI.
• Reduce the ‘troponin-blind’ interval leading to earlier detection of AMI.
• Result in 4% absolute and 20% relative increases in the detection of type 1 MI and a corresponding decrease in the diagnosis of unstable angina.
• Are associated with a 2-fold increase in the detection of type 2 MI.
Levels of hs-cTn should be interpreted as quantitative markers of cardiomyocyte damage (i.e. the higher the level, the greater the likelihood of MI):
• Elevations beyond 5-fold the upper reference limit have high (>90%) PPV for acute type 1 MI.
• Elevations up to 3-fold the upper reference limit have only limited (5060%) PPV for AMI and may be associated with a broad spectrum of conditions.
• It is common to detect circulating levels of cardiac troponin in healthy individuals.
Rising and/or falling cardiac troponin levels differentiate acute (as in MI) from chronic cardiomyocyte damage (the more pronounced the change, the higher the likelihood of AMI).
AMI = acute myocardial infarction; hs-cTn = high-sensitivity cardiac troponin; MI = myocardial infarction; NPV = negative predictive value; PPV = positive predictive value.
Table 4
Conditions other than acute type 1 myocardial infarction associated with cardiomyocyte injury
(5 cardiac troponin elevation)
Tachyarrhythmias
Heart failure
Hypertensive emergencies
Critical illness (e.g. shock/sepsis/burns)
Myocarditisa
Takotsubo syndrome
Valvular heart disease (e.g. aortic stenosis)
Aortic dissection
Pulmonary embolism, pulmonary hypertension
Renal dysfunction and associated cardiac disease
Acute neurological event (e.g. stroke or subarachnoid haemorrhage)
Cardiac contusion or cardiac procedures (CABG, PCI, ablation, pacing,
cardioversion, or endomyocardial biopsy)
Hypo- and hyperthyroidism
Inﬁltrative diseases (e.g. amyloidosis, haemochromatosis, sarcoidosis,
scleroderma)
Myocardial drug toxicity or poisoning (e.g. doxorubicin, 5-ﬂuorouracil,
herceptin, snake venoms)
Extreme endurance efforts
Rhabdomyolysis
Bold = most frequent conditions.
CABG = coronary artery bypass graft(ing); PCI = percutaneous coronary intervention.
aIncludes myocardial extension of endocarditis or pericarditis.
ESC Guidelines
1301


<!-- PAGE 14 -->

### Page 14

...................................................................
derived and well-validated in large multicentre diagnostic studies using central adjudication of the final diagnosis for all currently available hs-cTn assays.33,35,36,39,6769 Optimal thresholds for rule-out were selected to allow for a minimal sensitivity and NPV of 99%.
Optimal thresholds for rule-in were selected to allow for a minimal positive predictive value (PPV) of 70%. The algorithms were developed in large derivation cohorts and then validated in large independent validation cohorts. As an alternative, the previous European
Society of Cardiology (ESC) 0 h/3 h algorithm70 should be considered.1 However, three recent large diagnostic studies have suggested that the ESC 0 h/3 h algorithm seems to balance efficacy and safety less well in comparison to more rapid protocols using lower rule-out concentrations including the ESC 0 h/1 h algorithm.7173 Moreover,
the very high safety and high efficacy of applying the ESC 0 h/1 h algorithm has recently been confirmed in three real-life implementation studies, including one randomized controlled trial (RCT) .66,73,74
The 0 h/1 h and 0 h/2 h algorithms rely on two concepts: first, hscTn is a continuous variable and the probability of MI increases with increasing hs-cTn values,35,36,39,68,69,75,76 second, early absolute changes of the levels within 1 h or 2 h can be used as surrogates for absolute changes over 3 h or 6 h and provide incremental diagnostic value to the cardiac troponin assessment at presentation.33,35,36,39,68,69,75,76 The cut-off concentrations within the
0
h/1
h and
0
h/2
h algorithms are assay specific
(Table 5).33,35,36,39,68,69,75,76 The NPV for MI in patients assigned ‘ruleout’ exceeded 99% in several large validation cohorts.35,36,39,68,69,77
Used in conjunction with clinical and ECG findings, the 0 h/1 h and 0
h/2 h algorithm will allow the identification of appropriate candidates for early discharge and outpatient management. Even after the ruleout of MI, elective non-invasive or invasive imaging may be indicated according to clinical assessment. Invasive coronary angiography (ICA)
will still be the best option in patients with very high clinical likelihood of unstable angina, even after NSTEMI has been ruled out. In contrast,
stress testing with imaging or coronary computed tomography angiography (CCTA) will be the best option in patients with low-tomodest clinical likelihood of unstable angina. No testing is necessary in patients with a clear alternative diagnosis.
The PPV for MI in patients meeting the ‘rule-in’ criteria is about
7075%.35,36,39,69 Most of the ‘rule-in’ patients with diagnoses other than MI did have conditions that usually still require ICA or cardiac magnetic resonance (CMR) imaging for accurate diagnosis, including
Takotsubo syndrome and myocarditis.35,36,39,68,69,75,76 Therefore, the vast majority of patients triaged towards the rule-in group are candidates for early ICA and admission to a coronary care unit (CCU).
©ESC 2020
Figure 3 0 h/1 h rule-out and rule-in algorithm using high-sensitivity cardiac troponin assays in haemodynamically stable patients presenting with suspected non-ST-segment elevation acute coronary syndrome to the emergency department. 0 h and 1 h refer to the time from first blood test. NSTEMI
can be ruled out at presentation if the hs-cTn concentration is very low. NSTEMI can also be ruled out by the combination of low baseline levels and the lack of a relevant increase within 1 h (no 1hD). Patients have a high likelihood of NSTEMI if the hs-cTn concentration at presentation is at least moderately elevated or hs-cTn concentrations show a clear rise within the first hour (1hD).1,68,1013,2931,33 Cut-offs are assay specific (see Table 3) and derived to meet predefined criteria for sensitivity and specificity for NSTEMI. CCU = coronary care unit; CCTA = coronary computed tomography angiography;
CPO = chest pain onset; hs-cTn = high-sensitivity cardiac troponin; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; NSTEMI = nonST-segment elevation myocardial infarction. aOnly applicable if CPO >3 h. Listen to the audio guide of this figure online.


<!-- PAGE 15 -->

### Page 15

...........................................................................................
These algorithms should always be integrated with a detailed clinical assessment and 12-lead ECG, and repeat blood sampling is mandatory in case of ongoing or recurrent chest pain.
The same concept applies to the 0 h/2 h algorithm. Cut-off levels are assay-specific and shown in Table 5. Cut-off levels for other hscTn assays are in development.
3.3.4 Observe
Patients who do not qualify for ‘rule-out’ or ‘rule-in’, are assigned to observe. They represent a heterogeneous group that usually requires a third measurement of cardiac troponin at 3 h and echocardiography as the next steps.85 ICA should be considered in patients for whom there is a high degree of clinical suspicion of NSTE-ACS (e.g. relevant increase in cardiac troponin from presentation to 3 h), while in patients with low-to-intermediate likelihood for this condition according to clinical judgment, non-invasive imaging using CCTA or stress testing
[stress echocardiography, positron emission tomography, singlephoton-emission tomography (SPECT), or CMR for the detection of
ACS features (oedema, late gadolinium enhancement, perfusion defect,
etc.)] should be considered after discharge from the emergency department to the ward. No further diagnostic testing is indicated when alternative conditions, such as rapid ventricular rate response to atrial fibrillation (AF) or hypertensive emergency, have been identified.
3.3.4.1 Caveats of using rapid algorithms. When using any algorithm,
three main caveats apply i.
Algorithms should only be used in conjunction with all available clinical information, including detailed assessment of chest pain characteristics and ECG.
ii. The ESC 0 h/1h and 0 h/2 h algorithms apply to all patients irrespective of chest pain onset. The safety (as quantified by the NPV) and sensitivity are very high (>99%), including in the subgroup of patients presenting very early (e.g. <2 h).69 However, due to the time dependency of troponin release and the only moderate number of patients presenting <1 h after chest pain onset in previous studies, obtaining an additional cardiac troponin concentration at 3 h in patients presenting <1 h and triaged towards rule-out should be considered.
iii. As late increases in cardiac troponin have been described in 1% of patients, serial cardiac troponin testing should be pursued if the clinical suspicion remains high or whenever the patient develops recurrent chest pain.35,36,39,68,69,75,76,86
3.3.4.2 Confounders of cardiac troponin concentration. In patients presenting with suspected NSTE-ACS, beyond the presence or absence of
MI,
four clinical variables affect hs-cTn concentrations:35,36,39,69,79,8793
i. Age (to a large extent as a surrogate for pre-existing cardiac disease).
ii. Renal dysfunction (to a large extent as a surrogate for pre-existing cardiac disease).
iii. Time from chest pain onset.
iv. Sex.
The effect of age (differences in concentration between healthy very young vs. healthy very old individuals up to 300%), renal dysfunction
(differences in concentration between otherwise healthy patients with very high vs. very low eGFR up to 300%), and chest pain onset
(>300%)
is substantial,
and modest for sex
(40%).11,35,36,39,69,79,8893 Until information technology tools that allow the incorporation of the effect of all four variables are available,
Table 5
Assay speciﬁc cut-off levels in ng/l within the 0 h/1 h and 0 h/2 h algorithms
0 h/1 h algorithm
Very low
Low
No 1hD
High
1hD
hs-cTn T (Elecsys; Roche)
<5
<12
<3
>_52
>_5
hs-cTn I (Architect; Abbott)
<4
<5
<2
>_64
>_6
hs-cTn I (Centaur; Siemens)
<3
<6
<3
>_120
>_12
hs-cTn I (Access; Beckman Coulter)
<4
<5
<4
>_50
>_15
hs-cTn I (Clarity; Singulex)
<1
<2
<1
>_30
>_6
hs-cTn I (Vitros; Clinical Diagnostics)
<1
<2
<1
>_40
>_4
hs-cTn I (Pathfast; LSI Medience)
<3
<4
<3
>_90
>_20
hs-cTn I (TriageTrue; Quidel)
<4
<5
<3
>_60
>_8
0 h/2 h algorithm
Very low
Low
No 2hD
High
2hD
hs-cTn T (Elecsys; Roche)
<5
<14
<4
>_52
>_10
hs-cTn I (Architect; Abbott)
<4
<6
<2
>_64
>_15
hs-cTn I (Centaur; Siemens)
<3
<8
<7
>_120
>_20
hs-cTn I (Access; Beckman Coulter)
<4
<5
<5
>_50
>_20
hs-cTn I (Clarity; Singulex)
<1
TBD
TBD
>_30
TBD
hs-cTn I (Vitros; Clinical Diagnostics)
<1
TBD
TBD
>_40
TBD
hs-cTn I (Pathfast; LSI Medience)
<3
TBD
TBD
>_90
TBD
hs-cTn I (TriageTrue; Quidel)
<4
TBD
TBD
>_60
TBD
These cut-offs apply irrespective of age and renal function. Optimized cut-offs for patients above 75 years of age and patients with renal dysfunction have been evaluated, but not consistently shown to provide better balance between safety and efﬁcacy as compared to these universal cut-offs.35,36,69 The algorithms for additional assays are in development.
hs-cTn = high-sensitivity cardiac troponin; TBD = to be determined.3537,39,40,68,69,7584
ESC Guidelines
1303


<!-- PAGE 16 -->

### Page 16

.................................
the use of uniform cut-off concentrations should remain the standard of care in the early diagnosis of MI.35,36,39,68,69,75,76
3.3.4.3 Practical guidance on how to implement the European Society of
Cardiology 0 h/1 h algorithm
In order to maximize the safety and feasibility of the process, the nursing team should, in general, obtain blood samples for hs-cTn at
0 h and 1 h irrespective of other clinical details and pending results.
This introduces unnecessary cardiac troponin measurements in perhaps 1015% of patients with very low 0 h concentrations and chest pain onset >3 h, but substantially facilitates the process and thereby further increases patient safety. Documentation of the time of the 0 h blood draw allows exact determination of the time window
(± 10 min) of the 1 h blood draw. If the 1 h (± 10 min) blood draw was not feasible, then blood should be drawn at 2 h and the ESC
0 h/2 h algorithm applied.
3.3.4.4 Avoiding misunderstandings: time to decision ¼ time of blood draw þ turn-around time
The use of the ESC 0 h/1 h algorithm is irrespective of the local turnaround time. 0 h and 1 h refer to the time point at which blood is taken (Figure 4).
©ESC 2020
Figure 4 Timing of the blood draws and clinical decisions when using the European Society of Cardiology 0 h/1 h algorithm. 0 h and 1 h refer to the time points at which blood is taken. The turn-around time is the time period from blood draw to reporting back the results to the clinician. It is usually about
1 h using an automated platform in the central laboratory. It includes transport of the blood tube to the lab, scanning of the probe, centrifugation, putting plasma on the automated platform, the analysis itself, and the reporting of the test result to the hospital information technology/electronic patient record.
The turn-around time is identical whether using a hs-cTn assay vs. a conventional assay, as long as both are run on an automated platform. Adding the local turn-around time to the time of blood draw determines the earliest time point for clinical decision making based on hs-cTn concentrations. e.g. for the 0 h time point, time to decision is at 1 h if the local turn-around time is 1 h. For the blood drawn at 1 h, the results are reported back at 2 h (1 h þ 1 h) if the local turn-around time is 1 h. Relevant 1 h changes are assay dependent and listed in Table 3. CPO = chest pain onset; CPR = cardiopulmonary resuscitation; ECG = electrocardiogram/electrocardiography; hs-cTn = high-sensitivity cardiac troponin; MACE = major adverse cardiovascular events; MI = myocardial infarction. Listen to the audio guide of this figure online.


<!-- PAGE 17 -->

### Page 17

.............................................................................................................................................................................
The clinical and economic benefit of the ESC 0 h/1 h algorithm vs.
the ESC 0 h/3 h algorithm or other algorithms with the second blood draw later than 1 h is therefore independent of the local turn-around time.61
3.3.5 Non-invasive imaging
3.3.5.1 Functional evaluation
Transthoracic echocardiography should be routinely available in emergency rooms and chest pain units and performed/interpreted by trained physicians in all patients during hospitalization for NSTE-ACS.
This imaging modality is useful to identify abnormalities suggestive of myocardial ischaemia or necrosis (i.e. segmental hypokinesia or akinesia). In the absence of significant wall motion abnormalities, impaired myocardial perfusion detected by contrast echocardiography or reduced regional function using strain and strain rate imaging might improve the diagnostic and prognostic value of conventional echocardiography.9496 Moreover, echocardiography can help in detecting alternative pathologies associated with chest pain, such as acute aortic dissection, pericardial effusion, aortic valve stenosis, hypertrophic cardiomyopathy, mitral valve prolapse, or right ventricular dilatation suggestive of acute pulmonary embolism.
Similarly,
echocardiography is the diagnostic tool of choice for patients with haemodynamic instability of suspected cardiac origin.96,97 Evaluation of left ventricular (LV) systolic function, at the latest by the time of hospital discharge, is important to estimate prognosis, and echocardiography
(as well as other imaging modalities) can provide this information.
In patients without ischaemic changes on 12-lead ECGs and normal hs-cTn, who are free from chest pain for several hours, stress imaging can be performed during hospitalization or shortly after discharge.
Stress imaging is preferred over exercise ECG due to its greater diagnostic accuracy.98 Various studies have shown that normal exercise or dobutamine or dipyridamole stress echocardiograms have high NPV
for ischaemia and are associated with excellent patient outcomes.99,100
Moreover, stress echocardiography has demonstrated superior prognostic value over exercise ECG.101 If the acoustic window is not adequate to assess regional wall motion abnormalities, the use of echocardiographic contrast is recommended to improve the accuracy of such an assessment and facilitate the detection of ischaemia.98,101103
CMR can assess both perfusion and wall motion abnormalities, and patients presenting with acute chest pain with a normal stress CMR
have an excellent short- and mid-term prognosis.104 Additionally,
CMR permits detection of scar tissue (using late gadolinium enhancement) and can differentiate this from recent infarction (using T2weighted imaging to delineate myocardial oedema).98 Moreover,
CMR can facilitate the differential diagnosis between infarction, myocarditis, or Takotsubo syndrome, among others.98 In a recent randomized trial in patients with unclear NSTEMI diagnosis, upfront imaging with CMR reduced the need for ICA and provided an alternative diagnosis in a relevant proportion of patients.105
Similarly, SPECT has been shown to be useful for the risk stratification of patients with acute chest pain suggestive of ACS. Resting myocardial scintigraphy, by detecting fixed perfusion defects suggestive of myocardial necrosis, can be helpful for the initial triage of patients presenting with chest pain without ECG changes or elevated cardiac troponins.98 Combined stressrest imaging and/or stress-only imaging may further enhance assessment of ischaemia, while a normal study is associated with an excellent outcome.106,107 Stressrest imaging modalities are usually not widely available on 24 h service and some (e.g. SPECT) are associated with substantial radiation exposure.
3.3.5.2 Anatomical evaluation
CCTA allows visualization of the coronary arteries and a normal scan excludes CAD. CCTA has a high NPV to exclude ACS (by excluding
CAD) and an excellent outcome in patients presenting to the emergency department with low-to-intermediate pre-test probability for
ACS and a normal CCTA.108 Seven RCTs have tested CCTA vs.
usual care in the triage of low-to-intermediate-risk patients presenting with acute chest pain to emergency departments without signs of ischaemia on ECG and normal cardiac troponins.109 However, the majority of studies used only conventional,
less sensitive assays.110113 At a follow-up of 16 months, there were no deaths,
and a meta-analysis demonstrated comparable outcomes with the two approaches (i.e. no difference in the incidence of MI, postdischarge emergency department visits, or re-hospitalizations) and showed that CCTA was associated with a reduction in emergency department costs and length of stay.114 However, none of these studies used hs-cTn assays, which also reduce hospital stay. In a randomized study, in which the standard of care included hs-cTn, CCTA was no longer able to improve patient flow.115 It was also noted that
CCTA was associated with an increase in the use of invasive angiography.114 In contrast, in a recent randomized trial of unclear NSTEMI
diagnosis, upfront imaging with CCTA reduced the need for ICA105
Similar results were observed in a sub-analysis of the Very EaRly vs
Deferred Invasive evaluation using Computerized Tomography
(VERDICT) trial, where upfront CCTA in NSTE-ACS patients had an
NPV of 90.9%.116 However, a relatively large patient group had to be excluded for specific reasons and an NPV of 90.9% is not entirely perfect.116 Accordingly, CCTA can be used to exclude CAD and is thus less useful in patients with known CAD. Other factors limiting CCTA
include severe calcifications (high calcium score) and elevated or irregular heart rate; in addition, a 24 h service is currently not widely available. Finally, the use of CCTA in the acute setting in patients with stents or previous CABG has not been validated. Importantly, computed tomography (CT) imaging can effectively exclude other causes of acute chest pain that, if untreated, are associated with high mortality, namely pulmonary embolism and aortic dissection.
3.4 Differential diagnosis
Among unselected patients presenting with acute chest pain to the emergency department, disease prevalence can be expected to be the following: 510% STEMI, 1520% NSTEMI, 10% unstable angina, 15% other cardiac conditions, and 50% non-cardiac diseases.35,36,39,69,79,8793 Several cardiac and non-cardiac conditions may mimic NSTE-ACS (Table 6).
Conditions that should always be considered in the differential diagnosis of NSTE-ACS because they are potentially life-threatening but also treatable include aortic dissection, pulmonary embolism, and tension pneumothorax. Echocardiography should be performed urgently in all patients with haemodynamic instability of suspected cardiovascular origin. Takotsubo syndrome has recently been
ESC Guidelines
1305


<!-- PAGE 18 -->

### Page 18

.....................
observed more often as a differential diagnosis and usually requires coronary angiography to rule out ACS.117
Chest X-ray is recommended in all patients in whom NSTEACS is considered unlikely in order to detect pneumonia, pneumothorax, rib fractures, or other thoracic disorders. Stroke may be accompanied by ECG changes, myocardial wall motion abnormalities, and cardiomyocyte injury (= increase in cardiac troponin concentrations). The majority of patients presenting to the emergency department with acute chest pain have non-cardiac conditions causing the chest discomfort.35,36,39,69,79,8793 In many instances, the pain is musculoskeletal and is therefore benign, selflimiting, and does not require hospitalization. Chest pain characteristics help  to some extent  in the early identification of these patients.
Table 6
Differential diagnoses of acute coronary syndromes in the setting of acute chest pain
Cardiac
Pulmonary
Vascular
Gastro-intestinal
Orthopaedic
Other
Myopericarditis
Pulmonary embolism
Aortic dissection
Oesophagitis,
reﬂux, or spasm
Musculoskeletal disorders
Anxiety disorders
Cardiomyopathiesa
(Tension)-
pneumothorax
Symptomatic aortic aneurysm
Peptic ulcer, gastritis
Chest trauma
Herpes zoster
Tachyarrhythmias
Bronchitis, pneumonia
Stroke
Pancreatitis
Muscle injury/inﬂammation
Anaemia
Acute heart failure
Pleuritis
Cholecystitis
Costochondritis
Hypertensive emergencies
Cervical spine pathologies
Aortic valve stenosis
Takotsubo syndrome
Coronary spasm
Cardiac trauma
Bold = common and/or important differential diagnoses.
aDilated, hypertrophic and restrictive cardiomyopathies may cause angina or chest discomfort.
Recommendations for diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-STsegment elevation acute coronary syndrome
Recommendations
Classa
Levelb
Diagnosis and risk stratiﬁcation
It is recommended to base diagnosis and initial short-term risk stratiﬁcation on a combination of clinical history, symptoms,
vital signs, other physical ﬁndings, ECG, and laboratory results including hs-cTn.3
I
B
It is recommended to measure cardiac troponins with high-sensitivity assays immediately after admission and obtain the results within 60 min of blood sampling.3,1013,2931,34
I
B
It is recommended to obtain a 12-lead ECG within 10 min after ﬁrst medical contact and to have it immediately interpreted by an experienced physician.21
I
B
It is recommended to obtain an additional 12-lead ECG in case of recurrent symptoms or diagnostic uncertainty.
I
C
The ESC 0 h/1 h algorithm with blood sampling at 0 h and 1 h is recommended if an hs-cTn test with a validated 0 h/1 h algorithm is available.30,33,35,36,39,68,69,75,76
I
B
Additional testing after 3 h is recommended if the ﬁrst two cardiac troponin measurements of the 0 h/1 h algorithm are not conclusive and the clinical condition is still suggestive of ACS.85
I
B
As an alternative to the ESC 0 h/1 h algorithm, it is recommended to use the ESC 0 h/2 h algorithm with blood sampling at 0
h and 2 h, if an hs-cTn test with a validated 0 h/2 h algorithm is available.33,39,75,78,84
I
B
Additional ECG leads (V3R, V4R, V7V9) are recommended if ongoing ischaemia is suspected when standard leads are inconclusive.
I
C
As an alternative to the ESC 0 h/1 h algorithm, a rapid rule-out and rule-in protocol with blood sampling at 0 h and 3 h should be considered, if a high-sensitivity (or sensitive) cardiac troponin test with a validated 0 h/3 h algorithm is available.7073
IIa
B
The routine use of copeptin as an additional biomarker for the early rule-out of MI should be considered where hs-cTn assays are not available.
IIa
B
It should be considered to use established risk scores for prognosis estimation.
IIa
C
For initial diagnostic purposes, it is not recommended to routinely measure additional biomarkers such as h-FABP or copeptin, in addition to hs-cTn.47,48,51,52,54,118
III
B
Continued


<!-- PAGE 19 -->

### Page 19

.................................................................................
4 Risk assessment and outcomes
4.1 Electrocardiogram indicators
(Supplementary Data)
4.2 Biomarkers
Beyond diagnostic utility, initial cardiac troponin levels add prognostic information in terms of short- and long-term mortality to clinical and
ECG variables. While hs-cTn T and I have comparable diagnostic accuracy, hs-cTn T has greater prognostic accuracy.38,119 Serial measurements are useful to identify peak levels of cardiac troponin for risk stratification purposes in patients with established MI. The higher the hs-cTn levels, the greater the risk of death.12,76,120 However, evidence is limited regarding the optimal time points of serial hs-cTn measurement. Serum creatinine and eGFR should also be determined in all patients with NSTE-ACS because they affect prognosis and are key elements of the Global Registry of Acute Coronary
Events (GRACE) risk score (see section 4.3). Similarly, natriuretic peptides [BNP and N-terminal pro-BNP (NT-proBNP)] provide prognostic information regarding the risk of death, acute heart failure, as well as the development of AF in addition to cardiac troponin.121 In addition, quantifying the presence and severity of haemodynamic stress and heart failure using BNP or NT-proBNP concentrations in patients with left main CAD or three-vessel CAD without NSTEACS may help the heart team to select either PCI or CABG as the revascularization strategy of choice.122124 However, this needs confirmation in randomized trials and has not been tested in NSTEACS patients so far. Similarly, natriuretic peptides provide prognostic information on top of cardiac troponin.121,125,126 Other biomarkers,
such as high-sensitivity C-reactive protein, mid-regional pro-adrenomedullin, growth differentiation factor 15 (GDF-15), heart-type fatty acid-binding protein (h-FABP), and copeptin may also have some prognostic value.50,118,127132 However, the assessment of these markers has, so far, not been shown to improve patient management and their added value in risk assessment on top of the GRACE risk calculation and/or BNP/NT-proBNP seems marginal. At the present time, the routine use of these biomarkers for prognostic purposes is not recommended.
4.3 Clinical scores for risk assessment
(Supplementary Data)
A number of prognostic models that aim to estimate the future risk of all-cause mortality or the combined risk of all-cause mortality or MI have been developed. These models have been formulated into clinical risk scores and, among these, the GRACE risk score offers the best discriminative performance.133135 It is important to recognize, however, that there are several GRACE
risk scores, and each refers to different patient groups and predicts different outcomes.136139 The GRACE risk score models have been externally validated using observational data.140
Further information concerning the GRACE risk scores is presented in Supplementary Data section 4.3, Supplementary Table 1,
Imaging
In patients presenting with cardiac arrest or haemodynamic instability of presumed cardiovascular origin, echocardiography is recommended and should be performed by trained physicians immediately following a 12-lead ECG.
I
C
In patients with no recurrence of chest pain, normal ECG ﬁndings, and normal levels of cardiac troponin (preferably high sensitivity), but still with a suspected ACS, a non-invasive stress test (preferably with imaging) for inducible ischaemia or CCTA is recommended before deciding on an invasive approach.91,92,98,101,105108
I
B
Echocardiography is recommended to evaluate regional and global LV function and to rule in or rule out differential diagnoses.c
I
C
CCTA is recommended as an alternative to ICA to exclude ACS when there is a low-to-intermediate likelihood of CAD and when cardiac troponin and/or ECG are normal or inconclusive.105,108,110114
I
A
Monitoring
Continuous rhythm monitoring is recommended until the diagnosis of NSTEMI has been established or ruled out.
I
C
It is recommended to admit NSTEMI patients to a monitored unit.
I
C
Rhythm monitoring up to 24 h or to PCI (whichever comes ﬁrst) is recommended in NSTEMI patients at low risk for cardiac arrhythmias.d
I
C
Rhythm monitoring for >24 h is recommended in NSTEMI patients at increased risk for cardiac arrhythmias.e
I
C
In the absence of signs or symptoms of ongoing ischaemia, rhythm monitoring in unstable angina may be considered in selected patients (e.g. suspicion of coronary spasm or associated symptoms suggestive of arrhythmic events).
IIb
C
0 h = time of ﬁrst blood test; 1 h, 2 h, 3 h = 1, 2, or 3 h after the ﬁrst blood test.
ACS = acute coronary syndromes; CAD = coronary artery disease; CCTA = coronary computed tomography angiography; ECG = electrocardiogram/electrocardiography;
ESC = European Society of Cardiology; GRACE = Global Registry of Acute Coronary Events; h-FABP = heart-type fatty acid-binding protein; hs-cTn = high-sensitivity cardiac troponin; ICA = invasive coronary angiography; LV = left ventricular; LVEF = left ventricular ejection fraction; NSTEMI = non-ST-segment elevation myocardial infarction; PCI =
percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
cDoes not apply to patients discharged the same day in whom NSTEMI has been ruled out.
dIf none of the following criteria: haemodynamically unstable, major arrhythmias, LVEF <40%, failed reperfusion, additional critical coronary stenoses of major vessels, complications related to percutaneous revascularization, or GRACE risk score >140 if assessed.
eIf one or more of the above criteria are present.
ESC Guidelines
1307


<!-- PAGE 20 -->

### Page 20

.......................................................................................................
and Supplementary Figure 3. The nomogram to calculate the original GRACE risk score, which estimates the risk of in-hospital death, is shown in Supplementary Figure 3 and online risk calculators are available for other GRACE risk scores: https://www.out comes-umassmed.org/risk_models_grace_orig.aspx for the
GRACE risk score 1.0 and www.outcomes-umassmed.org/grace/
acs_risk2/index.html for the GRACE risk score 2.0.
Given that the GRACE risk score predicts clinical outcomes, it is possible to stratify patients according to their estimated risk of future ischaemic events. A GRACE risk score-based risk assessment has been found to be superior to (subjective) physician assessment for the occurrence of death or MI.141,142 Moreover, it is well recognized that the delivery of guideline-directed care is inversely related to the estimated risk of the patient with NSTE-ACS143
 the so called ‘risk-treatment paradox’.144,145 Guideline-directed care is associated with proportionally greater survival gains among those with higher baseline risk, therefore objective risk assessment may help to identify NSTE-ACS patients who would benefit from risk-determined care interventions.144,145 The Australian GRACE
Risk score Intervention Study (AGRIS)146 and the ongoing UK
GRACE Risk score Intervention Study (UKGRIS)147 have  or are for the first time  investigating the impact of the utilization of the
GRACE risk score on outcomes of patients with NSTE-ACS in a randomized manner. The AGRIS cluster-randomized trial failed to demonstrate any add-on value, especially for the guideline-directed treatments with the routine implementation of the GRACE risk score. This was largely explained by better-than-expected performance of the control hospitals. Given temporal improvements in early mortality from NSTE-ACS,148 the prediction of long-term risk is important. Deaths in the early phase following NSTE-ACS are more attributable to ischaemia/thrombosis-related events, whereas in the later phase they are more likely to be associated with the progression of atherosclerosis and non-cardiovascular causes.149152
4.4 Bleeding risk assessment
Major bleeding events are associated with increased mortality in
NSTE-ACS.157 In order to estimate bleeding risk in this setting,
scores such as the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/American Heart Association (AHA)
guidelines
(CRUSADE;
https://www.mdcalc.com/crusade-score-post-mibleeding-risk)
and the
Acute
Catheterization and
Urgent
Intervention Triage strategY (ACUITY) bleeding risk scores have been developed. Overall, the two scores have reasonable predictive value for major bleeding in ACS patients undergoing coronary angiography, with CRUSADE being the most discriminatory.155157
Changes in interventional practice, such as the use of radial access for coronary angiography and PCI, as well as in antithrombotic treatment, may modify the predictive value of risk scores. In addition, in medically treated patients or those on oral anticoagulants
(OACs), the predictive value of these scores has not been established. Given these limitations, the use of the CRUSADE bleeding risk score may be considered in patients undergoing coronary angiography to quantify bleeding risk.
An alternative to these scores may be the assessment of bleeding risk according to the Academic Research Consortium for High
Bleeding Risk (ARC-HBR) (Table 7).158 This consensus definition of patients at high bleeding risk (HBR) was recently developed to provide consistency for clinical trials evaluating the safety and effectiveness of devices and drug regimens for patients undergoing PCI.158
This proposed ARC-HBR represents a pragmatic approach that includes the most recent trials performed in HBR patients, who were previously excluded from clinical trials of dual antiplatelet therapy
(DAPT) duration or intensity (Table 7).159161 However, bleeding risk assessment based on ARC-HBR criteria may be difficult to apply in routine clinical practice as several of the criteria are quite detailed and so far, this score has not been validated.
Recommendations on biomarker measurements for prognostic stratiﬁcation
Recommendations
Classa
Levelb
Beyond its diagnostic role, it is recommended to measure hs-cTn serially for the estimation of prognosis.12,13,119,120
I
B
Measuring BNP or NT-proBNP plasma concentrations should be considered to gain prognostic information.121,125,126
IIa
B
The measurement of additional biomarkers, such as mid-regional pro-A-type natriuretic peptide, high-sensitivity
C-reactive protein, mid-regional pro-adrenomedullin, GDF-15, copeptin, and h-FABP is not recommended for routine risk or prognosis assessment.50,127,129
III
B
Score to risk stratify in NSTE-ACS
GRACE risk score models should be considered for estimating prognosis.137139
IIa
B
The use of risk scores designed to evaluate the beneﬁts and risks of different DAPT durations may be considered.153,154
IIb
A
To estimate bleeding risk, the use of scores may be considered in patients undergoing coronary angiography.155,156
IIb
B
BNP = B-type natriuretic peptide; DAPT = dual antiplatelet therapy; GDF-15 = growth differentiation factor 15; GRACE = Global Registry of Acute Coronary Events; h-FABP
= heart-type fatty acid-binding protein; hs-cTn = high-sensitivity cardiac troponin; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; NT-proBNP = N-terminal pro-B-type natriuretic peptide.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 21 -->

### Page 21

...................................................................................
4.5 Integrating ischaemic and bleeding risks
Major bleeding events affect prognosis in a similar way to spontaneous ischaemic complications.163,164 Given the trade-off between ischaemic vs. bleeding risks for any antithrombotic regimen, the use of scores might prove useful to tailor antithrombotic duration,
as well as intensity, to maximize ischaemic protection and minimize bleeding risk in the individual patient. Specific risk scores have been developed for patients on DAPT following PCI, in the setting of both CCS as well as ACS. To date, no risk score has been tested in patients requiring long-term anticoagulation. The DAPT and the
PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent
Dual
Anti
Platelet
Therapy
(PRECISE-DAPT) scores have been designed to guide and inform decision making on DAPT duration.153,154 The applicability of the
PRECISE-DAPT score is at patient discharge, while the DAPT
score is a bleeding risk estimation to be calculated at 1 year from the index event. The usefulness of the PRECISE-DAPT score was retrospectively assessed within patients randomized to different
DAPT durations (n = 10 081) to identify the effect on bleeding and ischaemia of a long (1224 months) or short (36 months) treatment duration in relation to baseline bleeding risk.154 Among HBR
patients based on PRECISE-DAPT (i.e. PRECISE-DAPT score
>_25), prolonged DAPT was associated with no ischaemic benefit but a large bleeding burden.154 Conversely, longer treatment in patients without HBR (i.e. PRECISE-DAPT score <25) was associated with no increase in bleeding and a significant reduction in the composite ischaemic endpoint of MI, definite stent thrombosis,
stroke, and target vessel revascularization. The findings remained valid in analyses restricted to ACS. However, for the majority of patients in the study, DAPT consisted of aspirin and clopidogrel.
An external validation of the PRECISE-DAPT score  in 4424
ACS patients undergoing PCI and treated with prasugrel or ticagrelor  showed a modest predictive value for major bleeding at a median follow-up of 14 months (c-statistic = 0.653).165 In addition,
none of these risk prediction models have been prospectively tested in RCTs, therefore, their value in improving patient outcomes remains unclear. The DAPT study has been less well validated, with a retrospective analysis in 1970 patients and a score calculation at a different time point (6 vs. 12 months) than in the derivation cohort used to generate the score.166
5 Pharmacological treatments
5.1 Antithrombotic treatment
Antithrombotic treatment is mandatory in NSTE-ACS patients with and without invasive management. Its choice, the combination, the time point of initiation, and the treatment duration depend on various intrinsic and extrinsic (procedural) factors (Figure 5). Notably,
both ischaemic and bleeding complications significantly influence the outcome of NSTE-ACS patients and their overall mortality risk.167
Thus, the choice of treatment should equally reflect the ischaemic and bleeding risk of the patient.
Table 7
Major and minor criteria for high bleeding risk according to the Academic Research Consortium for High
Bleeding Risk at the time of percutaneous coronary intervention (bleeding risk is high if at least one major or two minor criteria are met)
Major
Minor
• Anticipated use of long-term OACa
• Age >_ 75 years
• Severe or end-stage CKD (eGFR <30 mL/min)
• Moderate CKD (eGFR 3059 mL/min)
• Haemoglobin <11 g/dL
• Haemoglobin 1112.9 g/dL for men or 1111.9 g/dL for women
• Spontaneous bleeding requiring hospitalization and/or transfusion in the past 6 months or at any time, if recurrent
• Spontaneous bleeding requiring hospitalization and/or transfusion within the past 12 months not meeting the major criterion
• Moderate or severe baseline thrombocytopeniab
(platelet count <100  109/L)
• Chronic use of oral non-steroidal anti-inﬂammatory drugs or steroids
• Chronic bleeding diathesis
• Any ischaemic stroke at any time not meeting the major criterion
• Liver cirrhosis with portal hypertension
• Active malignancyc (excluding non-melanoma skin cancer)
within the past 12 months
• Previous spontaneous intracranial haemorrhage (at any time)
• Previous traumatic intracranial haemorrhage within the past 12 months
• Presence of a brain arteriovenous malformation
• Moderate or severe ischaemic stroked within the past 6 months
• Recent major surgery or major trauma within 30 days prior to PCI
• Non-deferrable major surgery on DAPT
CKD = chronic kidney disease; DAPT = dual antiplatelet therapy; eGFR = estimated glomerular ﬁltration rate; OAC = oral anticoagulation/anticoagulant; PCI = percutaneous coronary intervention.
aThis excludes vascular protection doses.162
bBaseline thrombocytopenia is deﬁned as thrombocytopenia before PCI.
cActive malignancy is deﬁned as diagnosis within 12 months and/or ongoing requirement for treatment (including surgery, chemotherapy, or radiotherapy).
dNational Institutes of Health Stroke Scale score >5.
ESC Guidelines
1309


<!-- PAGE 22 -->

### Page 22

©ESC 2020
Figure 5 Determinants of antithrombotic treatment in coronary artery disease. Intrinsic (in blue: patient’s characteristics, clinical presentation & comorbidities) and extrinsic (in yellow: co-medication & procedural aspects) variables influencing the choice, dosing, and duration of antithrombotic treatment.
ACS = acute coronary syndromes; CABG = coronary artery bypass graft(ing); CCS = chronic coronary syndromes; CKD = chronic kidney disease;
NSTE-ACS = non-ST-segment elevation acute coronary syndrome; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; STEMI =
ST-segment elevation myocardial infarction.
©ESC 2020
Figure 6 Antithrombotic treatments in non-ST-segment elevation acute coronary syndrome patients: pharmacological targets. Drugs with oral administration are shown in black letters and drugs with preferred parenteral administration in red. Abciximab (in brackets) is not supplied anymore. ADP =
adenosine diphosphate; DAPT = dual antiplatelet therapy; FXa = factor Xa; GP = glycoprotein; TxA2 = thromboxane A2; UFH = unfractionated heparin;
VKA = vitamin K antagonist.


<!-- PAGE 23 -->

### Page 23

............................................................
Recommended anticoagulant and antiplatelet drugs and their dosing (for use during and after NSTE-ACS) are summarized in Figure 6
and Table 8.
5.1.1 Antiplatelet drugs and pre-treatment
5.1.1.1 Antiplatelet drugs and dual antiplatelet therapy
Activation of blood platelets and the coagulation cascade play a key role in the initial phase and evolution of NSTE-ACS. Hence, sufficient platelet inhibition and (temporary) anticoagulation is essential in
NSTE-ACS patients, especially in those undergoing myocardial revascularization by PCI. Aspirin is considered to be the cornerstone of treatment for inhibition of thromboxane A2 generation (Figure 6),
which is normally complete with a dose >_75 mg/d. Aspirin treatment is started with a loading dose (LD) followed by maintenance treatment (Table 8). Current evidence supports a maintenance dose (MD)
of 75100 mg once daily (o.d.).169 Based on the results of the phase
III PLATelet inhibition and patient Outcomes (PLATO) and TRial to
Assess Improvement in Therapeutic Outcomes by Optimizing
Platelet InhibitioN with PrasugrelThrombolysis In Myocardial
Infarction 38 (TRITON-TIMI 38) trials,170,171 DAPT including aspirin and a potent P2Y12 receptor inhibitor (ticagrelor or prasugrel) is the recommended standard treatment for
NSTE-ACS
patients.
Clopidogrel, characterized by less potent and variable platelet inhibition,172,173 should only be used when prasugrel or ticagrelor are contraindicated, not available, or cannot be tolerated due to an unacceptable HBR. P2Y12 receptor inhibitors differ with respect to their pharmacokinetic and pharmacodynamic properties. Table 9
summarizes the essential features of the available oral and intravenous (i.v.) drugs. For further details on recent DAPT trials, please refer to the 2017 ESC focused update on DAPT in CAD.169
Trial data on the head-to-head comparison of prasugrel vs. ticagrelor became available with the open-label randomized Intracoronary stenting and Antithrombotic regimenRapid Early Action for
Coronary Treatment (ISAR-REACT) 5 trial.174 This study was conducted in 4018 ACS patients (NSTE-ACS and STEMI) for whom an invasive evaluation was planned. The trial demonstrated that treatment with prasugrel vs. ticagrelor significantly reduced the composite rate of death, MI, or stroke (6.9 vs. 9.3%, P=0.006) without any increase in bleeding complications (4.8 vs. 5.4%, P=0.46). Limitations
Table 8
Dose regimen of antiplatelet and anticoagulant drugs in non-ST-segment elevation acute coronary syndrome patientsa
I. Antiplatelet drugs
Aspirin
LD of 150300 mg orally or 75250 mg i.v. if oral ingestion is not possible, followed by oral MD of 75100 mg o.d.
P2Y12 receptor inhibitors (oral or i.v.)
Clopidogrel
LD of 300600 mg orally, followed by a MD of 75 mg o.d., no speciﬁc dose adjustment in CKD patients.
Prasugrel
LD of 60 mg orally, followed by a MD of 10 mg o.d. In patients with body weight <60 kg, a MD of 5 mg o.d. is recommended.
In patients aged >_75 years, prasugrel should be used with caution, but a dose of 5 mg o.d. should be used if treatment is deemed necessary. No speciﬁc dose adjustment in CKD patients. Prior stroke is a contraindication for prasugrel.
Ticagrelor
LD of 180 mg orally, followed by a MD of 90 mg b.i.d., no speciﬁc dose adjustment in CKD patients.
Cangrelor
Bolus of 30 mg/kg i.v. followed by 4 mg/kg/min infusion for at least 2 h or the duration of the procedure (whichever is longer).
GP IIb/IIIa receptor inhibitors (i.v.)
Abciximab
Bolus of 0.25 mg/kg i.v. and 0.125 lg/kg/min infusion (maximum 10 lg/min) for 12 h (drug is not supplied anymore).
Eptiﬁbatide
Double bolus of 180 lg/kg i.v. (given at a 10-min interval) followed by an infusion of 2.0 lg/kg/min for up to18 h.
Tiroﬁban
Bolus of 25 lg/kg i.v. over 3 min, followed by an infusion of 0.15 lg/kg/min for up to 18 h.
II. Anticoagulant drugs (for use before and during PCI)
UFH
70100 U/kg i.v. bolus when no GP IIb/IIIa inhibitor is planned followed up by an IV infusion until the invasive procedure. 5070 U/kg i.v. bolus with GP IIb/IIIa inhibitors.
Enoxaparin
0.5 mg/kg i.v. bolus.
Bivalirudin
0.75 mg/kg i.v. bolus followed by i.v. infusion of 1.75 mg/kg/h for up to 4 h after the procedure as clinically warranted.
Fondaparinux
2.5 mg/d subcutaneously (only before PCI).
III. Oral anticoagulant drugsb
Rivaroxaban
Very low MD of 2.5 mg b.i.d. (in combination with aspirin) for long-term extended antithrombotic treatment in a secondary prevention setting of CAD patients.
AF = atrial ﬁbrillation; b.i.d. = bis in die (twice a day); CAD = coronary artery disease; CKD = chronic kidney disease; GP = glycoprotein; i.v. = intravenous; MD = maintenance dose; LD = loading dose; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation/anticoagulant; o.d. = once daily; PCI = percutaneous coronary intervention; UFH = unfractionated heparin; VKA = vitamin K antagonist.
aAll dosing regimens refer to doses given for the respective drugs for protection against thrombosis within the arterial system.
bSection III lists the dosing for rivaroxaban in a secondary prevention setting in CAD patients. For a comprehensive summary on dosing of OACs (NOACs and VKAs) in a setting of full-dose anticoagulation please see: The 2018 European Heart Rhythm Association Practical Guide on the use of NOACs in patients with AF.168
ESC Guidelines
1311


<!-- PAGE 24 -->

### Page 24

........................................................................................
of the study, amongst multiple others, include its open-label design and the limited data on medically managed or CABG-treated patients, which were more prominent in the PLATO trial.170
Ticagrelor also led to more patients stopping medication because of side effects. The actual treatment strategy was PCI in >80% of randomized patients and, consequently, prasugrel should be considered the preferred P2Y12 receptor inhibitor for NSTE-ACS patients who proceed to PCI. The possible benefit of prasugrel, in comparison with ticagrelor or clopidogrel, may be related to improved endothelial function.175 Recommended treatment algorithms and treatment durations, as well as options for extended treatment (>12 months) in
NSTE-ACS patients, are shown in Figure 7.
5.1.1.2 Pre-treatment
Pre-treatment defines a strategy according to which antiplatelet drugs, usually a P2Y12 receptor inhibitor, are given before coronary angiography and when the coronary anatomy is unknown.176
Although a rationale for pre-treatment in NSTE-ACS may seem obvious, for achieving sufficient platelet inhibition at the time of
PCI, large-scale randomized trials supporting a routine pretreatment strategy with either clopidogrel or the potent P2Y12
receptor inhibitors  prasugrel and ticagrelor  are lacking. The randomized Comparison of Prasugrel at the Time of Percutaneous
Coronary Intervention or as Pretreatment at the Time of
Diagnosis in Patients with Non-ST Elevation Myocardial Infarction
(ACCOAST) trial177 demonstrated a lack of any ischaemic benefit for pre-treatment in NSTE-ACS patients, but instead, a substantially higher bleeding risk with prasugrel pre-treatment. In line with these results, observational data on pre-treatment with ticagrelor,
prasugrel, and clopidogrel were reported from the Swedish
Coronary Angiography and Angioplasty Registry (SCAAR) in 64
857 NSTE-ACS patients.178 In this large dataset on pre-treatment,
the authors reported that P2Y12 receptor inhibitor pre-treatment in NSTE-ACS patients was not associated with improved ischaemic outcomes, but instead, with a significantly increased risk of bleeding events. With respect to pre-treatment data for ticagrelor,
the recently published ISAR-REACT 5 trial showed that a prasugrel-based strategy with deferred loading after knowledge of coronary anatomy in NSTE-ACS patients was superior to a ticagrelor-based strategy that implied a routine pre-treatment strategy.174 Importantly, there was no apparent benefit of a pretreatment strategy (that utilized ticagrelor) in that study.
Based upon the available evidence,174,177 it is not recommended to administer routine pre-treatment with a P2Y12 receptor inhibitor in
NSTE-ACS patients in whom coronary anatomy is not known and an early invasive management is planned. For patients with a delayed invasive management, pre-treatment with a P2Y12 receptor inhibitor may be considered in selected cases and according to the bleeding risk of the patient.
Fortunately, the recommended standard treatment with potent
P2Y12 receptor inhibitors (ticagrelor or prasugrel) exhibits a fast onset of action (Table 9), thereby allowing LD administration after diagnostic coronary angiography and directly before PCI. Of note, a routine pre-treatment strategy may be deleterious for a relevant proportion of patients with diagnoses other than NSTE-ACS (e.g. aortic dissection or bleeding complications including intracranial bleeding)
and may increase bleeding risk or delay procedures in patients scheduled for CABG after diagnostic angiography.
Table 9
P2Y12 receptor inhibitors for use in non-ST-segment elevation acute coronary syndrome patients
Oral administration i.v. administration
Clopidogrel
Prasugrel
Ticagrelor
Cangrelor
Drug class
Thienopyridine
Thienopyridine
Cyclopentyl-triazolopyrimidine
Adenosine triphosphate analogue
Reversibility
Irreversible
Irreversible
Reversible
Reversible
Bioactivation
Yes (pro-drug, CYP
dependent, 2 steps)
Yes (pro-drug, CYP
dependent, 1 step)
Noa
No
(Pretreatment)-Dose
600 mg LD, 75 mg MD
60 mg LD, 10 (5) mg MD
180 mg LD, 2  90 (60) mg MD
30 mg/kg i.v. bolus, 4 mg/kg/min i.v.
infusion for PCI
Onset of effect
Delayed: 26 h
Rapid: 0.54 h
Rapid: 0.52 h
Immediate: 2 min
Offset of effect
310 days
510 days
34 days
3060 min
Delay to surgery
5 days
7 days
5 days
No signiﬁcant delay
Kidney failure
No dose adjustment
No dose adjustment
No dose adjustment
No dose adjustment
Dialysis or CrCl
<15 mL/min
Limited data
Limited data
Limited data
Limited data
CrCl = creatine clearance; CYP = cytochrome P450; i.v. = intravenous; LD = loading dose, MD = maintenance dose, PCI = percutaneous coronary intervention.
aFollowing intestinal absorption, ticagrelor does not need to be metabolized to inhibit platelets. Of note, a metabolite (AR-C124910XX) of ticagrelor is also active.


<!-- PAGE 25 -->

### Page 25

©ESC 2020
Figure 7 Algorithm for antithrombotic therapy in non-ST-segment elevation acute coronary syndrome patients without atrial fibrillation undergoing percutaneous coronary intervention. HBR is considered as an increased risk of spontaneous bleeding during DAPT (e.g. PRECISE-DAPT score >_25 or
ARC-HBR158). Colour-coding refers to the ESC classes of recommendations (green = class I; yellow = IIa; orange = Class IIb). Very HBR is defined as recent bleeding in the past month and/or not deferrable planned surgery. A = aspirin; ARC-HBR = Academic Research Consortium  High Bleeding Risk;
C = clopidogrel; DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy (here: aspirin þ rivaroxaban); eGFR = estimated glomerular filtration rate; ESC = European Society of Cardiology; HBR = high bleeding risk; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; P = prasugrel; PCI = percutaneous coronary intervention; PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy; R = rivaroxaban; T = ticagrelor; UFH = unfractionated heparin. aClopidogrel during 12 months DAPT if patient is not eligible for treatment with prasugrel or ticagrelor or in a setting of DAPT de-escalation with a switch to clopidogrel (class IIb). bClopidogrel or prasugrel if patient is not eligible for treatment with ticagrelor. cClass IIa indication for DAT or DAPT >12 months in patients at high risk for ischaemic events (see
Table 11 for definitions) and without increased risk of major bleeding (= prior history of intracranial haemorrhage or ischaemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible gastrointestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, renal failure requiring dialysis, or with eGFR <15
mL/min/1.73 m2); Class IIb indication for DAT or DAPT >12 months in patients with moderately increased risk of ischaemic events (see Table 11 for definitions)
and without increased risk of major bleeding. Listen to the audio guide of this figure online.
ESC Guidelines
1313


<!-- PAGE 26 -->

### Page 26

....................................
5.1.2 Peri-interventional anticoagulant treatment
Peri-interventional treatment for NSTE-ACS patients consists of anticoagulation to inhibit thrombin generation and thrombin activity
(Figure 6). Anticoagulation is recommended for all patients in addition to antiplatelet therapy during invasive management for NSTEACS.192 Table 8 provides an overview of the relevant drugs and their dosing in NSTE-ACS patients. Unfractionated heparin (UFH) is the standard of care for NSTE-ACS patients due to its favourable riskbenefit profile. In general, a crossover between anticoagulants should be avoided [especially between UFH and low-molecular-weight heparin (LMWH)], with the exception of adding UFH to fondaparinux when a patient proceeds to PCI after fondaparinux treatment.196,199
The respective drugs should be discontinued immediately after PCI,
except in specific clinical settings such as the confirmed presence of
LV aneurysm with thrombus formation or AF requiring anticoagulation, which is usually done with UFH in (per)-acute settings.
Adjunctive treatment [e.g. glycoprotein (GP) IIb/IIIa inhibitors] and procedural aspects (radial vs. femoral access) have been subject to change in recent years. In contrast to older studies, recent and contemporary trials have pursued a balanced and more selective use of
GP IIb/IIIa inhibitors, with both bivalirudin and UFH. These trials have been reviewed extensively in a number of meta-analyses.200203 A
recent meta-analysis, which included the Minimizing Adverse
Haemorrhagic Events by TRansradial Access Site and Systemic
Recommendations for antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients without atrial ﬁbrillation undergoing percutaneous coronary intervention
Recommendations
Classa
Levelb
Antiplatelet treatment
Aspirin is recommended for all patients without contraindications at an initial oral LD of 150300 mg (or 75250 mg i.v.), and at a
MD of 75100 mg o.d. for long-term treatment.179181
I
A
A P2Y12 receptor inhibitor is recommended in addition to aspirin, and maintained over 12 months unless there are contraindications or an excessive risk of bleeding.170,171,182
Options are:
I
A
 Prasugrel in P2Y12 receptor inhibitor-naı¨ve patients proceeding to PCI (60 mg LD, 10 mg/d as standard dose, 5 mg/d for patients aged >_75 years or with a body weight <60 kg).171
I
B
 Ticagrelor irrespective of the planned treatment strategy (invasive or conservative) (180 mg LD, 90 mg b.i.d.).170
I
B
 Clopidogrel (300600 mg LD, 75 mg daily dose), only when prasugrel or ticagrelor are not available, cannot be tolerated, or are contraindicated.182,183
I
C
Prasugrel should be considered in preference to ticagrelor for NSTE-ACS patients who proceed to PCI.174
IIa
B
GP IIb/IIIa antagonists should be considered for bail-out if there is evidence of no-reﬂow or a thrombotic complication.
IIa
C
Cangrelor may be considered in P2Y12 receptor inhibitor-naı¨ve patients undergoing PCI.184187
IIb
A
Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients with NSTE-ACS who are not planned to undergo an early invasive strategy and do not have an HBR.
IIb
C
Treatment with GP IIb/IIIa antagonists in patients in whom coronary anatomy is not known is not recommended.188,189
III
A
It is not recommended to administer routine pre-treatment with a P2Y12 receptor inhibitor in patients in whom coronary anatomy is not known and an early invasive management is planned.174,177,178,190,191
III
A
Peri-interventional anticoagulant treatment
Parenteral anticoagulation is recommended for all patients, in addition to antiplatelet treatment, at the time of diagnosis and, especially, during revascularization procedures according to both ischaemic and bleeding risks.192,193
I
A
UFH (weight-adjusted i.v. bolus during PCI of 70100 IU/kg, or 5070 IU/kg in combination with a GP IIb/IIIa inhibitor; activated clotting time target range of 250350 s, or 200250 s if a GP IIb/IIIa inhibitor is given) is recommended in patients undergoing PCI.
I
A
In cases of medical treatment or logistical constraints for transferring the patient to PCI within the required time frame, fondaparinux is recommended and, in such cases, a single bolus of UFH is recommended at the time of PCI.183
I
B
It is recommended to select anticoagulation according to both ischaemic and bleeding risks, and according to the efﬁcacysafety proﬁle of the chosen agent.
I
C
Enoxaparin (i.v.) should be considered in patients pre-treated with subcutaneous enoxaparin.194196
IIa
B
Discontinuation of parenteral anticoagulation should be considered immediately after an invasive procedure.
IIa
C
Bivalirudin may be considered as an alternative to UFH.189,197,198
IIb
A
Crossover of UFH and LMWH is not recommended.196
III
B
b.i.d. = bis in die (twice a day); GP = glycoprotein; HBR = high bleeding risk; i.v. = intravenous; LD = loading dose; LMWH = low-molecular-weight heparin; MD = maintenance dose; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; o.d. = once daily; PCI = percutaneous coronary intervention; UFH = unfractionated heparin.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 27 -->

### Page 27

.............................................................................................................................................................................
Implementation of angioX (MATRIX) trial,197 showed no significant benefit of bivalirudin vs. UFH for ischaemic outcomes.202 Bivalirudin was associated with a significant increase in the risk of stent thrombosis and a significant decrease in bleeding risk. Bleeding risk reduction was linked to unbalanced use of GP IIb/IIIa inhibitors, predominantly with UFH. Recently, the Swedish Web-system for Enhancement and
Development of Evidence-based care in Heart disease Evaluated
According to
Recommended
Therapies
(VALIDATESWEDEHEART) study204 compared UFH vs. bivalirudin on a background of radial access and limited use of GP IIb/IIIa inhibitors. The study demonstrated similar risks for both ischaemia and bleeding when comparing the two drugs. Another meta-analysis, updated with the results of the VALIDATE-SWEDEHEART study, confirmed that bivalirudin vs. UFH was associated with a similar incidence of allcause death and ischaemic events after PCI in ACS.203 A significant association between bivalirudin and decreased risk of bleeding was only found with unbalanced use of GP IIb/IIIa inhibitors in conjunction with UFH.
In summary, and based on the aforementioned trials, UFH is primarily recommended as an anticoagulant for PCI. Due to its short half-life and favourable results in some of the studies, bivalirudin may be considered as an alternative to UFH in selected cases. For a more detailed description and a historical summary of the older clinical trials (with unbalanced use of GP IIb/IIIa inhibitors) comparing UFH
with bivalirudin, please refer to the 2018 ESC/EACTS Guidelines on myocardial revascularization.205
Patients may undergo cardiac catheterization after a conservative treatment phase and these patients might be treated with fondaparinux during this period. This regimen is based on the Fifth
Organization to Assess Strategies in Acute Ischemic Syndromes
(OASIS-5) trial.206 Of note, catheter thrombus formation was an issue with fondaparinux and, therefore, full-dose UFH must be added to prevent thrombus formation when the patient proceeds to PCI.
Enoxaparin, a LMWH with a predictable dose-effect relationship and a lower risk for heparin-induced thrombocytopenia (HIT) compared to UFH, should be considered as an anticoagulant for PCI in patients pre-treated with subcutaneous enoxaparin. A benefit of enoxaparin over UFH reduced mortality and bleeding complications  was reported in a meta-analysis that included NSTE-ACS
patients,194 but dedicated large-scale trials comparing enoxaparin vs.
UFH in NSTE-ACS are lacking.
5.1.3 Peri-interventional antiplatelet treatment
Drugs for peri-interventional i.v. antiplatelet treatment include cangrelor and GP IIb/IIIa inhibitors (abciximab, eptifibatide, and tirofiban).
Most of the trials evaluating GP IIb/IIIa inhibitors in PCI-treated ACS
patients predated the era of routine DAPT with early DAPT initiation including a P2Y12 receptor inhibitor LD.205,207 Today, with routine and potent oral P2Y12 receptor inhibitors, there is no compelling evidence for an additional benefit of routine upstream use of GP IIb/IIIa inhibitors in NSTE-ACS patients scheduled for coronary angiography.188,189 Even more so, in a setting of potent platelet inhibition with ticagrelor or prasugrel, where randomized data on GP IIb/IIIa use is limited, routine use of these agents cannot be recommended.
Nevertheless, use should be considered for bail-out situations or thrombotic complications and may be considered for high-risk PCI in patients without pre-treatment with P2Y12 receptor inhibitors (see
2018 ESC/EACTS Guidelines on myocardial revascularization for more details).205
Cangrelor is a direct reversible, short-acting P2Y12 receptor inhibitor that has been evaluated during PCI for stable CCS and ACS in clinical trials comparing cangrelor with clopidogrel, administered before PCI [Cangrelor versus Standard Therapy to Achieve Optimal
Management of Platelet Inhibition (CHAMPION)] or after PCI
(CHAMPION PLATFORM and CHAMPION PHOENIX).185187 A
meta-analysis of these trials showed a benefit with respect to major ischaemic endpoints that was counter-balanced by an increase in minor bleeding complications.184 Moreover, the benefit of cangrelor with respect to ischaemic endpoints was attenuated in CHAMPION
PCI with upfront administration of clopidogrel, while data for its use in conjunction with ticagrelor or prasugrel treatment are limited.
Due to its proven efficacy in preventing intra-procedural and postprocedural stent thrombosis in P2Y12 receptor inhibitor-naı¨ve patients, cangrelor may be considered on a case-by-case basis in
P2Y12 receptor inhibitor-naı¨ve NSTE-ACS patients undergoing PCI
(see 2018 ESC/EACTS Guidelines on myocardial revascularization for more details).205
5.1.4 Post-interventional and maintenance treatment
Following PCI for NSTE-ACS, DAPT consisting of a potent P2Y12
receptor inhibitor in addition to aspirin is generally recommended for 12 months, irrespective of the stent type, unless there are contraindications.170,171,182 In specific clinical scenarios, DAPT duration can be shortened (<12 months), extended (>12 months, see Figure 7 and
Tables 10 and 11), or modified (switching DAPT, DAPT deescalation) and these decisions depend on individual clinical judgement being driven by the patient’s ischaemic and bleeding risk, the occurrence of adverse events, comorbidities, co-medications, and the availability of the respective drugs. For a detailed description of the pertinent and numerous trials that have compared different
DAPT treatment durations (especially 36 vs. 12 months in NSTEACS patients), please refer to the 2017 ESC focused update on
DAPT in CAD169 and recent trial publications.208,209 In patients with
NSTE-ACS and stent implantation who are at high risk of bleeding
(e.g. PRECISE-DAPT >_25 or ARC-HBR criteria met), discontinuation of P2Y12 receptor inhibitor therapy after 36 months should be considered.154 In patients at very high risk of bleeding, defined as a recent bleeding episode in the past month or planned, not deferrable surgery in the near future, 1 month of aspirin and clopidogrel should be considered.
Four recent trials (n = 29 089) have explored the benefit of a shortened DAPT duration of 13 months.208211 Low-to-intermediate ischaemic risk and low bleeding risk patients were included and early monotherapy with clopidogrel/ticagrelor was used. All bleeding events were reduced, with a favourable trend towards less ischaemic events including MI. Importantly, more than 50% had ACS
as an inclusion criterion. In particular, the Ticagrelor With Aspirin or
Alone in
High-Risk
Patients
After
Coronary
Intervention
(TWILIGHT) trial211 examined the effect of ticagrelor alone vs. ticagrelor plus aspirin with regard to clinically relevant bleeding among patients at high risk for bleeding or ischaemic events who had undergone PCI, according to the inclusion criteria. However, these patients
ESC Guidelines
1315


<!-- PAGE 28 -->

### Page 28

...........................
were not at HBR according to current HBR criteria and event rates at follow-up. Based on this, these patients were more a low bleeding and ischaemic risk cohort even though more than two thirds had an
ACS. After 3 months of treatment with ticagrelor plus aspirin,
patients who did not have a major bleeding or ischaemic event continued to take ticagrelor and were randomly assigned to receive aspirin or placebo for 1 year. The primary endpoint of Bleeding
Academic Research Consortium (BARC) type 2, 3, or 5 bleeding was significantly reduced by omitting aspirin (4.0 vs. 7.1%; HR 0.56, 95%
CI 0.450.68, P<0.001), with a significant interaction according to
ACS at presentation. The trial was not powered for the composite endpoint of death from any cause, non-fatal MI, or non-fatal stroke.
However, in exploratory non-inferiority hypothesis testing, there was no signal of increased ischaemic risk.211 It should be acknowledged that the actual ischaemic event rate in TWILIGHT was low compared to other trials for deemed high-risk PCI patients.
Contrary to this, and based on the results of the DAPT and
Prevention of Cardiovascular Events in Patients With Prior Heart
Table 10
Treatment options for extended dual antithrombotic or antiplatelet therapies
Drug
Dose
Indication
NNT
(ischaemic outcomes)
NNH
(bleeding outcomes)
DAT regimens for extended treatment (including aspirin 75100 mg o.d.)
Rivaroxaban (COMPASS trial)
2.5 mg b.i.d.
Patients with CAD or symptomatic
PAD at high risk of ischaemic events
77
84
DAPT regimens for extended treatment (including aspirin 75100 mg o.d.)
Clopidogrel (DAPT trial)
75 mg/d
Post MI in patients who have tolerated DAPT for 1 year
63
105
Prasugrel (DAPT trial)
10 mg/d (5 mg/d if body weight
<60 kg or age >75 years)
Post PCI for MI in patients who have tolerated DAPT for 1 year
63
105
Ticagrelor (PEGASUS-TIMI 54)
60/90 mg b.i.d.
Post MI in patients who have tolerated DAPT for 1 year
84
81
Drugs (in addition to aspirin 75100 mg/d) for extended DAPT treatment options are in alphabetical order. For indications and deﬁnitions for high/moderately increased risk and bleeding risk see Table 9 and Figure 7. NNT refers to the primary ischaemic endpoints of the respective trials and NNH refers to the key safety (bleeding) endpoints. NNT
and NNH numbers from the DAPT trial are pooled numbers for clopidogrel and prasugrel.
b.i.d. = bis in die (twice a day); CAD = coronary artery disease; COMPASS = Cardiovascular OutcoMes for People using Anticoagulation StrategieS; DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy; MI = myocardial infarction; NNH = number needed to harm; NNT = number needed to treat; o.d. = once daily; PAD = peripheral artery disease; PCI = percutaneous coronary intervention; PEGASUS-TIMI 54 = Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54.
Table 11
Risk criteria for extended treatment with a second antithrombotic agent
High thrombotic risk (Class IIa)
Moderate thrombotic risk (Class IIb)
Complex CAD and at least 1 criterion
Non-complex CAD and at least 1 criterion
Risk enhancers
Diabetes mellitus requiring medication
Diabetes mellitus requiring medication
History of recurrent MI
History of recurrent MI
Any multivessel CAD
Polyvascular disease (CAD plus PAD)
Polyvascular disease (CAD plus PAD)
CKD with eGFR 1559 mL/min/1.73 m2
Premature (<45 years) or accelerated (new lesion within a 2-year time frame) CAD
Concomitant systemic inﬂammatory disease (e.g. human immunodeﬁciency virus,
systemic lupus erythematosus, chronic arthritis)
CKD with eGFR 1559 mL/min/1.73 m2
Technical aspects
At least 3 stents implanted
At least 3 lesions treated
Total stent length >60 mm
History of complex revascularization (left main, bifurcation stenting with >_2 stents implanted, chronic total occlusion, stenting of last patent vessel)
History of stent thrombosis on antiplatelet treatment
In line with guideline recommendations, CAD patients are stratiﬁed into two different risk groups (high vs. moderately increased thrombotic or ischaemic risk). Stratiﬁcation of patients towards complex vs. non-complex CAD is based on individual clinical judgement with knowledge of patients’ cardiovascular history and/or coronary anatomy.
Selection and composition of risk-enhancing factors are based on the combined evidence of clinical trials on extended antithrombotic treatment in CAD patients162,212,214 and on data from related registries.228230
CAD = coronary artery disease; CKD = chronic kidney disease; eGFR = estimated glomerular ﬁltration rate; MI = myocardial infarction; PAD = peripheral artery disease.


<!-- PAGE 29 -->

### Page 29

Attack Using Ticagrelor Compared to Placebo on a Background of
Aspirin-Thrombolysis in Myocardial Infarction (PEGASUS-TIMI)
54 trials, in patients with ACS who have tolerated DAPT without a bleeding complication, a prolonged DAPT course >12 months should be considered in those with high thrombotic risk and without an increased risk for major or life-threatening bleeding, and may be considered in patients with moderately elevated thrombotic risk (see Figure 7 and Tables 10 and 11).212,213 Of note, the
60 mg bis in die [b.i.d. (twice a day)] dose for ticagrelor was better tolerated than the 90 mg b.i.d dose214,215 and this dose is now approved in many (albeit not all) countries for this indication.
Switching between oral P2Y12 receptor inhibitors is common and triggers may include bleeding complications (or concerns for bleeding), non-bleeding side effects (e.g. dyspnoea on ticagrelor, allergic reactions), as well as socio-economic factors.216,217 Switching between oral P2Y12 receptor inhibitors may be considered in selected cases, and for a more detailed description on switching antiplatelet drugs, please refer to the International Expert Consensus on
Switching Platelet P2Y12 Receptor-Inhibiting Therapies217 and the
2017 ESC DAPT focused update.169
DAPT de-escalation (switch from potent drugs like prasugrel or ticagrelor to clopidogrel) in NSTE-ACS patients may be considered as an alternative treatment regimen.216,217 However, it is important to note that there is a potential for increased ischaemic risk with a uniform de-escalation of P2Y12 receptor inhibiting therapy after PCI, particularly if performed early (<30 days) after the index event. Indeed, dedicated large-scale trials on a uniform and unguided DAPT de-escalation are lacking and the available data on uniform de-escalation are conflicting.218,219 Based on the results of the Testing Responsiveness to Platelet Inhibition on Chronic
Antiplatelet
Treatment for
Acute
Coronary
Syndromes
(TROPICAL-ACS)
and
POPULAR
Genetics trials,220,221
an approach of DAPT de-escalation guided by either platelet function testing
(TROPICAL-ACS:
NSTE-ACS
and
STEMI
patients)
or CYP2C19-directed genotyping (POPULAR Genetics: STEMI
patients) may be considered in selected NSTE-ACS patients as an alternative to 12 months of potent platelet inhibition,
especially for patients deemed unsuitable for maintained potent platelet inhibition. For further details, please refer to the updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in
PCI.222
Recently, data on a novel strategy of dual antithrombotic therapy (DAT) consisting of factor-Xa inhibition with a very low dose of rivaroxaban (2.5 mg b.i.d.) plus aspirin has emerged, and such a regimen should be considered as a treatment option for maintenance treatment beyond 12 months post ACS PCI. In a secondary prevention setting, the Cardiovascular OutcoMes for People using
Anticoagulation StrategieS (COMPASS) trial162,223 investigated very low-dose rivaroxaban (2.5 mg b.i.d.) in combination with aspirin vs. aspirin alone or rivaroxaban 5 mg b.i.d. alone.
Rivaroxaban 2.5 mg b.i.d. plus aspirin 100 mg o.d. reduced the risk of the combined ischaemic endpoint, overall mortality (without reaching the threshold P-value according to the Hochberg procedure), and cardiovascular mortality alone, while this combination increased the risk for major bleeding complications without a
Recommendations for post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome
Recommendations
Classa
Levelb
In patients with NSTE-ACS treated with coronary stent implantation, DAPT with a P2Y12 receptor inhibitor on top of aspirin is recommended for 12
months unless there are contraindications such as excessive risk of bleeding.170,171,225
I
A
Prolonging antithrombotic treatment duration
Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention should be considered in patients with a high risk of ischaemic events and without increased risk of major or life-threatening bleeding (see
Tables 9 and 11 for options).162,212,213,214,223
IIa
A
Adding a second antithrombotic agent to aspirin for extended long-term secondary prevention may be considered in patients with moderately increased risk of ischaemic events and without increased risk of major or life-threatening bleeding
(see Tables 9 and 11 for options).162,212,213,214,223
IIb
A
In ACS patients with no prior stroke/transient ischaemic attack who are at high ischaemic risk and low bleeding risk and are receiving aspirin and clopidogrel, low-dose rivaroxaban (2.5 mg b.i.d. for approximately 1 year) may be considered after discontinuation of parenteral anticoagulation.224
IIb
B
Shortening antithrombotic treatment duration
After stent implantation with high risk of bleeding (e.g. PRECISE-DAPT >_25 or ARC-HBR criteria met), discontinuation of P2Y12 receptor inhibitor therapy after 3 months should be considered.154,226
IIa
B
After stent implantation in patients undergoing a strategy of DAPT, stopping aspirin after 36
months should be considered, depending on the balance between the ischaemic and bleeding risk.208,209,227
IIa
A
De-escalation of P2Y12 receptor inhibitor treatment (e.g. with a switch from prasugrel or ticagrelor to clopidogrel) may be considered as an alternative DAPT strategy, especially for ACS
patients deemed unsuitable for potent platelet inhibition. De-escalation may be done unguided based on clinical judgment or guided by platelet function testing or CYP2C19 genotyping,
depending on patient’s risk proﬁle and availability of respective assays.218,220,221
IIb
A
ACS = acute coronary syndromes; ARC-HBR = Academic Research Consortium
 High Bleeding Risk; b.i.d. = bis in die (twice a day); DAPT = dual antiplatelet therapy; NSTE-ACS = non-ST-segment elevation acute coronary syndrome;
PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing
Stent implantation and subsEquent Dual Anti Platelet Therapy.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
1317


<!-- PAGE 30 -->

### Page 30

......................................................................................................................................................................
significant increase in the risk of fatal, intracranial, or critical organ bleeding events. Greater absolute risk reductions were seen in high-risk patients, including those with diabetes or polyvascular disease [CAD plus peripheral artery disease (PAD)]. Thus, rivaroxaban (2.5 mg b.i.d.) should be considered, in addition to aspirin
75 - 100 mg/d in patients at high thrombotic risk and without an increased risk for major or life-threatening bleeding, and may be considered in patients with moderately elevated thrombotic risk
(see Figure 7 and Tables 10 and 11 for selection criteria and for ischaemic and bleeding risk definitions).
Rivaroxaban has also been studied in the Anti-Xa Therapy to
Lower Cardiovascular Events in Addition to Standard Therapy in
Subjects with Acute Coronary Syndrome 2Thrombolysis In
Myocardial Infarction 51 (ATLAS ACS 2TIMI 51) trial on a background of clopidogrel treatment. The study showed a reduction of ischaemic events and cardiovascular mortality along with a higher risk for bleeding.224 However, data are lacking on a background of ticagrelor or prasugrel treatment and it is therefore difficult to extrapolate trial results to contemporary practice including the use of potent
P2Y12 receptor inhibitors.
5.2 Pharmacological treatment of ischaemia (Supplementary Data)
5.2.1 Supportive pharmacological treatment
(Supplementary Data)
5.2.2 Nitrates and beta-blockers (Supplementary
Data)
5.3 Managing oral antiplatelet agents in patients requiring long-term oral anticoagulants
5.3.1 Patients with atrial fibrillation without mechanical prosthetic heart valves or moderate-to-severe mitral stenosis undergoing percutaneous coronary intervention or managed medically (Supplementary Data)
In 68% of patients undergoing PCI, long-term OAC is indicated and should also be continued during the procedure because its interruption and bridging with parenteral anticoagulants may lead to increased thromboembolic episodes and bleeds.232234 In patients undergoing PCI, it is unknown whether it is safe to bridge non-vitamin K antagonist (VKA) OACs (NOACs) with parenteral anticoagulants or continue NOACs without additional parenteral anticoagulation, while no parenteral anticoagulation is needed if the international normalized ratio (INR) is >2.5 in VKA-treated patients.235237 Strategies to minimize PCI-related complications in patients on OACs are listed in Table 12.
In NSTE-ACS patients, evidence on the management of patients undergoing PCI requiring long-term OAC is derived from subgroups of RCTs (see Table 13 and Supplementary Data section 5.3.1).238242
Overall, in patients with AF without mechanical prosthetic valves or moderate-to-severe mitral stenosis, the evidence supports the use of NOACs over VKA in terms of safety (i.e. lower bleeding risk).
DAT with a NOAC at the recommended dose for stroke prevention and single antiplatelet therapy (SAPT) (preferably clopidogrel, chosen in more than 90% of cases in available trials) is recommended as the default strategy up to 12 months after a short period (up to 1 week)
of triple antithrombotic therapy (TAT) (with NOAC and DAPT)
(Figure 8). Although none of the available RCTs were designed to detect subtle differences in ischaemic events, the numerically higher risk of stent thrombosis or MIs observed in some trials might have been offset by the higher risk of bleeding, resulting in a neutral effect on major adverse cardiovascular events (MACE) or overall death.243,244 At variance with the default strategy, in patients with
HBR, DAT should be shortened to 6 months by withdrawing the ongoing antiplatelet therapy; while in patients with high coronary ischaemic risk, TAT should be prolonged up to 1 month, followed by
DAT for up to 12 months. There is currently limited evidence to support the use of OACs with ticagrelor or prasugrel as dual therapy after PCI as an alternative to TAT.241,245 Following coronary stenting,
DAPT with aspirin and ticagrelor or prasugrel, without OAC, may be considered as an alternative to TAT in patients with high ischaemic risk NSTE-ACS and AF and one non-sex stroke risk factor within the first 4 weeks. Regarding the need to continue with any antiplatelet agent beyond 12 months, the AFIRE trial randomized 2236 AF
patients treated with PCI or CABG more than 1 year earlier or with documented CAD to receive either monotherapy with rivaroxaban or combination therapy with rivaroxaban plus a single antiplatelet agent.246 Rivaroxaban monotherapy (15 mg o.d. or 10 mg o.d. with creatinine clearance (CrCl) 1549 mL/min) was non-inferior to combination therapy for the primary efficacy composite endpoint of stroke, systemic embolism, MI, unstable angina requiring revascularization,
or overall death
(HR
0.72,
95%
CI
0.550.95).
Recommendations for anti-ischaemic drugs in the acute phase of non-ST-segment elevation acute coronary syndrome
Recommendations
Classa
Levelb
Sublingual or i.v. nitrates and early initiation of beta-blocker treatment are recommended in patients with ongoing ischaemic symptoms and without contraindications.
I
C
It is recommended to continue chronic betablocker therapy unless the patient is in overt heart failure.
I
C
i.v. nitrates are recommended in patients with uncontrolled hypertension or signs of heart failure.
I
C
In patients with suspected/conﬁrmed vasospastic angina, calcium channel blockers and nitrates should be considered and beta-blockers avoided.231
IIa
B
i.v. = intravenous.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 31 -->

### Page 31

Table 12
Suggested strategies to reduce bleeding risk related to percutaneous coronary intervention
• Anticoagulant doses adjusted to body weight and renal function, especially in women and older patients
• Radial artery approach as default vascular access
• Proton pump inhibitors in patients on DAPT at higher-than-average risk of gastrointestinal bleeds (i.e. history of gastrointestinal ulcer/haemorrhage, anticoagulant therapy, chronic non-steroidal anti-inﬂammatory drugs/corticosteroid use, or two or more of:
a.
Age >_65 years b.
Dyspepsia c.
Gastro-oesophageal reﬂux disease d.
Helicobacter pylori infection e.
Chronic alcohol use
• In patients on OAC
a.
PCI performed without interruption of VKAs or NOACs b.
In patients on VKAs, do not administer UFH if INR >2.5
c.
In patients on NOACs, regardless of the timing of the last administration of NOACs, add low-dose parenteral anticoagulation
(e.g. enoxaparin 0.5 mg/kg i.v. or UFH 60 IU/kg)
• Aspirin is indicated but avoid pre-treatment with P2Y12 receptor inhibitors
• GP IIb/IIIa inhibitors only for bailout or periprocedural complications
DAPT = dual antiplatelet therapy; GP = glycoprotein; INR = international normalized ratio; i.v. = intravenous; NOAC = non-vitamin K antagonist oral anticoagulant; OAC =
oral anticoagulation/anticoagulant; PCI = percutaneous coronary intervention; UFH = unfractionated heparin; VKA = vitamin K antagonist.
Table 13
Randomized controlled trials including patients with non-ST-segment elevation acute coronary syndrome requiring anticoagulation and antiplatelet therapy
RCT
n
Comparison
Primary Endpoint
Secondary endpoints
WOEST239
573
DAT (VKA þ C) for 12 months vs.
TAT (VKA þ A þ C) for
12 months
TIMI bleeding lower with DAT vs. TAT
at 1 year (HR 0.36, 95% CI 0.260.50)
MI þ stroke þ target vessel revascularization þ stent thrombosis: no difference.
All-cause mortality lower with DAT vs. TAT
at 1 year (HR 0.39, 95% CI 0.160.93)
ISAR-TRIPLE250
614
6 weeks TAT (VKA þ A þ C) followed by DAT (VKA þ A) vs.
6 months TAT (VKA þ A þ C)
Death þ MI þ stent thrombosis þ
stroke or TIMI major bleeds at
9 months: no difference
Cardiac death þ MIþ stent thrombosis
þ stroke: no difference. TIMI major bleeding: no difference
PIONEER
AF-PCI240
2124
DAT (rivaroxaban 15 mg/day þ C)
for 12 months) vs. modiﬁed TAT
(rivaroxaban 2.5 mg b.i.d. þ A þ C
for 1, 6, or 12 months) vs. TAT (VKA
þ A þ C for 1, 6, or 12 months)
Clinically signiﬁcant bleeding lower with DAT (HR 0.59, 95% CI
0.470.76) or modiﬁed TAT (HR 0.63,
95% CI 0.500.80) vs. TAT
Cardiovascular death þ MI þ stroke:
no difference. All-cause death þ rehospitalization lower with DAT (HR 0.79,
CI 0.690.94) or modiﬁed TAT (HR
0.75, CI 0.620.90) vs. TAT
RE-DUAL PCI238
2725
TAT (VKA þ A þ C) up to 3
months vs. DAT (dabigatran 110 or
150 mg b.i.d. þ C or T)
Major or clinically relevant non-major bleeding lower in DAT 110 mg (HR 0.52,
95% CI 0.420.63) or DAT 150 mg (HR
0.72, 95% CI 0.580.88) vs. TAT
MI þ stroke þ systemic embolism,
death, unplanned revascularization: no difference
AUGUSTUS241
4614
DAT1 (apixaban 5 mg b.i.d. þ C or T
or P) vs. DAT2 (VKA þ C or T or P)
vs. TAT1 (apixaban 5 mg b.i.d. þ A þ
C or T or P) vs. TAT2 (VKA þ A þ
C or T or P)
Major or clinically relevant non-major bleeds lower with DAT1 (HR 0.69,
95% CI 0.580.81) vs. other regimens
Death þ hospitalization lower with apixaban (HR 0.83, 95% CI 0.740.93)
No difference with aspirin
ENTRUSTAF PCI251
1506
DAT (edoxaban 60 mg þ C or T or
P) vs. TAT (VKA þ A þ C or T or
P)
Major or clinically relevant non-major bleeds non-inferior between DAT or
TAT (HR 0.83, 95% CI 0.651.05,
P=0.0010 for non-inferiority)
Cardiovascular death þ stroke þ systemic embolism þ MI þ stent thrombosis not different between DAT and
TAT
A = aspirin; AF = atrial ﬁbrillation; AUGUSTUS = Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation; b.i.d. = bis in die (twice a day); C = clopidogrel; CI = conﬁdence interval; DAT = dual antithrombotic therapy; ENTRUST-AF PCI = EdoxabaN TRreatment versUS VKA in paTients with AF undergoing PCI; HR =
hazard ratio; ISAR-TRIPLE = Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation; MI = myocardial infarction; OAC = oral anticoagulation/
anticoagulant; P = prasugrel; PIONEER AF-PCI = Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a DoseAdjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects with Atrial Fibrillation who Undergo Percutaneous Coronary Intervention; RCT = randomized controlled trial; RE-DUAL PCI = Randomized Evaluation of Dual Antithrombotic Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with Nonvalvular Atrial
Fibrillation Undergoing Percutaneous Coronary Intervention; T = ticagrelor; TAT = triple antithrombotic therapy; TIMI = Thrombolysis In Myocardial Infarction; VKA = vitamin
K antagonist; WOEST = What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing.
ESC Guidelines
1319


<!-- PAGE 32 -->

### Page 32

......................................................
Rivaroxaban monotherapy was superior for the primary safety endpoint of major bleeding (HR 0.59, 95% CI 0.390.89).
In NSTE-ACS patients managed medically, available data support
DAT over TAT, with a single antiplatelet agent (most commonly clopidogrel) for at least 6 months.247 In a registry, bleeding risk was increased on TAT compared to VKA plus a single antiplatelet agent at 90 days, but not at 1 year, without differences in ischaemic events.248 In addition, warfarin plus clopidogrel resulted in a nonsignificant reduction in major bleeds compared with TAT, with a non-significant reduction in MI or cardiovascular death.249 In the randomized
Antithrombotic
Therapy after
Acute
Coronary
Syndrome or PCI in Atrial Fibrillation (AUGUSTUS) trial,241 approximately 23% of enrolled patients presented with medically managed
ACS. In these patients, apixaban significantly reduced bleeding events vs. VKA (HR 0.44, 95% CI 0.280.68) and death or hospitalization
(HR 0.71, 95% CI 0.540.92), while no significant differences were observed in death or ischaemic events (HR 0.71, 95% CI
0.461.09]). Aspirin vs. placebo presented a strong trend towards higher bleeding events (HR 1.49, 95% CI 0.982.26), but no significant differences in death or hospitalization (HR 1.16, 95% CI
0.901.51) or ischaemic events (HR 1.01, 95% CI 0.661.55).
5.3.2 Patients requiring vitamin K antagonists or undergoing coronary artery bypass surgery
In patients where VKA is mandated (e.g. patients with mechanical prosthetic valves), DAT with VKA and SAPT (preferably clopidogrel)
is indicated after a short in-hospital period of TAT (with aspirin and clopidogrel).239 Compared with TAT (consisting of VKA plus aspirin and clopidogrel), DAT (VKA plus clopidogrel) was associated with a trend towards a reduction in Thrombolysis In Myocardial Infarction
(TIMI) major bleeding (OR 0.58, 95% CI 0.311.08) in a network meta-analysis, while no significant difference was observed in MACE
(OR 0.96, 95% CI 0.601.46).243
CABG in fully anticoagulated patients is associated with an increased bleeding risk, thus interruption of VKA prior to CABG is recommended in non-emergent cases. In emergency surgery, a
©ESC 2020
Figure 8 Algorithm for antithrombotic therapy in non-ST-segment elevation acute coronary syndrome patients with atrial fibrillation undergoing percutaneous coronary intervention or medical management. Green (class I) and yellow (class IIa) colours denote the classes of recommendation. OAC: preference for a NOAC over VKA for the default strategy and in all other scenarios if no contraindications. For both TAT and DAT regimens, the recommended doses for the NOACs are as follows:
1) Apixaban 5 mg b.i.d.241
2) Dabigatran 110 mg or 150 mg b.i.d.238
3) Edoxaban 60 mg/d
4) Rivaroxaban 15 mg or 20 mg/d240
NOAC dose reductions are recommended in patients with renal failure and may be considered in patients with ARC-HBR (see Table 7).158 SAPT: preference for a P2Y12 receptor inhibitor over aspirin. Ticagrelor may be considered in patients with high ischaemic risk and low bleeding risk. Treatment >1
month: OAC þ DAPT (TAT) may be considered for up to 6 months in selected patients with high ischaemic risk (IIa C). Treatment >12 months: OAC þ
SAPT may be considered in selected patients with high ischaemic risk. ARC-HBR = see Table 7 and in addition with a PRECISE-DAPT score of >_25. High thrombotic or ischaemic risk is defined in Table 11. AF = atrial fibrillation; ARC-HBR = Academic Research Consortium  High Bleeding Risk; b.i.d. = bis in die (twice a day); DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy; NOAC = non-vitamin K antagonist oral anticoagulant; NSTEACS = non-ST-segment elevation acute coronary syndrome; OAC = oral anticoagulation/anticoagulant; PCI = percutaneous coronary intervention;
PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy; SAPT = single antiplatelet therapy; TAT = triple antithrombotic therapy; VKA = vitamin K antagonist. Listen to the audio guide of this figure online.


<!-- PAGE 33 -->

### Page 33

......................
combination of prothrombin complex concentrate of four inactivated factors (25 IU/kg) and oral vitamin K is required to obtain fast and sustained restoration of haemostasis at the time of surgery.252
While experience with urgent major surgery in patients treated with
NOACs is limited, it has been suggested to use prothrombin complex concentrate of activated factors to restore haemostasis.253
Reversal agents might represent an additional option in these patients.254 In the setting of planned CABG, a 48-h interruption of
NOACs is recommended (a longer period might be necessary in patients with impaired renal function). In ACS patients with an established indication for OAC, anticoagulation should be resumed after
CABG as soon as the bleeding is controlled, possibly with a combination with SAPT, while TAT should be avoided. For antithrombotic therapy and CABG, see Valgimigli et al.169
Recommendations for combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation
Recommendations
Classa
Levelb
Stroke prevention is recommended to AF patients with >_1 non-sex CHA2DS2-VASc stroke risk factors (score of >_1 in males or
>_2 in females).For patients with >_2 non-sex stroke risk factors, OAC is recommended.255259
I
A
For patients with 1 non-sex stroke risk factor, OAC should be considered and treatment may be individualized based on net clinical beneﬁt and consideration of patient values and preferences.260263
IIa
B
An early ICA should be considered in HBR patients, irrespective of OAC exposure, to expedite treatment allocation (medical vs.
PCI vs. CABG) and to determine the optimal antithrombotic regimen.
IIa
C
Patients undergoing coronary stenting
Anticoagulation
During PCI, additional parenteral anticoagulation is recommended, irrespective of the timing of the last dose of all NOACs and if
INR is <2.5 in VKA-treated patients.
I
C
In patients with an indication for OAC with VKA in combination with aspirin and/or clopidogrel, the dose intensity of VKA should be carefully regulated with a target INR of 2.02.5 and a time in the therapeutic range >70%.236,238241
IIa
B
Uninterrupted therapeutic anticoagulation with VKA or NOACs should be considered during the periprocedural phase.
IIa
C
Antiplatelet treatment
In patients with AF and CHA2DS2-VASc score >_1 in men and >_2 in women, after a short period of TAT (up to 1 week from the acute event), DAT is recommended as the default strategy using a NOAC at the recommended dose for stroke prevention and a single oral antiplatelet agent (preferably clopidogrel).238241,244,245
I
A
Periprocedural DAPT administration consisting of aspirin and clopidogrel up to 1 week is recommended.238241,244,245
I
A
Discontinuation of antiplatelet treatment in patients treated with an OAC is recommended after 12 months.236239,246
I
B
In patients treated with a VKA (e.g. mechanical prosthetic valves), clopidogrel alone should be considered in selected patients
(HAS-BLED >_3 or ARC-HBR met and low risk of stent thrombosis) for up to 12 months.236
IIa
B
When rivaroxaban is used and concerns about HBR prevail over stent thrombosis or ischaemic stroke, rivaroxaban 15 mg o.d.
should be considered in preference to rivaroxaban 20 mg o.d. for the duration of concomitant SAPT or DAPT.240,245
IIa
B
In patients at HBR (HAS-BLED >_3), dabigatran 110 mg b.i.d. should be considered in preference to dabigatran 150 mg b.i.d. for the duration of concomitant SAPT or DAPT to mitigate bleeding risk.238
IIa
B
In patients treated with an OAC, aspirin plus clopidogrel for longer than 1 week and up to 1 month should be considered in those with high ischaemic risk or other anatomical/procedural characteristics which outweigh the bleeding risk (Table 11).
IIa
C
DAT (with an OAC and either ticagrelor or prasugrel) may be considered as an alternative to TAT (with an OAC, aspirin, and clopidogrel) in patients with a moderate or high risk of stent thrombosis, irrespective of the type of stent used.
IIb
C
The use of ticagrelor or prasugrel as part of TAT is not recommended.
III
C
Medically managed patients
One antiplatelet agent in addition to an OAC should be considered for up to 1 year.241,247
IIa
C
In patients with AF, apixaban 5 mg b.i.d. and SAPT (clopidogrel) for at least 6 months may be considered.241,247
IIb
B
AF = atrial ﬁbrillation; ARC-HBR = Academic Research Consortium  High Bleeding Risk; b.i.d. = bis in die (twice a day); CABG = coronary artery bypass graft(ing);
CHA2DS2-VASc = Congestive heart failure, Hypertension, Age >_75 years (2 points), Diabetes, Stroke (2 points)Vascular disease, Age 6574, Sex category (female); DAPT =
dual antiplatelet therapy; DAT = dual antithrombotic therapy; HAS-BLED = hypertension, abnormal renal and liver function (1 point each), stroke, bleeding history or predisposition, labile INR, older patients (>65 years), drugs and alcohol (1 point each); HBR = high bleeding risk (see Table 7); ICA = invasive coronary angiography; INR = international normalized ratio; NOAC = non-vitamin K antagonist oral anticoagulant; OAC = oral anticoagulation/anticoagulant; o.d. = once daily; PCI = percutaneous coronary intervention;
SAPT = single antiplatelet therapy; TAT = triple antithrombotic therapy; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
1321


<!-- PAGE 34 -->

### Page 34

........................................................................................
5.4 Management of acute bleeding events
(Supplementary Data)
5.4.1 General supportive measures (Supplementary Data)
5.4.2 Bleeding events on antiplatelet agents
(Supplementary Data)
5.4.3 Bleeding events on vitamin K antagonists
(Supplementary Data)
5.4.4 Bleeding events on non-vitamin K antagonist oral anticoagulants (Supplementary Data)
5.4.5 Non-access-related bleeding events (Supplementary
Data)
5.4.6 Bleeding events related to percutaneous coronary intervention (Supplementary Data)
5.4.7 Bleeding events related to coronary artery bypass surgery (Supplementary Data)
5.4.8 Transfusion therapy (Supplementary Data)
5.4.9 Recommendations for bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients
6 Invasive treatments
6.1 Invasive coronary angiography and revascularization
Coronary angiography facilitates clarification as to whether presumed anginal chest pain originates from myocardial ischaemia, as a consequence of a culprit lesion, or not. In the former case, the culprit lesion can subsequently be treated by means of PCI within the same procedure or by CABG, depending on lesion morphology and the patient’s risk profile (see section 6.4). In the latter case, exclusion of a culprit lesion paves the way to subsequent diagnostic investigations ultimately revealing the cause of chest pain and/or myocardial injury
(see section 7). However, ICA carries a certain risk for procedurerelated complications, which has to be considered in management decisions.
6.1.1 Routine invasive vs. selective invasive approach
(Supplementary Data)
Routine invasive strategy means the patient is deemed to undergo
ICA. Following a selective invasive strategy, ICA will only be performed after recurrent symptoms, objective evidence of inducible ischaemia on non-invasive testing, or detection of obstructive CAD
by CCTA. Multiple RCTs comparing a routine invasive with a selective invasive strategy have been conducted and their results have been pooled in several meta-analyses.266270 The available evidence
(Supplementary Table 2) indicates that a routine invasive strategy:
• Does not reduce all-cause mortality risk in the overall population of NSTE-ACS patients.
Recommendations for bleeding management and blood transfusion in non-ST-segment elevation acute coronary syndromes for anticoagulated patients
Recommendations
Classa
Levelb
In patients with dabigatran-associated ongoing life-threatening bleeding, the administration of the speciﬁc antidote for dabigatran
 idarucizumab  should be considered.264
IIa
B
In patients with VKA-associated life-threatening bleeding events, rapid reversal of anticoagulation with four-factor prothrombin complex concentrate rather than with fresh frozen plasma or recombinant activated factor VII should be considered.
In addition, repetitive 10 mg i.v. doses of vitamin K should be administered by slow injection.
IIa
C
In patients with NOAC-associated ongoing life-threatening bleeding, the administration of prothrombin complex concentrates or activated prothrombin complex concentrates should be considered when the speciﬁc antidote is unavailable.
IIa
C
In patients with rivaroxaban-, apixaban-, or edoxaban-associated ongoing life-threatening bleeding, the administration of the speciﬁc antidote  andexanet-alpha  may be considered.265
IIb
B
In patients with anaemia and no evidence of active bleeding, blood transfusion may be considered in case of compromised haemodynamic status, haematocrit <25%, or haemoglobin level <8 g/dL.
IIb
C
i.v. = intravenous; NOAC = non-vitamin K antagonist oral anticoagulant; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.


<!-- PAGE 35 -->

### Page 35

.......................................................................
• Increases the risk of periprocedural complications such as periprocedural MI and bleeding.
• Reduces the risk of composite ischaemic endpoints, particularly in high-risk patients.
However, the currently available evidence is based on old RCTs that were conducted before critical improvements such as radial access, modern drug-eluting stents (DES), complete functional revascularization for multivessel CAD, modern DAPT, intensified lipid lowering therapy, and contemporary biomarker assays and/or cut-off values for diagnosing spontaneous/periprocedural MI
became available.
In summary, the results of RCTs and their meta-analyses highlight the role of risk stratification in the decision process and support a routine invasive strategy in high-risk patients.
6.1.2 Timing of invasive strategy
6.1.2.1 Immediate invasive strategy (<2 h)
Very high-risk NSTE-ACS patients (i.e. with at least one very highrisk criterion according to Figure 9) have generally been excluded from RCTs. Owing to a poor short- and long-term prognosis if left untreated, an immediate invasive strategy (i.e. <2 h from hospital admission, analogous to STEMI management) with the intent to perform revascularization is recommended, irrespective of ECG or biomarker findings. Centres without 24/7 PCI availability must transfer the patient immediately.
6.1.2.2 Early invasive strategy (<24 h)
An early invasive strategy is defined as coronary angiography performed within 24 h of hospital admission. It is recommended in high-risk patients defined according to Figure 9. Multiple RCTs have investigated the optimal timing of ICA and revascularization in NSTEACS (Figure 10, Supplementary Table 3). A main limitation for the interpretation of these RCTs is the calculation of time to ICA, which rather than being based on pain onset or on hospital admission time,
was based on randomization time. While ICA was virtually always performed within 24 h of randomization in the early invasive strategy groups, the time from randomization to ICA was more heterogeneous in the delayed invasive groups (Figure 10). The two largest RCTs,
with more than 1000 patients in each treatment group, are Timing of
Intervention in Patients with Acute Coronary Syndromes (TIMACS)
and the more contemporary VERDICT trial.271,272 There are several important messages that can be derived from these RCTs:
(1)
Among unselected NSTE-ACS patients, an early invasive strategy is not superior over a delayed invasive strategy with regard to composite clinical endpoints (Supplementary Table 3).271,272
©ESC 2020
Figure 9 Selection of non-ST-segment elevation acute coronary syndrome treatment strategy and timing according to initial risk stratification. EMS =
emergency medical services; GRACE = Global Registry of Acute Coronary Events; MI = myocardial infarction; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; NSTEMI = non-ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention. Listen to the audio guide of this figure online.
ESC Guidelines
1323


<!-- PAGE 36 -->

### Page 36

............................................................................
(2)
Benefit with an early invasive strategy is strongly associated with the patient’s risk profile. In a pre-specified subgroup analysis, patients with a GRACE risk score >140 benefited from an early invasive strategy while those with a GRACE risk score <140 did not
(TIMACS trial: HR 0.65, 95% CI 0.480.89 vs. HR 1.12, 95% CI
0.811.56, Pinteraction = 0.01;271 VERDICT trial: HR 0.81, 95% CI
0.671.00 vs. HR 1.21, 95% CI 0.921.60; Pinteraction = 0.02).272
With regard to the GRACE risk score, it must be highlighted that both RCTs calculated the original GRACE risk score for in-hospital death (see Supplementary Figure 3).139 Due to different weighting of variables, scores of other GRACE risk scores (see Supplementary
Table 1 for more details) might be considerably different for the same patient, possibly leading to different treatment decisions.
Furthermore, in both studies, GRACE risk score calculation was based on elevations of CK-MB or conventional troponin. The value of a GRACE risk score >140 to guide timing of ICA and revascularization in the era of hs-cTn has not been determined.
(3)
Benefit with an early invasive strategy is not modified by STsegment/T-wave changes, despite the fact that ST-segment depression has been consistently identified as a predictor for an adverse outcome (Supplementary Figure 2).
In patients with transient ST-segment elevation and relief of symptoms, an immediate invasive strategy did not reduce CMR-assessed infarct size compared to an early invasive strategy.273
Several meta-analyses have pooled data of multiple RCTs assessing different timing intervals of ICA (Supplementary Table 4). None of them observed a benefit with an early invasive strategy with respect to the endpoints death, non-fatal MI, or stroke among unselected
NSTE-ACS patients.274278 However, a collaborative meta-analysis comparing an early/immediate invasive to a delayed invasive strategy using a modified individual patient data approach observed a survival benefit in high-risk patients, although tests for interaction were inconclusive.277 Only the VERDICT trial studied the impact of timing on the endpoint hospital admission for heart failure and observed a trend towards less heart failure hospitalization in favour of an early invasive strategy (HR 0.78, 95% CI 0.601.01).272Meta-analyses have consistently reported that an early invasive strategy is associated with a lower risk of recurrent/refractory ischaemia and a shorter length of hospital stay.274276,278 Taken together, an early invasive strategy is recommended in patients with at least one high-risk criterion
(Figure 9).
6.1.2.3 Selective invasive strategy
Patients with no recurrence of symptoms and none of the very highor high-risk criteria listed in the recommendation table regarding timing of invasive strategy are to be considered at low risk of short-term acute ischaemic events (Figure 9). These patients should be managed according to the 2019 ESC Guidelines for the diagnosis and management of CCS.231 In this setting, stress echocardiography or stress
Figure 10 Time to coronary angiography in the early/immediate invasive and delayed invasive groups of included trials.271,272,279287 Bars depict interquartile ranges and median times from randomization to coronary angiography in the early invasive group (red) and delayed invasive group (blue). In addition, description of the main finding of the primary endpoint with an early vs. delayed invasive strategy. Adapted and updated from Jobs et al.277 Based on the individual patient-based meta-analysis patients with elevated biomarkers, GRACE score >140, age >75 years, and diabetes showed a mortality benefit from an early invasive approach.277 ABOARD = Angioplasty to Blunt the Rise of Troponin in Acute Coronary Syndromes Randomized for an Immediate or Delayed Intervention; CK-MB = creatine kinase myocardial band; EARLY = Early or Delayed Revascularization for Intermediate- and High-Risk NonST-Segment Elevation Acute Coronary Syndromes?; ELISA = Early or Late Intervention in unStable Angina; GRACE = Global Registry of Acute Coronary
Events; ISAR-COOL = Intracoronary Stenting and Antithrombotic Regimen - Cooling off strategy; LIPSIA-NSTEMI = Leipzig Immediate versus early and late PercutaneouS coronary Intervention triAl in NSTEMI; MACE = major adverse cardiovascular events; MI = myocardial infarction; PCI = percutaneous coronary intervention; RIDDLE-NSTEMI = Randomized Study of Immediate Versus Delayed Invasive Intervention in Patients With Non-ST-Segment
Elevation Myocardial Infarction; SISCA = Comparison of Two Treatment Strategies in Patients With an Acute Coronary Syndrome Without ST Elevation;
TIMACS = Timing of Intervention in Patients with Acute Coronary Syndromes; VERDICT = Very EaRly vs Deferred Invasive evaluation using
Computerized Tomography.


<!-- PAGE 37 -->

### Page 37

........................................................................................
CMR may be preferred over non-invasive anatomical testing.109 With routine use of hs-cTn and established diagnostic algorithms for
NSTE-ACS assessment, ongoing myocardial injury  even low level
 can be identified. Therefore, patients previously regarded to be at intermediate risk (e.g. those with a history of revascularization or diabetes mellitus), but ruled out according to a diagnostic algorithm using hs-cTn, should be regarded as low risk and follow a selective invasive strategy.1
6.1.3 Pattern of coronary artery disease in non-ST-segment elevation acute coronary syndrome
(Supplementary Data)
6.1.4 How to identify the culprit lesion? (Supplementary
Data)
6.1.5 Spontaneous coronary artery dissection
Spontaneous coronary artery dissection (SCAD) is defined as a non-atherosclerotic, non-traumatic, or iatrogenic separation of the coronary arterial tunics secondary to vasa vasorum haemorrhage or intimal tear, which creates a false lumen, coronary compression, and downstream myocardial ischaemia.288,289
SCAD accounts for up to 4% of all ACS, but the incidence is reported to be much higher (2235% of ACS) in women <60 years of age, in pregnancy-related MI, and in patients with a history of fibromuscular dysplasia, anxiety, depression, or previous neuropsychiatric disorders.290,291 Clinical presentations can vary considerably, but elevation of cardiac biomarkers associated with chest discomfort is the most common presentation.292 There are three angiographic types of SCAD, which range from no obstruction to complete occlusion of the affected coronaries. SCAD Type 1 (contrast dye staining of the arterial wall with multiple radiolucent lumen) and SCAD Type 2
(long diffuse and smooth narrowing) with non-obstructive coronary arteries (stenosis <50%) are described as possible causes of MI with non-obstructive coronary arteries (MINOCA) (see section 7), while
SCAD Type 2 with severe coronary obstruction (>50%) and SCAD
Type 3 (focal or tubular stenosis that mimics atherosclerosis) should be considered separately. As SCAD may be missed or not be detectable on CCTA, a negative CCTA should not exclude a diagnosis of
SCAD.293 Intracoronary imaging [optical coherence tomography
(OCT) and intravascular ultrasound (IVUS)] might be the most accurate options in unclear situations to prove the presence of intramural haematoma or double lumen.294 This may be fundamental to making a proper diagnosis.294
The optimal management of SCAD is still unclear, since no RCTs have compared medical therapy to revascularization strategies.
According to available data, with the exception of very high-risk profile patients, a conservative approach should be the preferred strategy.295297 The decision to treat either with a conservative medical approach or to perform PCI or CABG surgery must be individualized and based on both clinical and angiographic factors. A possible treatment algorithm is shown in Figure 11. Optimal medical treatment for patients with SCAD is still undetermined, but because hypertension is an independent predictor of recurrent SCAD,292,295,298 an aggressive anti-hypertensive therapy should be considered to ensure optimal blood pressure control. Beta-blockers, which have been reported to be significantly associated with a reduced risk of
©ESC 2020
Figure 11 Diagnosis and treatment of patients with non-ST-segment elevation acute coronary syndrome related to spontaneous coronary artery dissection. CABG = coronary artery bypass graft(ing); CAD = coronary artery disease; CCTA = coronary computed tomography angiography; DAPT = dual antiplatelet therapy; ICA = invasive coronary angiography; IVUS = intravascular ultrasound; OCT = optical coherence tomography; OMT = optimal medical therapy; PCI = percutaneous coronary intervention; SCAD = spontaneous coronary artery dissection. aSelection of revascularization strategy for highrisk anatomy according to local expertise. bBeta-blocker recommended while benefit of DAPT is questionable. cLeft main or proximal left anterior descendent or circumflex or right coronary artery, multivessel SCAD. Listen to the audio guide of this figure online.
ESC Guidelines
1325


<!-- PAGE 38 -->

### Page 38

.............................................................................................................................................................................
recurrent events, should be the preferred antihypertensive class in this subset of patients.298 There is controversy regarding the benefit of antithrombotic therapy among these patients,292,298 however,
among PCI-treated patients, the DAPT algorithms stated in section 5
should be used. Among SCAD patients treated medically and having persistent or recurrent symptoms, even in the absence of recurrent
MI or ischaemia, CCTA might be considered for follow-up.
6.1.6 Fractional flow reserve, instantaneous wave-free ratio, and other resting indices (Supplementary Data)
6.1.6.1 Fractional flow reserve
Fractional flow reserve (FFR) is the current standard for the functional assessment of lesion severity in patients with intermediategrade stenosis (4090%) without evidence of ischaemia in noninvasive testing, or in those with multivessel disease. Due to microvascular obstruction,299 the haemodynamic relevance of the culprit lesion in NSTE-ACS may be underestimated.300 However, it appears reliable for non-culprit lesion estimation when compared to postponed repeat FFR, CMR perfusion, or SPECT.301304 In ACS
patients, deferred revascularization based on FFR or instantaneous wave-free ratio (iFR) is associated with worse clinical outcome compared to patients with stable CAD.305308 Persistent instability of non-haemodynamically significant stenoses or presence of more than one unstable lesion may account for the higher risk.
The majority of the evidence relating to the value of FFR in NSTEACS is derived from small subgroups of registries and randomized trials (Supplementary Table 5). In the small Fractional flow reserve versus angiography in guiding management to optimize outcomes in nonST-elevation myocardial infarction (FAMOUS-NSTEMI) randomized trial,309 significantly more NSTEMI patients were treated medically with FFR vs. an angio-guided PCI strategy (22.7 vs. 13.2%, P¼0.022).
This strategy of functional revascularization seems to be safe without any impact on clinical outcomes in NSTE-ACS. However, adequately powered dedicated randomized trials are still lacking.
6.1.6.2 Instantaneous wave-free ratio and other resting indices
There has been renewed interest in resting indices derived from resting gradients alone [distal coronary to aortic pressure ratio (Pd/Pa),
iFR, coronary flow reserve (CFR), resting full-cycle ratio (RFR), or the index of microcirculatory resistance (IMR)]. Two large-scale randomized trials showed broadly comparable results between FFRguided and iFR-guided revascularization strategies in patients with intermediate-grade stenosis.310,311 In these trials, the proportion of
ACS patients was 1517%, the non-culprit lesions were investigated,
and follow-up was limited to a 1-year duration. For resting indices other than iFR, randomized clinical outcome data are not available.
6.1.7 Intracoronary imaging
Both intracoronary imaging methods, IVUS and OCT, allow real-time tomographic assessment of vessel size, lumen area, plaque composition and volume, as well as stent coverage and expansion.312
IVUS-guided PCI has been reported to reduce target vessel failure
12 months after PCI compared to angio-guided PCI in the
Intravascular Ultrasound Guided Drug Eluting Stents Implantation in
“All-Comers” Coronary Lesions (ULTIMATE) randomized trial: 2.9
vs. 5.4%, respectively (HR 0.53, 95% CI 0.310.90, P¼0.019).313
Clinically driven target lesion revascularization or definite stent thrombosis was lower with the IVUS-guided strategy [1.2 vs. 2.6%,
relative risk (RR) 0.46, 95% CI 0.211.03, P¼0.05]. However, only
12% of the enrolled patients presented with STEMI or NSTE-ACS,
limiting its validity in NSTE-ACS settings.313
OCT-guided PCI is safe and results in a similar minimum stent area to that of IVUS-guided PCI.314 In addition, OCT-guided PCI has been shown to lead to higher post-PCI FFR compared to angio-guided PCI
among NSTE-ACS patients.315 Adequately powered trials for clinical endpoints, however, are lacking. Additionally, in patients with
MINOCA (see section 7), OCT is a diagnostic tool for evaluating
SCAD, erosions, and plaque ruptures.312
6.2 Conservative treatment
The established benefit associated with coronary revascularization in
NSTE-ACS patients has led to a significant reduction of medical management alone, from 60% two decades ago down to 1030% in the contemporary era of PCI.170,225,316319 Medical management comprises patients not undergoing coronary angiography, but also those with extensive CAD not amenable to revascularization or those without obstructive CAD (see MINOCA, section 7).
6.2.1 Patients who are not candidates for invasive coronary angiography
This group represents a small subgroup, where data indicating a hypothetical advantage of an invasive strategy are scarce. Depending on country and world region specific differences, advanced age,
female sex, chronic kidney disease (CKD), diabetes mellitus, prior heart failure/revascularization, history of cancer, and frailty are the major reported reasons accounting for withholding diagnostic
ICA.170,225,316,318,319 These features largely overlap with the predictors of bleeding and ischaemic adverse events320 and explain the poor prognosis of this population, with in-hospital mortality of 69%
that rises up to 20 and 50% at 6 months and 3 years, respectively.321
Medical management should be chosen after careful risk assessment,
keeping in mind that ICA using the radial approach is a low-risk procedure, that impaired LV function increases mortality risk, and that coronary anatomy and presence of diabetes may refine the risk stratification and the choice of pharmacological therapy (see Figures 57).
Advanced age or female sex alone, in the absence of severe comorbidities or frailty, should not be considered as a sufficient reason not to perform ICA and, likewise, ICA should not be denied for logistical reasons.322,323
6.2.2 Patients with coronary artery disease not amenable to revascularization
Patients diagnosed with severe CAD who are not amenable to any type of revascularization are at very high risk of recurrent ischaemic events.324 Frequently, these patients are women, old and/or suffering from severe CKD, with multivessel CAD, and a history of MI or prior revascularization. The decision not to perform PCI is an independent predictor of increased cardiovascular mortality, both in-hospital and long-term.188,318 Accordingly, the decision not to perform revascularization should be made in very selected patients only, where there is consensus that risk outweighs the benefit for clinical or anatomical reasons. These patients should undergo an aggressive secondary


<!-- PAGE 39 -->

### Page 39

.............................................................................................................................................................................
prevention treatment with potent antiplatelet therapy
(see
Figures 58) and anti-anginal agents, taking their comorbidities into account.325,326
6.3 Technical aspects
6.3.1 Technical aspects and challenges
The principal technical aspects of PCI in NSTE-ACS patients do not differ from the invasive assessment and revascularization strategies for other manifestations of CAD. In patients presenting with NSTEACS who are deemed eligible for PCI in one or more vessels, implantation of new-generation DES is the standard of care,159,327,328 while routine thrombectomy has not been proven beneficial in this setting.329,330 The combination and duration of antithrombotic treatment are explained in section 5.
6.3.2 Vascular access
A timely performance of PCI and the use of potent antithrombotic drugs have reduced ischaemic risk in patients with NSTE-ACS.
However, this strategy is also invariably associated with an increased bleeding risk, which affects prognosis at least as much as ischaemic complications and is associated with impaired survival.331333 Among patients undergoing PCI, access-related bleeding accounts for
3070% of total bleeding events.334 There is accumulative evidence showing that reducing access-site bleeding events with the use of radial access translates into significant clinical benefits. Two large randomized trials, the RadIal Vs femorAL access for coronary intervention (RIVAL) trial (n=7021 ACS patients) and the MATRIX trial
(n=8404 ACS patients)335,336 have demonstrated significantly lower rates of access site-related bleeding, surgical access site repair, and blood transfusion with radial compared to femoral access. A pairwise meta-analysis comparing radial vs. femoral access in the whole spectrum of patients with CAD, including 30-day follow-up of the
MATRIX trial, showed a significant reduction in major bleeds; death,
MI, or stroke; and all-cause mortality favouring radial vs. femoral access.337 Although this effect was diluted at 1-year follow-up, net clinical adverse events remained lower with a radial vs. femoral access site.336 Therefore, radial access is recommended as the preferred approach in NSTE-ACS patients undergoing invasive assessment with or without PCI. However, dependent on their haemodynamic situation during index PCI and procedural technical aspects, femoral access might be selectively chosen instead of radial access.
6.3.3 Revascularization strategies
Based on observational studies of patients with NSTE-ACS, the benefit of early intervention  when compared to a conservative approach  may mandate a complete revascularization strategy, irrespective of the possibility to identify and/or treat the culprit lesion.268,277,338340
Recently,
data from the
British
Cardiac
Intervention Society PCI database showed significantly lower cumulative mortality rates with single-stage complete revascularization compared to culprit-lesion-only PCI (22.5 vs. 25.9%, P=0.0005) at a median follow-up of 4.1 years (interquartile range 2.25.8) among
21 857 NSTE-ACS patients with multivessel CAD undergoing PCI.
This long-term benefit was observed despite an initial increase in inhospital mortality with single-stage complete revascularization (2.3
vs. 1.5%, P¼0.002).341 Whether this initial increased risk with singlestage complete revascularization can be reduced by staged complete revascularization needs to be further evaluated.
In contrast to the STEMI setting,342344 there is only one dedicated randomized trial examining the role of single vs. staged multivessel PCI in NSTE-ACS patients [Impact of Different Treatment in
Multivessel Non ST Elevation Myocardial Infarction Patients: One
Stage Versus Multistaged Percutaneous Coronary Intervention
(SMILE) trial].345 The complete single-stage coronary revascularization resulted in less major adverse cardiovascular and cerebrovascular events
(defined as cardiac death,
death,
reinfarction,
rehospitalization for unstable angina, repeat coronary revascularization, and stroke at 1 year) compared to complete coronary revascularization in multistage PCI during the index hospitalization (HR 0.55,
95% CI 0.360.83, P¼0.004).345 This benefit was largely determined by a significant reduction in repeat revascularization with single-stage multivessel PCI (HR 0.52, 95% CI 0.310.88, P¼0.01).345 However,
since pursuing completeness of revascularization for some patients with complex coronary anatomy may increase the risk of PCI or require CABG, it is reasonable, in the absence of robust clinical data,
to tailor the need for, and timing of, complete revascularization to functional relevance of all stenoses, age, general patient condition and comorbidities, and LV function. Furthermore, selection of the revascularization modality may rely on patient preference. For NSTE-ACS
patients presenting with CS, randomized evidence does not support routine immediate multivessel PCI (see details in section 8.1).346
6.4 Coronary artery bypass grafting
Approximately 510% of NSTE-ACS patients require CABG347 and these represent a challenging subgroup given their high-risk characteristics compared with patients undergoing elective CABG. In the absence of randomized data, optimal timing for non-emergency
CABG in NSTE-ACS patients should be determined individually.348
The risk of ischaemic events, possibly related to suboptimal antiplatelet therapy while awaiting surgery, is less than 0.1%, while perioperative bleeding complications associated with platelet inhibitors is higher than 10%.349 In patients with ongoing ischaemia or haemodynamic instability and with an indication for CABG, emergency surgery should be performed and not postponed as a consequence of antiplatelet treatment exposure.
If CABG is to be performed, every effort should be made to minimize aortic manipulation, work off-pump if there is a calcified aorta or the patient is high risk, achieve complete revascularization, and use graft flow measurement.
6.5 Percutaneous coronary intervention vs. coronary artery bypass surgery
There is no randomized comparison of PCI vs. CABG surgery in the specific setting of NSTE-ACS. In the individual patient data analysis from the Randomized Comparison of Coronary Artery Bypass
Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients with Multivessel Coronary Artery (BEST), Premier of
Randomized Comparison of Bypass Surgery versus Angioplasty
Using Sirolimus-Eluting Stent in Patients with Left Main Coronary
Artery Disease (PRECOMBAT), and Synergy between PCI with
Taxus and cardiac surgery (SYNTAX) trials, which compared PCI
with CABG, of the 3280 patients with multivessel CAD or left main
ESC Guidelines
1327


<!-- PAGE 40 -->

### Page 40

.........................................................
disease, only 77 patients (2.2%) presented with NSTEMI and 1169
patients (35.7%) presented with unstable angina.350 Among NSTEACS patients, at 5-year follow-up, the risk of death, MI, or stroke was significantly reduced with CABG compared to PCI (HR 0.74, 95% CI
0.560.98, P¼0.036). The difference was driven by a reduction in MI
rates with CABG (3.8% vs. 7.5%, HR 0.50, 95% CI 0.310.82,
P¼0.006).350 In a population-based analysis, the benefit of CABG
over PCI was confirmed in patients with diabetes who presented with ACS. At 3-year follow-up, the combined incidence of all-cause death, non-fatal MI, or non-fatal stroke was lower with CABG compared with PCI (20.8 vs. 33.4%, P<0.01).351 Taken together, evidence is limited from these aforementioned RCTs to support one revascularization strategy over the other, especially in NSTEMI patients.
Thus, the currently available evidence indirectly suggests that the criteria applied in patients with stable CAD to guide the choice of revascularization modality (2018 ESC/EACTS Guidelines on myocardial revascularization)205 should also be applied to stabilized patients with NSTE-ACS, particularly for patients with diabetes.350354
For complex cases, Heart Team discussion and use of the
SYNTAX score are recommended, particularly given its ability to predict death, MI, and revascularization in multivessel CAD NSTEACS patients undergoing PCI.355 Furthermore, calculation of a
Society of Thoracic Surgeons (STS) score is recommended to assess in-hospital or 30-day mortality, and in-hospital morbidity after CABG
among high-risk patients.356 Clinical and anatomical characteristics in favour of CABG are considered to be diabetes, reduced LV ejection fraction (LVEF) (<40%), contraindications to DAPT, recurrent diffuse in-stent restenosis, anatomical and technical aspects likely resulting in incomplete revascularization with PCI, and the need for concomitant cardiovascular surgery. Those in favour of PCI are clinical and anatomical characteristics, such as presence of severe comorbidity (not reflected by scores), advanced age/frailty or reduced life expectancy,
restricted mobility, conditions that affect the rehabilitation process,
anatomical and technical aspects likely resulting in incomplete revascularization with CABG surgery due to poor quality or missing conduits, severe chest deformation or scoliosis, sequelae of chest radiation, and porcelain aorta.
6.6 Specific situations
6.6.1 Management of patients with ongoing myocardial ischaemia
These patients are characterized by an overwhelming risk of developing STEMI, onset of life-threatening arrhythmias, acute heart failure,
and CS. They should undergo coronary angiography within 2 h of hospital admission with intent to perform revascularization. Based on published data, this approach reduces in-hospital mortality and mortality at early and mid-term follow-up,281,357 as well as reducing the risk of new MI in the pre-catheterization period and the length of hospital stay.278
6.6.2 Management of patients with cardiac arrest
The management of patients presenting with resuscitated cardiac arrest and concomitant NSTE-ACS needs to be individualized according to their haemodynamic and neurological status.
In out-of-hospital cardiac arrest and no ST-elevation without CS,
an unselected immediate invasive strategy is not superior over a delayed invasive strategy, as recently shown in the randomized
Coronary Angiography after Cardiac Arrest (COACT) trial.278 This trial enrolled 552 patients who had been successfully resuscitated after out-of-hospital cardiac arrest and had no signs of STEMI. No difference in 90-day survival was observed between these two strategies, 64.5% in the immediate vs. 67.2% in the delayed angiography strategy (OR 0.89, 95% CI 0.621.27, P=0.51).358 Therefore, it appears reasonable to delay performance of ICA among NSTE-ACS
patients.358 However, several ongoing trials will further define a possible benefit of an early invasive approach.359
In comatose survivors, echocardiography should be performed immediately for further evaluation of differential diagnoses. If aortic dissection or pulmonary embolism is suspected,
CT
is recommended.360,361
6.7 Recommendations for coronary revascularization
Recommendations for coronary revascularization
Recommendations
Classa
Levelb
Timing of invasive strategy
An immediate invasive strategy (<2 h) is recommended in patients with at least one of the following very high-risk criteria:
• Haemodynamic instability or CS.
• Recurrent or refractory chest pain despite medical treatment.
• Life-threatening arrhythmias.
• Mechanical complications of MI.
• Heart failure clearly related to NSTE-ACS.
• Presence of ST-segment depression >1 mm in >_6 leads additional to ST-segment elevation in aVR and/or V1.
I
C
An early invasive strategy within 24 h is recommended in patients with any of the following highrisk criteria:
• Diagnosis of NSTEMI suggested by the diagnostic algorithm recommended in section 3.
• Dynamic or presumably new contiguous
ST/T-segment changes suggesting ongoing ischaemia.
• Transient ST-segment elevation.273,362
• GRACE risk score >140.271,272,277
I
A
A selective invasive strategy after appropriate ischaemia testing or detection of obstructive CAD
by CCTA is recommended in patients considered at low risk.267,268,363
I
A
Delayed as opposed to immediate angiography should be considered among haemodynamically stable patients without ST-segment elevation successfully resuscitated after out-of-hospital cardiac arrest.358,364
IIa
B
Continued


<!-- PAGE 41 -->

### Page 41

.............................................................................................................................................................................
7 Myocardial infarction with non-obstructive coronary arteries and alternative diagnoses
Although the occurrence of an AMI without significant CAD was initially reported almost 80 years ago,367 and outcomes were definitely described 13 years ago,368 the term MINOCA has only been used recently to describe these patients.369 Accordingly, MINOCA is initially considered at the time of angiography as a working diagnosis until further assessment excludes other possible causes for troponin elevation. This incorporates a heterogeneous group of underlying causes that may involve both coronary and non-coronary pathological conditions, with the latter including cardiac and extracardiac disorders.370 Compared with patients with obstructive CAD,
NSTE-ACS patients diagnosed with MINOCA are more likely to be younger and female, and less likely diabetic, hypertensive, or dyslipidaemic,371,372 suggesting a predominant role of non-atheroscleroticrelated aetiologies and of unusual or usual risk factors like psychosocial aspects, insulin-resistance, and inflammation.373 However, all studies assessing prognosis in patients with MINOCA are considerably heterogeneous in terms of inclusion criteria, outcomes measurements, and length of follow-up; some report the prevalence of hard endpoints like mortality or reinfarction,374,375 but few report outcomes for both MINOCA and CAD populations.376 Although associated with better prognosis compared to patients with ACS patients with obstructive CAD,371,372,376379 MINOCA patients have a lower survival rate than healthy individuals matched for age and sex.371,372,376379 Of importance, this excess of adverse events has been reported at both early and late follow-up.371,372,376379
The term MINOCA has been broadly used in the past and is often misclassified, limiting all aspects of disease description, management,
and treatment. Despite having a contemporary position statement from the ESC and the AHA, great variability exists in the manner in which patients with suspected MINOCA are evaluated and treated.380,381 The extent of the diagnostic and therapeutic strategies implemented often depends on local non-standardized practices and varies widely.
The ESC position statement on MINOCA proposed the following
MINOCA criteria:380
(1)
AMI criteria as defined by the ‘Third universal definition of MI’.369
(2)
Non-obstructive coronary arteries as per angiographic guidelines,
with no lesions >_50% in a major epicardial vessel.
(3)
No other clinically overt specific cause that can serve an alternative cause for the acute presentation.
Based on this ESC definition, myocarditis and Takotsubo syndrome patients, among other non-ischaemic conditions, were labelled as MINOCA.380
However, fundamental to the definition of MINOCA is the diagnosis of MI with elevated cardiac biomarkers, typically cardiac troponin
>99th percentile of the upper reference level with a rise or fall in the level on serial assessment. Although elevated troponin levels are indicative of myocyte injury with release of this intracellular protein into the systemic circulation, the process is not disease specific and can result from either ischaemic or non-ischaemic mechanisms.
Therefore, the most recent scientific statement from the AHA
provides a formal and updated definition for the broadly labelled term MINOCA incorporating the Fourth Universal Definition of
Myocardial Infarction.381 Table 14 provides the current criteria for the MINOCA definition, which by consensus now excludes myocarditis and
Takotsubo syndrome from the final diagnosis of
MINOCA.381 Interestingly, in some patients, Takotsubo syndrome may be triggered by NSTEMI or STEMI.382 Furthermore, with regard to Takotsubo syndrome, there are no RCTs to support a specific treatment and, therefore, all recommendations so far are based on expert opinions.383
It also provides a clinically useful framework and algorithms pertaining to the diagnostic evaluation and management of these
Technical aspects
Radial access is recommended as the standard approach, unless there are overriding procedural considerations.336,337
I
A
DES are recommended over bare-metal stents for any PCI irrespective of:
• Clinical presentation.
• Lesion type.
• Planned non-cardiac surgery.
• Anticipated duration of DAPT.
• Concomitant anticoagulant therapy.354,365,366
I
A
It is recommended to base the revascularization strategy (ad hoc culprit lesion PCI/multivessel PCI/
CABG) on the patient’s clinical status and comorbidities, as well as their disease severity [i.e. the distribution and angiographic lesion characteristics
(e.g. SYNTAX score)], according to the principles for stable CAD.350 However, the decision on immediate PCI of the culprit stenosis does not require Heart Team consultation.
I
B
Complete revascularization should be considered in NSTE-ACS patients without CS and with multivessel CAD.
IIa
C
Intracoronary imaging should be considered to diagnose SCAD if suspected.
IIa
C
Complete revascularization during index PCI may be considered in NSTE-ACS patients with multivessel disease.345
IIb
B
FFR-guided revascularization of a non-culprit
NSTE-ACS lesion may be used during index
PCI.302
IIb
B
CABG = coronary artery bypass graft(ing); CAD = coronary artery disease;
CCTA = coronary computed tomography angiography; CS = cardiogenic shock;
DAPT = dual antiplatelet therapy; DES = drug-eluting stent; FFR = fractional ﬂow reserve; GRACE = Global Registry of Acute Coronary Events; MI = myocardial infarction; NSTEMI = non-ST-segment elevation myocardial infarction; NSTEACS = non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention; SCAD = spontaneous coronary artery dissection;
SYNTAX = Synergy between PCI with Taxus and cardiac surgery.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
1329


<!-- PAGE 42 -->

### Page 42

.............................................................................................
patients, which mainly includes a ‘traffic light’ clinical algorithm
(Figure 12).
Based on the initial working diagnosis, proper initial assessment of
LV wall motion should be promptly performed in the acute setting using LV angiography, depending on renal function, or echocardiography. Regional wall motion abnormalities may indicate an epicardial cause of MINOCA or other specific causes, which may lead to the exclusion of MINOCA. CMR is one of the key diagnostic tools in this algorithm for the differential diagnosis of Takotsubo syndrome,384
myocarditis,385,386 or true MI.387 CMR has the ability to identify the underlying cause in as many as 87% of patients with MINOCA.388 In the sub-endocardium, late gadolinium enhancement may indicate an ischaemic cause, while sub-epicardial localization may indicate cardiomyopathies or myocarditis, and the absence of relevant late gadolinium enhancement with oedema and associated specific wall motion abnormalities is a hallmark of Takotsubo syndrome.387,388 In a metaanalysis of five studies involving 556 patients with an initial diagnosis of MINOCA, CMR identified myocarditis as the primary cause in 33%
of patients.389
Intracoronary acetylcholine or ergonovine testing may be performed when coronary or microvascular spasm is suspected.390,391
Intracoronary imaging with IVUS392 or OCT393,394 may also be valuable for the detection of unrecognized causes at coronary angiography, especially when thrombus, plaque rupture or erosion, or SCAD
are suspected.
Pulmonary embolism should also be considered as an alternative diagnosis as a possible cause of myocardial injury, and this diagnosis may be excluded with additional D-dimer testing, BNP, and/or CT
pulmonary angiography,361 as appropriate. Furthermore, other conditions with an imbalance between myocardial oxygen supply and demand or elevation of cardiac troponin should be considered as potential causes of myocardial injury, such as hypertensive crisis,
tachyarrhythmias, sepsis, severe anaemia, and cardiac contusion,
among others.
Patients with an initial diagnosis of MINOCA, and an underlying cause identified during the diagnostic work-up, should be treated and followed up according to the guidelines of the specific diagnosis. For example, MINOCA patients discharged with a final diagnosis of
NSTE-ACS or MINOCA of unknown cause should be followed up as
ACS patients with obstructive CAD.
However, despite optimal work-up, the cause of MINOCA
remains undetermined in 825% of patients.5,380,395 This condition, identified as ‘myocardial infarction of unknown/unclear causes’, represents a therapeutic dilemma. Treatment should target the most probable causes of MINOCA, with negative provocative tests and CMR, namely vasospastic angina, coronary plaque disruption, and thromboembolism. The benefit of DAPT (aspirin
þ P2Y12 receptor inhibitor) should be considered based on pathophysiological considerations. However, evidence is scarce.
Pharmacological therapy with aspirin,
statins,
angiotensinconverting enzyme (ACE) inhibitors/angiotensin receptor blockers (ARBs), and calcium channel blockers (in case vasospasm is still suspected) as routine treatment may be suggested.396 These medications have shown significant long-term beneficial effects in terms of all-cause mortality (statins, beta-blockers), cardiovascular death
(statins), AMI (beta-blockers), stroke (statins), and MACE (statins,
ACE inhibitor/ARB) at 12 months in a national registry.397
However, this registry did not apply current MINOCA criteria,397
therefore, the conclusions drawn must be interpreted with caution.
Table 14
Diagnostic criteria of myocardial infarction with non-obstructive coronary arteries
The diagnosis of MINOCA is made in patients with AMI fulﬁlling the following criteria:
1. AMI (modiﬁed from the ‘Fourth Universal Deﬁnition of Myocardial Infarction’ criteria):
• Detection of a rise or fall in cardiac troponin with at least one value above the 99th percentile upper reference limit and
• Corroborative clinical evidence of infarction as shown by at least one of the following:
a.
Symptoms of myocardial ischaemia b.
New ischaemic electrocardiographic changes c.
Development of pathological Q waves d.
Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischaemic cause e.
Identiﬁcation of a coronary thrombus by angiography or autopsy
2. Non-obstructive coronary arteries on angiography:
• Deﬁned as the absence of obstructive disease on angiography (i.e. no coronary artery stenosis >_50%) in any major epicardial vessela
This includes patients with:
• Normal coronary arteries (no angiographic stenosis)
• Mild luminal irregularities (angiographic stenosis <30% stenoses)
• Moderate coronary atherosclerotic lesions (stenoses >30% but <50%)
3. No speciﬁc alternate diagnosis for the clinical presentation:
• Alternate diagnoses include, but are not limited to, non-ischaemic causes such as sepsis, pulmonary embolism, and myocarditis
AMI = acute myocardial infarction; MINOCA = myocardial infarction with non-obstructive coronary arteries.
aNote that additional review of the angiogram may be required to ensure the absence of obstructive disease.


<!-- PAGE 43 -->

### Page 43

...............
8 Special populations
8.1 Heart failure and cardiogenic shock
Acute heart failure is a frequent complication of NSTE-ACS and is associated with a two to four-fold higher risk of in-hospital mortality compared with
NSTE-ACS
without acute heart failure.398401
The diagnosis of NSTE-ACS in the context of acute heart failure can be challenging because patients with acute heart failure may present with chest discomfort, myocardial injury with troponin
Figure 12 Diagnostic algorithm for myocardial infarction with non-obstructive coronary arteries using a traffic light scheme. Red indicates immediate alternative diagnosis without further additional testing. Yellow indicates initial working diagnosis that may lead to the final MINOCA diagnosis or alternative diagnoses. Green indicates final MINOCA diagnosis. CAD = coronary artery disease; IVUS = intravascular ultrasound; MINOCA = myocardial infarction with non-obstructive coronary arteries; CMR = cardiac magnetic resonance; Echo = echocardiogram; LV = left ventricular; OCT = optical coherence tomography; SCAD = spontaneous coronary artery dissection; ULN = upper limit of normal. Listen to the audio guide of this figure online.
Recommendations for myocardial infarction with non-obstructive coronary arteries
Recommendations
Classa
Levelb
In all patients with an initial working diagnosis of MINOCA, it is recommended to follow a diagnostic algorithm to differentiate true
MINOCA from alternative diagnoses.
I
C
It is recommended to perform CMR in all MINOCA patients without an obvious underlying cause.370
I
B
It is recommended to manage patients with an initial diagnosis of MINOCA and a ﬁnal established underlying cause according to the disease-speciﬁc guidelines.
I
C
Patients with a ﬁnal diagnosis of MINOCA of unknown cause may be treated according to secondary prevention guidelines for atherosclerotic disease.
IIb
C
CMR = cardiac magnetic resonance; MINOCA = myocardial infarction with non-obstructive coronary arteries.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
1331


<!-- PAGE 44 -->

### Page 44

.......................................
elevation can occur in the absence of obstructive CAD,3 and the
ECG may not be interpretable (bundle branch block or paced rhythm).402 Consequently, coronary angiography may be required to establish a diagnosis of NSTE-ACS.
The management of acute heart failure should follow current guideline recommendations.403,404 Emergency echocardiography should be performed to gather information about the LVEF, regional wall motion abnormalities, right ventricular function, presence of valvular heart disease, and volume loading.96,205,405 The revascularization strategy should be based on the coronary anatomy, LV function,
comorbidities, functional relevance of stenoses, and estimated surgical risk according to a Heart Team consensus, and based upon current recommendations.205
CS may occur in up to 4% of patients with NSTE-ACS.406,407
Ischaemia-related heart failure, acute severe mitral regurgitation, and mechanical complications are the major precipitating causes. These patients should be transferred, as soon as possible, to a tertiary care centre where ICA can be performed. In hub centres, immediate coronary angiography is indicated and PCI should be performed. Nearly
80% of such patients have multivessel CAD. Based on the Culprit
Lesion Only PCI versus Multivessel PCI in Cardiogenic Shock
(CULPRIT-SHOCK) trial,408 non-culprit lesions should not be routinely treated immediately, and the immediate PCI strategy should be limited to the culprit lesion only. In CULPRIT-SHOCK, culprit-lesiononly PCI led to a significant reduction in all-cause death or renalreplacement therapy at 30-day follow-up, favouring culprit-lesiononly PCI with possible staged revascularization [RR 0.83, (95% CI
0.710.96)].408 The risk of all-cause death in the culprit-lesion-only
PCI strategy was significantly lower compared to immediate multivessel PCI at 30-day follow-up (RR 0.84, 95% CI 0.720.98, P¼0.03).
Results for the composite endpoint were maintained at 1-year follow-up, whereas the mortality difference was mainly confined to the first 30 days.346,408
In patients with a coronary anatomy not suitable for PCI, emergency CABG is indicated.
Percutaneous mechanical circulatory support devices and/or venoarterial extracorporeal membrane oxygenation may be considered in selected patients, depending on age, comorbidities, neurological function, and severity of CS. Several RCTs are ongoing
(Supplementary Table 6). Currently, no survival benefit has been demonstrated for these devices compared with intra-aortic balloon pump (IABP) use.409,410 Moreover, in a large retrospective registry of
48 306 haemodynamically unstable patients (44% NSTEMI) undergoing PCI, higher mortality and bleeding rates were observed with
Impella support compared to IABP.411 Similar results were observed in another registry confined to CS patients where Impella support was also associated with more complications and higher mortality,
even after propensity matching.412
As shown in the Intraaortic Balloon Pump in cardiogenic shock
(IABP-SHOCK) II trial, IABP does not reduce 30-day, 1-year, or 6year mortality.413415 Therefore, IABP is not recommended on a routine basis, while its use in situations of ACS-related mechanical complications should be considered.
For NSTE-ACS and stabilized heart failure, evidence-based pharmacotherapies including beta-blockers, ACE inhibitors or ARBs, and mineralocorticoid receptor antagonists (MRAs) should be offered in keeping with current guidelines.404
8.2 Diabetes mellitus
Patients with diabetes more frequently present with non-typical symptoms than patients without diabetes. They more frequently have multifocal CAD,418 less frequently receive guideline-indicated care, and have worse clinical outcomes.419 Nonetheless, the selection of antithrombotics and an invasive strategy should not differ from those without diabetes. Compared with clopidogrel, more potent platelet inhibitors have higher absolute risk reductions in patients with diabetes.420,421
On admission to hospital, it is recommended that all patients with
NSTE-ACS have their glycaemic status evaluated, regardless of a history of diabetes, and for it to be monitored frequently in patients with diabetes or hyperglycaemia. Given that, during the acute phase
Recommendations for non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock
Recommendations
Classa
Levelb
Emergency coronary angiography is recommended in patients with CS complicating
ACS.205,416,417
I
B
Emergency PCI of the culprit lesion is recommended for patients with CS due to NSTE-ACS, independent of the time delay from symptom onset, if the coronary anatomy is amenable to PCI.205,417
I
B
Emergency CABG is recommended for patients with CS if the coronary anatomy is not amenable to PCI.205,417
I
B
It is recommended to perform emergency echocardiography without delay to assess LV and valvular function and exclude mechanical complications.
I
C
In cases of haemodynamic instability, emergency surgical or catheter-based repair of mechanical complications of ACS is recommended, as decided by the Heart Team.
I
C
For NSTE-ACS-related mechanical complications,
the use of IABP should be considered.
IIa
C
In selected patients with ACS and CS, short-term mechanical circulatory support may be considered, depending on patient age, comorbidities,
neurological function, and the prospects for longterm survival and predicted quality of life.
IIb
C
Routine use of IABP in patients with CS and no mechanical complications due to ACS is not recommended.413,414,415
III
B
Routine immediate revascularization of non-culprit lesions in NSTE-ACS patients with multivessel disease presenting with CS is not recommended.346,408
III
B
ACS = acute coronary syndromes; CABG = coronary artery bypass graft(ing);
CS = cardiogenic shock; IABP = intra-aortic balloon pump; LV = left ventricular;
NSTE-ACS = non-ST-segment elevation acute coronary syndrome; PCI = percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
.....................................................................................................................................


<!-- PAGE 45 -->

### Page 45

................................................................................
of NSTEMI, there may be hyperglycaemia, there is the potential for a false positive diagnosis of diabetes. Therefore, the diagnosis of diabetes should be confirmed subsequent to the hospital stay. In critically ill patients, there is a risk of hypoglycaemia-related events when using intensive insulin therapy.422 It is not unreasonable to manage hyperglycaemia in patients with NSTE-ACS by keeping their blood glucose concentration <11.0 mmol/L or <200 mg/dL) while avoiding hypoglycaemia, but intensive insulin therapy should not routinely be offered unless clinically indicated. Intensive lipid modification is indicated for secondary prevention.423 A multifactorial approach to diabetes mellitus management, with treatment targets, should be considered in patients with diabetes mellitus and cardiovascular disease (CVD).
8.3 Chronic kidney disease
In all patients with NSTE-ACS, assessment of kidney function by eGFR is recommended for prognostic reasons and to identify patients at risk of contrast-induced nephropathy. Although individuals with CKD have a worse prognosis in the setting of NSTE-ACS than individuals with normal renal function, they less frequently receive evidence-based treatments such as antithrombotic agents and early invasive strategy.437,438
The diagnosis of NSTE-ACS in patients with CKD may be challenging, as both mild elevations in cardiac troponin and ECG abnormalities
(e.g. associated with electrolyte disturbances or hypertensive heart disease) are frequent. Therefore, new ECG changes should be differentiated from pre-existing abnormalities and absolute changes in cardiac troponin (i.e. increase and/or decrease) should be assessed to differentiate MI from conditions associated with chronic cardiac injury.
Hs-cTn assays maintain high diagnostic and prognostic accuracy and, therefore, clinical utility in patients with renal dysfunction.35,89,439
A threshold of <5 ng/L may rule out myocardial injury in this population.89 Moreover, patients with troponin concentrations >99th percentile have a two-fold greater risk of cardiac events at 1 year,
irrespective of the diagnosis.89
Patients with advanced kidney disease are less likely to receive an invasive strategy.440 Whilst the overall 1-year mortality is lower with an invasive strategy, the benefit of such a strategy declines with greater reductions in renal function, and with no impact on mortality among patients with eGFR <15 mL/min/1.73m2 and in those receiving dialysis.
When an invasive strategy is selected, measures should be taken to prevent contrast-induced nephropathy, for which adequate hydration is the main approach.441446 High-dose statins, irrespective of the risk of contrast-induced nephropathy, are indicated for secondary prevention.442 For detailed recommendations for contrast-induced nephropathy prevention, consult the 2018 ESC/EACTS Guidelines on myocardial revascularization, section 10.2.205
The choice and dose of antithrombotic drugs should be carefully considered in patients with CKD, as these patients have an increased risk of bleeding. While most anticoagulants need dose adjustment in patients with renal insufficiency, this is not the case for oral antiplatelet agents.447 However, for patients with stage 5 CKD
(i.e. eGFR <15 mL/min/1.73 m2), there are insufficient safety and efficacy data for the use of P2Y12 receptor inhibitors.
Recommendations for diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients
Recommendations
Classa
Levelb
It is recommended to screen all patients with
NSTE-ACS for diabetes and to monitor blood glucose levels frequently in patients with known diabetes or admission hyperglycaemia.
I
C
Avoidance of hypoglycaemia is recommended.424427
I
B
Glucose-lowering therapy should be considered in ACS patients with blood glucose >10 mmol/L
(>180 mg/dL), with the target adapted to comorbidities, while episodes of hypoglycaemia should be avoided.422,428430
IIa
B
A multifactorial approach to diabetes mellitus management, with treatment targets, should be considered in patients with diabetes and CVD.431436
IIa
B
Less stringent glucose control should be considered, both in the acute phase and at follow-up, in patients with more advanced CVD, older age, longer diabetes duration, and more comorbidities.
IIa
C
ACS = acute coronary syndromes; CVD = cardiovascular disease; NSTE-ACS =
non-ST-segment elevation acute coronary syndrome.
aClass of recommendation.
bLevel of evidence.
Recommendations for patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome
Recommendations
Classa
Levelb
Risk stratiﬁcation in CKD
It is recommended to apply the same diagnostic and therapeutic strategies in patients with CKD
(dose adjustment may be necessary) as for patients with normal renal function.
I
C
It is recommended to assess kidney function by eGFR in all patients.
I
C
Myocardial revascularization in patients with CKD
Use of low- or iso-osmolar contrast media (at lowest possible volume) are recommended in invasive strategies.205,441,442,445,446
I
A
Pre- and post-hydration with isotonic saline should be considered if the expected contrast volume is >100 mL in invasive strategies.
IIa
C
As an alternative to the pre- and post-hydration regimen, tailored hydration regimens may be considered.441,448
IIb
B
CABG should be considered over PCI in patients with multivessel CAD whose surgical risk proﬁle is acceptable and life expectancy is >1 year.449,450
IIa
B
CABG = coronary artery bypass graft(ing); CAD = coronary artery disease; CKD
= chronic kidney disease; eGFR = estimated glomerular ﬁltration rate; PCI = percutaneous coronary intervention.
aClass of recommendation.
bLevel of evidence.
.............................................................................................
ESC Guidelines
1333


<!-- PAGE 46 -->

### Page 46

....................
8.4 Anaemia
Anaemia is common in patients with NSTE-ACS.451 Persistent or worsening anaemia in patients with NSTE-ACS is associated with increased mortality, recurrent MI, and major bleeding.452 However, it is uncertain whether anaemia itself is the determinant for poorer outcome or rather a marker of comorbidity.
Given that the treatment of NSTE-ACS includes antithrombotic therapy (which may exacerbate bleeding), it is important to identify the cause of anaemia and, in particular, occult bleeds in patients presenting with NSTE-ACS. The indication for ICA, access site choice
(radial approach favoured), and the need for revascularization should be carefully considered to avoid further blood loss.453,454 Equally, the choice of antithrombotic agent requires evaluation of ischaemic and bleeding risks, favouring the use of shorter half-life or reversible agents. In the setting of anaemia related to an unknown/untreatable source, the use of DES should be limited to the new-generation devices with proven safety profiles on short-term DAPT.455 Blood transfusion is discussed in section 5.4.9.
8.5 Thrombocytopenia (Supplementary
Data)
8.5.1 Thrombocytopenia related to glycoprotein IIb/IIIa inhibitors (Supplementary Data)
8.5.2 Heparin-induced thrombocytopenia (Supplementary
Data)
8.6 The older person
The clinical presentation of NSTE-ACS in the older person is more often atypical. Among the atypical presentations, dyspnoea is the leading symptom, while syncope, malaise, and confusion are less frequently encountered.456 Electrocardiographic ST elevation is less frequently present in older than in younger patients.457Hs-cTn assays have an excellent diagnostic performance for diagnosing early MI in the older person. However, the specificity of the test is lower than in younger patients, and elevated troponin levels are more commonly associated with conditions other than ACS.458
For NSTE-ACS, age is a predictor of in-hospital and 6-month mortality.140,457 Decisions as to how to manage older patients should be based on ischaemic and bleeding risks, estimated life expectancy,
comorbidities, the need for non-cardiac surgery, quality of life, frailty,
cognitive and functional impairment, patient values and preferences,
and the estimated risks and benefits of revascularization.459,460
The choice of antithrombotic agent and dosage should be adapted to renal function, as well as specific contraindications.461
Despite the lower rate of revascularization in the older person, its benefit appears to be maintained at older age.462,463 The effectiveness of an invasive strategy in the context of the older patient with NSTEACS is, however, the subject of ongoing research, including the
SENIOR-RITA RCT (NCT03052036). Recent data have shown that,
for patients aged 80 years and over with NSTE-ACS, an invasive strategy was superior to a conservative strategy for the reduction of MI,
urgent revascularisation, stroke, and death, with no increase in bleeding complications.464 In this RCT, the primary composite endpoint was predominantly driven by fewer MIs and urgent revascularisation and was not sufficiently powered to test efficacy for individual endpoints. Furthermore, in the context of revascularization  both
PCI and CABG  procedure-related complications are more frequent in the older patient, including MI, heart failure, stroke, renal failure, and bleeding.457,465
High-intensity lipid modification is indicated for secondary prevention.466
8.7 Frailty
Frailty is a syndrome characterized by reduced biological reserve,
leading to a failure of homeostatic mechanisms following stressors events.468,469 A combination of an aging population, improved disease survival, treatable conditions, and greater awareness has increased the prevalence of frailty.470 Frail patients with NSTE-ACS less frequently receive ACS pharmacotherapies and an invasive strategy,
have more complex CAD,471,472 have longer lengths of hospital stay,
and are at higher risk of death.459,473 Specifically, they are reported to have a higher rate of a composite of all-cause mortality, MI, stroke,
unplanned revascularization, and major bleeding at 1 year.474 In the absence of robust data to inform healthcare professionals about the management of frail people with NSTE-ACS,475 it is recommended that the risk of individual treatments is balanced against their risk of harm, whilst being mindful of potential for healthcare professional aversion to treatment due to misperception of risk. Following risk stratification, it would not be unreasonable to offer optimal medical therapy plus an invasive strategy to frail patients at high risk of future cardiovascular events and low risk of complications, and to offer optimal medical therapy alone to those who are deemed at low risk of future events with a high risk of developing procedural complications.
A systematic review by de Vries et al. identified a range of outcomes instruments to measure frailty (Supplementary Table 7).476
8.8 Sex disparities
Data from registries and studies demonstrate discrepant results with respect to access to healthcare, the use of evidence-based therapy,
and clinical outcome between men and women presenting with
ACS.477483 Moreover, women are often under-represented in many RCTs.
Recommendations for older persons with non-ST-segment elevation acute coronary syndrome
Recommendations
Classa
Levelb
It is recommended to apply the same diagnostic strategies in older patients as for younger patients.458
I
B
It is recommended to apply the same interventional strategies in older patients as for younger patients.463,467
I
B
The choice of antithrombotic agent and dosage, as well as secondary preventions, should be adapted to renal function, as well as speciﬁc contraindications.461
I
B
aClass of recommendation.
bLevel of evidence.
........................................................................................................................................................


<!-- PAGE 47 -->

### Page 47

............................................................................................................
Although several non-invasive testing techniques exist, which may be more appropriate in the detection of microvascular CAD in women,484 catheterization remains the reference standard for highrisk NSTE-ACS and guidelines should be followed the same for both sexes. Specifically, women who present with NSTE-ACS should be provided with equal access to care, a prompt diagnosis, and treatments at the same rate and intensity as their male counterparts. It should be noted that women with NSTEMI may receive higher antithrombotic medication dosing than appropriate for their weight or renal function (or both), and this is partly responsible for the higher risk of in-hospital bleeds and access-related complications after PCI in women.485 For recommendations regarding the management of women who are pregnant and have NSTE-ACS, we refer the reader to the 2018 ESC Guidelines for the management of CVD during pregnancy.486
9 Long-term management of non-ST-segment elevation acute coronary syndrome
9.1 Lifestyle management
(Supplementary Data)
9.1.1 Smoking (Supplementary Data)
9.1.2 Diet and alcohol (Supplementary Data)
9.1.3 Weight management (Supplementary Data)
9.1.3 Physical activity (Supplementary Data)
9.1.4 Cardiac rehabilitation (Supplementary Data)
9.1.5 Psychosocial factors (Supplementary Data)
9.1.6 Environmental factors (Supplementary Data)
9.1.7 Sexual activity (Supplementary Data)
9.1.8 Adherence and sustainability (Supplementary Data)
9.1.9 Influenza vaccination (Supplementary Data)
9.2 Pharmacological management
(Supplementary Data)
9.2.1 Anti-ischaemic drugs
Often, patients do not continue to experience chest pain after
NSTEMI and revascularization. For anti-ischaemic drug management,
please refer to the 2019 ESC CCS Guidelines.231
9.2.1.1 Beta-blockers (Supplementary Data)
9.2.2 Antithrombotic treatments
Duration of antiplatelet treatment and/or anticoagulation are discussed in section 5.1.4.
9.2.3 Proton pump inhibitors (Supplementary Data)
9.2.4 Statins and other lipid-lowering agents
Dyslipidaemia should be managed, according to lipid guidelines, with pharmacological and lifestyle intervention.512 Patients with established CAD are regarded as being at very high risk for cardiovascular events, and statin treatment must be considered, irrespective of lowdensity lipoprotein cholesterol (LDL-C) levels. The goal of treatment is to lower LDL-C to <1.4 mmol/L (<55 mg/dL) and to reduce it by at least 50% if the baseline LDL-C level is 1.83.5 mmol/L (70135
mg/dL). When this level cannot be achieved, the addition of ezetimibe has been demonstrated to decrease cholesterol and cardiovascular events in post-ACS patients, and in patients with diabetes513
with no further impact on mortality.514 In addition to exercise, diet,
and weight control, which should be recommended to all patients,
dietary supplements including phytosterols may lower LDL-C to a lesser extent, but have not been shown to improve clinical outcomes.515 They may be considered (Class IIb) as an adjunct to pharmacological therapy in high- and very high-risk patients who fail to achieve LDL-C goals on statins and those who cannot be treated with statins.516 Trials published since 2015 have demonstrated that proprotein convertase subtilisin kexin
9
(PCSK9)
inhibitors
Recommendations for lifestyle managements after non-ST-segment elevation acute coronary syndrome
Recommendations
Classa
Levelb
Improvement of lifestyle factors in addition to appropriate pharmacological management is recommended in order to reduce allcause and cardiovascular mortality and morbidity and improve health-related quality of life.487497
I
A
Cognitive behavioural interventions are recommended to help individuals achieve a healthy lifestyle.498500
I
A
Multidisciplinary exercise-based cardiac rehabilitation is recommended as an effective means for patients with CAD to achieve a healthy lifestyle and manage risk factors in order to reduce all-cause and cardiovascular mortality and morbidity, and improve healthrelated quality of life.487,497,501
I
A
Involvement of multidisciplinary healthcare professionals (cardiologists, general practitioners, nurses, dieticians, physiotherapists, psychologists, pharmacists) is recommended in order to reduce all-cause and cardiovascular mortality and morbidity, and improve health-related quality of life.492,499,502,503
I
A
Psychological interventions are recommended to improve symptoms of depression in patients with CAD in order to improve healthrelated quality of life.504,505
I
B
Annual inﬂuenza vaccination is recommended for patients with CAD, especially in the older person, in order to improve morbidity.505511
I
B
CAD = coronary artery disease.
aClass of recommendation.
bLevel of evidence.
ESC Guidelines
1335


<!-- PAGE 48 -->

### Page 48

(evolocumab517 and alirocumab518520) are very effective at reducing cholesterol, lowering LDL-C in a stable fashion to nearly
50 mg/dL (1.3 mmol/L) or less.521 In outcome trials, these agents have demonstrated a reduction of cardiovascular events, with little or no impact on mortality.522 Very low levels of cholesterol are generally well tolerated and associated with fewer events,523 but the high cost of PCSK9 inhibitors, unaffordable for many health systems,524
and unknown long-term safety have limited widespread use to date.
LDL apheresis and new therapies, such as mipomersen and lomitapide, need further research. For patients undergoing PCI, high-dose atorvastatin has been shown to reduce the frequency of periprocedural events in both statin-naı¨ve patients and those receiving chronic statin therapy.525 The recent Reduction of Cardiovascular Events with Icosapent EthylIntervention Trial (REDUCE-IT),526 which included 8179 participants (70.7% for secondary prevention of cardiovascular events) with a median follow-up of 4.9 years, demonstrated a significant effect of a pure prescription-grade eicosapentaenoic acid omega-3 fatty acid, icosapent ethyl, on a composite of cardiovascular death, non-fatal MI, non-fatal stroke, coronary revascularization, or unstable angina in comparison to placebo (17.2 vs. 22.0%, HR 0.75,
95% CI 0.680.83). Of note, very high doses of icosapent ethyl (two times 2 g daily) were used.526 The 2019 ESC/EAS Guidelines for the management of dyslipidaemias give icosapent ethyl a
IIa recommendation.512
9.2.5 Glucose-lowering therapy in patients with diabetes
This topic is beyond the scope of the present document and was discussed in recent guidelines.231 As a general rule, the more advanced the CVD, the older the patient, the longer the diabetes duration, and the more comorbidities that are present, the less stringent the glucose control should be.
For the first time in the history of diabetes mellitus, there are data from several RCTs indicating cardiovascular benefits from the use of glucose-lowering agents in patients with CVD or at very high/high cardiovascular risk. The results obtained from these trials, using glucagon-like peptide-1-receptor antagonists527529 and sodiumglucose cotransporter-2 inhibitors,530532 strongly suggest that these agents should be recommended in patients with type 2 diabetes mellitus with prevalent atherosclerotic CVD.
9.2.6 Renin-angiotensin-aldosterone system blockers
(Supplementary Data)
9.2.7 Mineralocorticoid receptor antagonist therapy
(Supplementary Data)
9.2.8 Antihypertensive therapy (Supplementary Data)
9.2.9 Hormone replacement therapy (Supplementary
Data)
Recommendations for pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments)
Recommendations
Classa
Levelb
Lipid-lowering drugs
Statins are recommended in all NSTE-ACS patients.
The aim is to reduce LDL-C by >_50% from baseline and to achieve LDL-C <1.4 mmol/L (<55 mg/
dL).533,534
I
A
If the LDL-C goalc is not achieved after 46 weeks with the maximally tolerated statin dose, combination with ezetimibe is recommended.514,535
I
B
If the LDL-C goalc is not achieved after 46 weeks despite maximally tolerated statin therapy and ezetimibe, the addition of a PCSK9 inhibitor is recommended.520,535
I
B
If the current NSTE-ACS episode is a recurrence within less than 2 years of a ﬁrst ACS, while taking maximally tolerated statin-based therapy, an LDL-C
goal of <1.0 mmol/L (<40 mg/dL) may be considered.520,535
IIb
B
ACE inhibitors or ARBs
ACE inhibitors (or ARBs in cases of intolerance to
ACE inhibitors) are recommended in patients with heart failure with reduced LVEF (<40%), diabetes, or
CKD unless contraindicated (e.g. severe renal impairment, hyperkalaemia, etc.) in order to reduce allcause and cardiovascular mortality and cardiovascular morbidity.536538
I
A
Beta-blockers
Beta-blockers are recommended in patients with systolic LV dysfunction or heart failure with reduced
LVEF (<40%).539541
I
A
In patients with prior MI, long-term oral treatment with a beta-blocker should be considered in order to reduce all-cause and cardiovascular mortality and cardiovascular morbidity.542547
IIa
B
MRAs
MRAs are recommended in patients with heart failure with reduced LVEF (<40%) in order to reduce allcause and cardiovascular mortality and cardiovascular morbidity.548,549
I
A
Proton pump inhibitors
Concomitant use of a proton pump inhibitor is recommended in patients receiving aspirin monotherapy,
DAPT, DAT, TAT, or OAC monotherapy who are at high risk of gastrointestinal bleeding in order to reduce the risk of gastric bleeds.169
I
A
ACE = angiotensin-converting enzyme; ACS = acute coronary syndromes; ARB
= angiotensin receptor blocker; CKD = chronic kidney disease; DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy; LDL-C = low-density lipoprotein cholesterol; LV = left ventricular; LVEF = left ventricular ejection fraction; MI = myocardial infarction; MRA = mineralocorticoid receptor antagonist;
NSTE-ACS = non-ST-segment elevation acute coronary syndrome; OAC = oral anticoagulation/anticoagulant; PCSK9 = proprotein convertase subtilisin kexin 9;
TAT = triple antithrombotic therapy.
aClass of recommendation.
bLevel of evidence.
cFor patients at very high cardiovascular risk (such as patients with ACS), an LDLC reduction of at least 50% from baseline and an LDL-C goal <1.4 mmol/L (<55
mg/dL) are recommended.512


<!-- PAGE 49 -->

### Page 49

.............................................................................
10 Quality measures
Quality indicators (QIs) are sets of measures that enable the quantification of adherence to guideline recommendations and provide a mechanism for measuring opportunities to improve cardiovascular care and outcomes.550 QIs are derived from evidence and should be feasible, concretely interpretable, and usable.551 They improve quality by identifying practices that may lead to high-quality care and illustrate how such care was delivered, and have been increasingly used by health authorities, professional organizations, healthcare payers, as well as the public.552555
Typically, QIs are divided into structural, process, and outcome indicators, depending on the aspect of care being measured.556
Although high-quality evidence tends to support process Qis,557 the inclusion of both outcome and process measures enables a more comprehensive evaluation.558 Additionally, patient-reported outcome measures (PROMs), which may not be underpinned by a strong class of recommendation within guidelines, can be seen as having a complementary role alongside other Qis.559
In 2016, the ESC Association for Acute Cardiovascular Care
(ACVC), formerly the Acute Cardiovascular Care Association, developed a suite of QIs for the management of AMI with or without
ST-segment elevation.560 These QIs were externally validated in international clinical registries, and most demonstrated an inverse association with mortality.561563 For this 2020 Guidelines for the management of ACS in patients presenting without persistent STsegment elevation, the QIs have been updated so that they align to the current recommendations, but also take into account the wider
NSTE-ACS pathway of care. Briefly, the ESC ACVC QIs for AMI
comprise seven domains, which include the evaluation of: (1) centre organization, (2) the reperfusion/invasive strategy, (3) in-hospital risk assessment, (4) antithrombotic treatment during hospitalization, (5)
secondary prevention discharge treatments, (6) patient satisfaction,
and (7) composite QI risk-adjusted 30-day mortality. The composite
QIs are combinations of individual indicators into a single number to summarize the multiple dimensions and facilitate comparisons and categorization of the centres and can be used by providers for decision making and benchmarking. In this document, however, only the
QIs relevant to the management of NSTE-ACS are described and are displayed in Table 15.
The QIs defined here are intended for quality improvement and performance measurement through meaningful surveillance, as well as for integration within registries that specifically aim to identify areas for improvement in clinical practice. The main and secondary QIs represent major and complementary components of the quality of
NSTE-ACS care, respectively, and are not intended for ranking healthcare professionals/providers or payment incentives.
Continuous monitoring and update will be required for these QIs based on feedback and ‘downstream’ clinical registries data, as well as according to changes in evidence and guideline recommendations.
Table 15
Quality indicators in non-ST-segment elevation acute coronary syndrome care
1. Centre organization
Classa
Levelb
Main QI: hospital use of hs-cTn.
QI: hs-cTn is available in the centre for testing.
Corresponding ESC CPG recommendation: it is recommended to measure cardiac troponins with high-sensitivity assays immediately after admission and obtain the results within 60 min of blood sampling.
I
B
Secondary QI: the centre should participate in a regular registry or programme for quality assessment.
QI: centres participating in a registry.
Corresponding ESC CPG recommendation: no ESC CPG recommendation.
NA
NA
2. Invasive strategy
Main QI (1): rate of NSTEMI patients who receive ICA within 24 h of their diagnosis.
Numerator: number of NSTEMI patients who receive ICA within 24 h of their diagnosis.
Denominator: all NSTEMI patients without contraindications.
Corresponding ESC CPG recommendation: an early invasive strategy within 24 h is recommended in patients with any of high-risk criteria, including the diagnosis of NSTEMI suggested by a diagnostic algorithm.
I
A
Main QI (2): use of radial access in case of invasive strategy.
Numerator: number of NSTE-ACS patients who receive ICA via radial access.
Denominator: number of NSTE-ACS patients who receive ICA without overriding procedural considerations against the use of radial access.
Corresponding ESC CPG recommendation: radial access is recommended as the standard approach, unless there are overriding procedural considerations.
I
A
Continued
ESC Guidelines
1337


<!-- PAGE 50 -->

### Page 50

### 3 In-hospital risk assessment

Main QI (1): the proportion of patients who have an assessment of LVEF before hospital discharge. LVEF should be assessed and the numerical value recorded for all patients admitted with NSTE-ACS.
Numerator: number of NSTE-ACS patients who have their LVEF measured before hospital discharge.
Denominator: number of NSTE-ACS patients.
Corresponding ESC CPG recommendation: echocardiography is recommended to evaluate regional and global LV function and to rule in or rule out differential diagnoses.
I
C
Main QI (2): LDL-C assessment should be performed during hospitalization.
Numerator: number of NSTE-ACS patients who have their LDL-C measured during hospitalization.
Denominator: number of NSTE-ACS patients.
Corresponding ESC CPG recommendation: statins are recommended in all NSTE-ACS patients. The aim is to reduce LDL-C
by at least 50% from baseline and/or achieve LDL-C <1.4 mmol/L (<55 mg/dL).
I
A
4. Anti-thrombotic treatment during hospitalization
Main QI: proportion of patients with ‘adequate P2Y12 receptor inhibition’.
Numerator: number of NSTE-ACS patients prescribed adequate P2Y12 inhibitors at the time of hospital discharge.
Denominator: NSTE-ACS patients alive at the time of hospital discharge with an indication for prasugrel, ticagrelor, or clopidogrel.
Corresponding ESC CPG recommendation: a P2Y12 receptor inhibitor is recommended in addition to aspirin, to be maintained over 12 months unless there are contraindications or an excessive risk of bleeding.
I
A
5. Secondary prevention discharge treatments
Main QI: proportion of patients discharged from hospital on high-intensity statins (deﬁned as atorvastatin >_40 mg or rosuvastatin
>_20 mg) unless contraindicated.
Numerator: number of NSTE-ACS patients who receive high-intensity statin therapy at the time of hospital discharge.
Denominator: number of NSTE-ACS patients alive at the time of hospital discharge and without contraindications, refusal, side effects, allergy, or history of intolerance to high-intensity statin therapy.
Corresponding ESC CPG recommendation: statins are recommended in all NSTE-ACS patients. The aim is to reduce LDL-C
by at least 50% from baseline and/or achieve LDL-C <1.4 mmol/L (<55 mg/dL).
I
A
Secondary QI (1): proportion of patients with LVEF <40% who are discharged from hospital on ACE inhibitor (or ARB if intolerant to ACE inhibitors).
Numerator: number of NSTE-ACS patients with LVEF <40%, prescribed ACE inhibitor/ARB at the time of hospital discharge.
Denominator: number of NSTE-ACS patients with LVEF<40% and alive at the time of hospital discharge who are eligible for ACE
inhibitor/ARB (no severe renal impairment, hyperkalaemia, other contraindication, refusal, side effects, or allergy).
Corresponding ESC CPG recommendation: ACE inhibitors (or ARB in cases of intolerance) are recommended in NSTE-ACS
patients with co-existing hypertension, LVEF <40%, diabetes, or CKD, unless contraindicated (e.g. severe renal impairment, hyperkalaemia, etc.).
I
A
Secondary QI (2): proportion of patients with LVEF <40% who are discharged from hospital on beta-blockers.
Numerator: number of patients with LVEF <40% prescribed beta-blockers at the time of hospital discharge.
Denominator: patients with LVEF<40% and alive at the time of hospital discharge who are eligible for beta-blockers.
Corresponding ESC CPG recommendation: beta-blockers are recommended in patients with systolic LV dysfunction or heart failure with reduced LVEF (<40%).
I
A
6. Patient satisfaction
Main QI: feedback regarding the patient’s experience should be systematically collected in an organized way from all patients. It should include the following points:
Explanations provided by doctors and nurses (about the coronary disease, the beneﬁt/risk of the discharge treatment, and medical follow-up).
Discharge information regarding what to do in case of recurrence of symptoms and timing of visit.
Numerator: number of NSTE-ACS patients alive at the time of discharge from hospital with feedback collected.
Denominator: number of NSTE-ACS patients discharged from hospital alive.
Corresponding ESC CPG recommendation (1): no ESC CPG recommendation.
NA
NA
Continued


<!-- PAGE 51 -->

### Page 51

Secondary QI: systematic assessment of health-related quality of life in all patients using a validated instrument.
Numerator: number of NSTE-ACS patients alive at the time of hospital discharge who have their health-related quality of life assessed during hospitalization using a validated instrument.
Denominator: number of NSTE-ACS patients discharged from hospital alive.
Corresponding ESC CPG recommendation: no ESC CPG recommendation.
NA
NA
7. CQI
Main CQI (opportunity based): with the following individual QIs (all indicators are weighted equally):
The centre should participate in a regular registry or programme for quality assessment.
Rate of NSTEMI patients who receive ICA within 24 h of their diagnosis.
Proportion of patients who have an assessment of LVEF before hospital discharge.
Proportion of patients with ‘adequate P2Y12 receptor inhibition’.
Proportion of patients discharged from hospital on high-intensity statins.
Proportion of patients with LVEF <40% who are discharged from hospital on an ACE inhibitor/ARB.
Proportion of patients with LVEF <40% who are discharged from hospital on beta-blockers.
Feedback regarding the patient’s experience systematically collected in an organized way from all patients.
Numerator: all NSTE-ACS patients discharged from hospital alive: sum of points (one point for each individual indicator).
Denominator: all NSTE-ACS patients discharged from hospital alive: sum of points (one point for each applicable indicator, according to patient and centre characteristics).
Corresponding ESC CPG recommendation: no ESC CPG recommendation.
NA
NA
Secondary CQI (all or none): based on three or ﬁve components, according to LVEF:
• Calculated on three individual QIs in patients with LVEF >_40%:
(1)
Rate of NSTEMI patients who receive ICA within 24 h of their diagnosis.
(2)
Proportion of patients with ‘adequate P2Y12 receptor inhibition’.
(3)
Proportion of patients discharged from hospital on high-intensity statins.
• Calculated on ﬁve individual QIs in patients with LVEF <40%:
(1)
Rate of NSTEMI patients who receive ICA within 24 h of their diagnosis.
(2)
Proportion of patients with ‘adequate P2Y12 receptor inhibition’.
(3)
Proportion of patients discharged from hospital on high-intensity statins.
(4)
Proportion of patients with LVEF <40% who are discharged from hospital on an ACE inhibitor/ARB.
(5)
Proportion of patients with LVEF <40% who are discharged from hospital on beta-blockers.
Numerator: all NSTE-ACS patients discharged from hospital alive: sum of points (one point for each individual indicator).
Denominator: all NSTE-ACS patients discharged from hospital alive: sum of points (one point for each applicable indicator, according to patient and centre characteristics).
8. Outcome QI
Secondary QI: risk adjusted 30-day mortality rate.c
Numerator: all NSTE-ACS patients who died within 30 days after admission.
Denominator: all NSTE-ACS patients at 30-day follow-up.
Corresponding ESC CPG recommendation: no ESC CPG recommendation.
NA
NA
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; CAD = coronary artery disease; CCS = chronic coronary syndromes; CKD = chronic kidney disease; CPG = clinical practice guidelines; CQI = composite quality indicator; ESC = European Society of Cardiology; hs-cTn = high-sensitivity cardiac troponin; ICA = invasive coronary angiography; LDL-C = low-density lipoprotein cholesterol; LV = left ventricular; LVEF = left ventricular ejection fraction; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; NSTEMI = non-ST-segment elevation myocardial infarction; QI = quality indicator.
aClass of recommendation.
bLevel of evidence.
cRisk-adjusted 30-day mortality rates (i.e. using a logistic regression model adjusted for the risk score (by a validated risk score assessment), with 30-day mortality as the dependent variable.
ESC Guidelines
1339


<!-- PAGE 52 -->

### Page 52

11 Management strategy
Figure 13 describes an overview and management pathway for NSTE-ACS patients.
Figure 13 Central illustration. Management strategy for non-ST-segment elevation acute coronary syndrome patients. BNP = B-type natriuretic peptide; CABG = coronary artery bypass graft(ing); CCU = coronary care unit; DAPT = dual antiplatelet therapy; DES = drug-eluting stent; ECG = electrocardiogram/electrocardiography; GP = glycoprotein; GRACE = Global Registry of Acute Coronary Events; hs-cTn = high-sensitivity cardiac troponin; NSTEACS = non-ST-segment elevation acute coronary syndrome; NSTEMI = non-ST-segment elevation myocardial infarction; NT-proBNP = N-terminal proB-type natriuretic peptide; PCI = percutaneous coronary intervention; PCSK9 = proprotein convertase subtilisin kexin 9; UFH = unfractionated heparin.
Listen to the audio guide of this figure online.


<!-- PAGE 53 -->

### Page 53

.............................................................................................................................................................................
12 Key messages
• Diagnosis. Chest discomfort without persistent ST-segment elevation (NSTE-ACS) is the leading symptom initiating the diagnostic and therapeutic cascade. The pathological correlate at the myocardial level is cardiomyocyte necrosis, measured by troponin release, or, less frequently, myocardial ischaemia without cell damage (unstable angina). Individuals with unstable angina have a substantially lower risk of death and derive less benefit from an aggressive pharmacological and invasive approach.
• Troponin assays. High-sensitivity troponin assays measurements are recommended over less sensitive ones, as they provide higher diagnostic accuracy at identical low cost. It should be noted that many cardiac pathologies other than MI also result in cardiomyocyte injury and, therefore, cardiac troponin elevations.
• Other biomarkers. Other biomarkers may have clinical relevance in specific clinical settings when used in combination with non hs-cTn T/I. CK-MB shows a more rapid decline after MI and may provide added value for detection of early reinfarction. The routine use of copeptin as an additional biomarker for the early rule-out of MI should be considered in the increasingly uncommon setting where hs-cTn assays are not available.
• Rapid ‘rule-in’ and ‘rule-out’ algorithms. Due to the higher sensitivity and diagnostic accuracy for the detection of MI at presentation, the time interval to the second cTn assessment can be shortened with the use of hs-cTn assays. It is recommended to use the 0 h/1 h algorithm (best option, blood draw at 0 h and 1 h)
or the 0 h/2 h algorithm (second-best option, blood draw at 0 h and 2 h). Optimal thresholds for rule-out and rule-in were selected to allow for a minimal sensitivity and NPV of 99% and a minimal PPV of 70%. Used in conjunction with clinical and ECG
findings, the 0 h/1 h and 0 h/2 h algorithm allows the identification of appropriate candidates for early discharge and outpatient management.
• Confounders of hs-cTn. Beyond the presence or absence of
MI, four clinical variables affect hs-cTn concentrations. The effect of age (differences in concentration between healthy very young vs. ‘healthy’ very old individuals up to 300%), renal dysfunction
(differences in concentration between otherwise healthy patients with very high vs. very low eGFR up to 300%), and chest pain onset (>300%) is substantial, and modest for sex (40%).
• Ischaemic risk assessment. Initial cTn levels add prognostic information in terms of short- and long-term mortality to clinical and ECG variables. The higher the hs-cTn levels, the greater the risk of death. Serum creatinine and eGFR should also be determined in all patients with NSTE-ACS because they affect prognosis and are key elements of the GRACE risk score, which assessment is superior to (subjective) physician assessment for the occurrence of death or MI. Natriuretic peptides may provide incremental prognostic information and may help in risk stratification.
• Bleeding risk assessment. ARC-HBR is a pragmatic approach that includes the most recent trials performed in HBR patients,
who were previously excluded from clinical trials of DAPT duration or intensity. The PRECISE-DAPT score may be used to guide and inform decision making on DAPT duration with a modest predictive value for major bleeding. Their value in improving patient outcomes remains unclear.
• Non-invasive imaging. Even after the rule-out of MI, elective non-invasive or invasive imaging may be indicated according to clinical assessment. CCTA may be an option in patients with lowto-modest clinical likelihood of unstable angina as a normal scan excludes CAD. CCTA has a high NPV to exclude ACS (by excluding CAD) and an excellent outcome in patients presenting to the emergency department with low-to-intermediate pre-test probability for ACS and a normal CCTA. In addition, upfront imaging with CCTA reduces the need for ICA in high risk patients. Stress imaging by cardiac magnetic resonance imaging,
stress echocardiography, or nuclear imaging may also be an option based on risk assessment.
• Risk stratification for an invasive approach. An early routine invasive approach within 24 h of admission is recommended for NSTEMI based on hs-cTn measurements, GRACE risk score
>140, and dynamic new, or presumably new, ST-segment changes as it improves major adverse cardiac events and possibly early survival. Immediate invasive angiography is required in highly unstable patients according to hemodynamic status, arrythmias,
acute heart failure, or persistent chest pain. In all other clinical presentation, a selective invasive approach may be performed according to non-invasive testing or clinical risk assessment.
• Revascularization strategies. The principal technical aspects of PCI in NSTE-ACS patients do not differ from the invasive assessment and revascularization strategies for other manifestations of CAD. Radial access is recommended as the preferred approach in NSTE-ACS patients undergoing invasive assessment with or without PCI. Multivessel disease is frequent in NSTEACS, timing and completeness of revascularization should be decided according to functional relevance of all stenoses, age,
general patient condition, comorbidities, and left ventricular function.
• Myocardial infarction with non-obstructive coronary arteries. MINOCA incorporates a heterogeneous group of underlying causes that may involve both coronary and noncoronary pathological conditions, with the latter including cardiac and extra-cardiac disorders. It excludes by consensus myocarditis and Takotsubo syndrome. Cardiac magnetic resonance imaging is one of the key diagnostic tools as it identifies the underlying cause in more than 85% of patients and the subsequent appropriate treatment.
• Spontaneous coronary artery dissection. Defined as a non-atherosclerotic, non-traumatic, or iatrogenic separation of the coronary arterial tunics secondary to vasa vasorum hemorrhage or intimal tear, it accounts for up to 4% of all ACS, but the incidence is reported to be much higher (2235% of ACS) in women <60 years of age. Intracoronary imaging is very useful for the diagnosis and treatment orientation. Medical treatment remains to be established.
• Pre-treatment with P2Y12 receptor inhibitors. Routine pre-treatment with a P2Y12 receptor inhibitor in NSTE-ACS
patients in whom coronary anatomy is not known and an early invasive management is planned is not recommended given the lack of established benefit. However, it may be considered in selected cases and according to the bleeding risk of the patient.
ESC Guidelines
1341


<!-- PAGE 54 -->

### Page 54

..............................
• Post-treatment antiplatelet therapy. DAPT consisting of a potent P2Y12 receptor inhibitor in addition to aspirin is generally recommended for 12 months, irrespective of the stent type,
unless there are contraindications. New scenarios have been implemented. DAPT duration can be shortened (<12 months),
extended (>12 months), or modified by switching DAPT or deescalation. These decisions depend on individual clinical judgment being driven by the patient’s ischaemic and bleeding risk, the occurrence of adverse events, comorbidities, co-medications,
and the availability of the respective drugs.
• Triple antithrombotic therapy. In at least 68% of patients undergoing PCI, long-term oral anticoagulation is indicated and should be continued. NOACs are preferred over VKAs in terms of safety when patients are eligible. DAT with a NOAC at the recommended dose for stroke prevention and SAPT (preferably clopidogrel, chosen in more than 90% of cases in available trials)
is recommended as the default strategy up to 12 months after a short period up to 1 week of TAT (with NOAC and DAPT).
TAT may be prolonged up to 1 month when the ischaemic risk outweighs the bleeding risk.
13 Gaps in evidence for non-ST-segment elevation acute coronary syndrome care and future research
Gaps in NSTE-ACS Care
Needed RCTs
RISK PREDICTION MODELLING
Whether risk stratiﬁcation of NSTE-ACS patients based on multivariable risk prediction models improves clinical outcomes remains unclear.
Patients randomized to treatment algorithms based on scores calculated at point of care or to usual treatment.
No dedicated RCT has evaluated the value of a management strategy based on a risk-prediction model (i.e. PRECISE-DAPT score, ARC-HBR criteria)
for DAPT duration following PCI for NSTE-ACS.
Patients randomized to management strategies based on risk prediction models for DAPT duration vs. usual care.
MEDICALTREATMENT STRATEGIES
The efﬁcacy and safety of pre-treatment NSTE-ACS patients with oral P2Y12
receptor inhibitors prior to ICA is unknown.
Dedicated RCTs for pre-treatment with ticagrelor (and separately, clopidogrel) vs. placebo as opposed to loading after angiography in PCI patients.
The efﬁcacy and safety of early i.v. beta-blockers before an early or late invasive strategy in NSTE-ACS patients remain under question.
Patients randomized to i.v. beta-blockers or usual care before ICA.
The value of long-term therapy with beta-blockers in patients with LVEF
>40% needs further evaluation.
Patients with LVEF>40% following 1 year of beta-blocker therapy after the event randomized to long-term therapy or not.
BIOMARKERS
The role of platelet function testing or genetic testing to de-escalate oral
P2Y12 receptor inhibitors after the ﬁrst month of therapy following PCI for
NSTE-ACS needs to be deﬁned.
Adequately powered RCTs of a strategy of platelet function testing- or genetic testing-based de-escalation vs. usual guideline-based care.
What is the added value of biomarkers other than hs-cTn for rapid rule-out of NSTE-ACS compared with usual care?
NSTE-ACS patients randomized to diagnostic pathways with or without biomarkers in addition to usual care.
TIMING OF ANGIOGRAPHYAND REVASCULARIZATION STRATEGIES
What is the optimal timing of invasive angiography in high-risk NSTE-ACS
patients?
Further RCTs with different time intervals until angiography within the 72-h window from presentation.
Should low-risk NSTE-ACS patients undergo routine or selective invasive assessment?
Appropriate risk-stratiﬁed patients randomized to routine or selective invasive strategy.
The optimal invasive strategy for women presenting with NSTE-ACS is unknown.
Adequately powered RCTs to identify potential sex differences in treatment strategies in patients presenting with NSTE-ACS.
What is the role of CCTA- or other imaging-based stress testing strategies for low-risk NSTE-ACS patients or uncertain NSTEMI patients?
Diagnostic RCTs of routine non-invasive anatomy- or functional imagingbased strategies prior to an ICA approach powered for clinical endpoints.
What is the value of FFR-CT added to CCTA in evaluating the role of adverse plaque characteristics and adverse haemodynamic characteristics in the determination of ACS?
Diagnostic RCTs comparing the adding value of FFR-CT on a non-invasive anatomical testing strategy (CCTA).
The safety and effectiveness of routine vs. selective invasive assessment of frail patients presenting with NSTE-ACS requires further evaluation.
Frail patients presenting with NSTE-ACS without ongoing ischaemia or haemodynamic instability should be randomized to routine vs. selective ICA.
Mainly due to difﬁculties in enrolment, older patients have been under-represented in clinical trials of invasive strategies for NSTE-ACS patients.
Multicentre RCTs evaluating the safety and effectiveness of different treatment strategies in sufﬁcient numbers of older NSTE-ACS patients.
Continued


<!-- PAGE 55 -->

### Page 55

14 ‘What to do’ and ‘what not to do’ messages
We do not know whether there are additional criteria for not waiting at all in the NSTE-ACS population, apart from those currently listed in the immediate invasive strategy.
Risk stratiﬁcation pathways to identify vulnerable populations having the greatest beneﬁt from an early invasive assessment (and perhaps also immediate invasive assessment) deserve appropriate evaluation.
It remains unclear whether coronary revascularization of the presumed culprit lesion only or complete revascularization in NSTE-ACS patients should be attempted.
RCTs of PCI of the presumed culprit lesion only based on non-invasive imaging and/or coronary angiography vs. complete revascularization with
PCI (or CABG).
The value of haemodynamic assessment based on FFR of non-culprit lesions to guide complete revascularization in the NSTE-ACS setting remains unclear.
Patients presenting with NSTE-ACS and multivessel disease randomized to
PCI as indicated with vs. without FFR of non-culprit lesions.
Should PCI or CABG be the preferred option in multivessel coronary disease in NSTE-ACS?
Dedicated trials focused on NSTE-ACS patients with multivessel coronary disease randomized to PCI vs. CABG including invasive and/or non-invasive assessment.
Should complete revascularization be achieved during the index intervention or as a staged approach?
Immediate vs. staged complete revascularization should be evaluated in
RCTs in patients with multivessel disease.
The role and type of percutaneous mechanical circulatory support device in patients presenting with NSTE-ACS and CS remains uncertain.
Strategies based on percutaneous mechanical circulatory support devices in
NSTE-ACS patients presenting with CS should be evaluated compared to standard of care.
LONG-TERM MANAGEMENT
The optimal mode of training programmes following NSTE-ACS should be determined.
Patients randomized to different modes of rehabilitation programmes after
NSTE-ACS.
It has to be determined whether neprilysin inhibitors  in the speciﬁc group of patients who have suffered NSTE-ACS with systolic LV dysfunction 
improve clinical outcomes and reduce hospitalizations.
NSTE-ACS patients with systolic LV dysfunction should be randomized to therapy with a neprilysin inhibitor vs. standard of care.
What is the value of long-term beta-blocker and long-term ACE inhibitor/
ARB in patients with normal LV function and no other indications for these therapies?
RCTs comparing the long-term continuation of therapy with beta-blockers and ACE inhibitor/ARB to withdrawal in patients with normal LV function in the absence of other indications following NSTE-ACS.
What is the optimal long-term antithrombotic therapy in NSTE-ACS
patients who have undergone percutaneous coronary revascularization?
Dedicated RCTs comparing different combinations of potent antithrombotic agents and examining the beneﬁt-risk balance for ischaemic/bleeding events.
The impact of heart valve disease in patients with CAD and NSTE-ACS is unknown and needs to be investigated.
Strategies based on revascularization only vs. revascularization and heart valve disease treatment should be evaluated (non-severe valvular heart disease including aortic stenosis and mitral regurgitation).
ACE = angiotensin-converting enzyme; ACS = acute coronary syndromes; ARB = angiotensin receptor blocker; ARC-HBR = Academic Research Consortium - High Bleeding
Risk; CABG = coronary artery bypass graft(ing); CAD = coronary artery disease; CCTA = coronary computed tomographic angiography; CS = cardiogenic shock; DAPT =
dual antiplatelet therapy; FFR = fractional ﬂow reserve; FFR-CT = fractional ﬂow reserve-computed tomography; hs-cTn = high-sensitivity cardiac troponin ; ICA = invasive coronary angiography; i.v. = intravenous; LV = left ventricular; LVEF = left ventricular ejection fraction; NSTE-ACS = non-ST elevation acute coronary syndrome; NSTEMI = nonST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; PRECISE-DAPT = PREdicting bleeding Complications In patients undergoing Stent implantation and subsEquent Dual Anti Platelet Therapy; RCT = randomized controlled trial.
Recommendations for diagnosis, risk stratiﬁcation, imaging, and rhythm monitoring in patients with suspected non-ST-segment elevation acute coronary syndrome
Classa
Levelb
Diagnosis and risk stratiﬁcation
It is recommended to base diagnosis and initial short-term risk stratiﬁcation on a combination of clinical history, symptoms, vital signs,
other physical ﬁndings, ECG, and laboratory results including hs-cTn.3
I
B
It is recommended to measure cardiac troponins with high-sensitivity assays immediately after admission and obtain the results within
60 min of blood sampling.3,1013,2931,34
I
B
It is recommended to obtain a 12-lead ECG within 10 min after ﬁrst medical contact and to have it immediately interpreted by an experienced physician.21
I
B
It is recommended to obtain an additional 12-lead ECG in case of recurrent symptoms or diagnostic uncertainty.
I
C
Continued
ESC Guidelines
1343


<!-- PAGE 56 -->

### Page 56

The ESC 0 h/1 h algorithm with blood sampling at 0 h and 1 h is recommended if an hs-cTn test with a validated 0 h/1 h algorithm is available.30,33,35,36,39,68,69,75,76
I
B
Additional testing after 3 h is recommended if the ﬁrst two cardiac troponin measurements of the 0 h/1 h algorithm are not conclusive and the clinical condition is still suggestive of ACS.85
I
B
As an alternative to the ESC 0 h/1 h algorithm, it is recommended to use the ESC 0 h/2 h algorithm with blood sampling at 0 h and 2
h, if an hs-cTn test with a validated 0 h/2 h algorithm is available.33,39,75,78,84
I
B
Additional ECG leads (V3R, V4R, V7V9) are recommended if ongoing ischaemia is suspected when standard leads are inconclusive.
I
C
For initial diagnostic purposes, it is not recommended to routinely measure additional biomarkers such as h-FABP or copeptin, in addition to hs-cTn.47,48,51,52,54,118
III
B
Imaging
In patients presenting with cardiac arrest or haemodynamic instability of presumed cardiovascular origin, echocardiography is recommended and should be performed by trained physicians immediately following a 12-lead ECG.
I
C
In patients with no recurrence of chest pain, normal ECG ﬁndings, and normal levels of cardiac troponin (preferably high sensitivity),
but still with a suspected ACS, a non-invasive stress test (preferably with imaging) for inducible ischaemia or CCTA is recommended before deciding on an invasive approach.91,92,98,101,105108
I
B
Echocardiography is recommended to evaluate regional and global LV function and to rule in or rule out differential diagnoses.c
I
C
CCTA is recommended as an alternative to ICA to exclude ACS when there is a low-to-intermediate likelihood of CAD and when cardiac troponin and/or ECG are normal or inconclusive.105,108,110114
I
A
Monitoring
Continuous rhythm monitoring is recommended until the diagnosis of NSTEMI has been established or ruled out.
I
C
It is recommended to admit NSTEMI patients to a monitored unit.
I
C
Rhythm monitoring up to 24 h or to PCI (whichever comes ﬁrst) is recommended in NSTEMI patients at low risk for cardiac arrhythmias.d
I
C
Rhythm monitoring for >24 h is recommended in NSTEMI patients at increased risk for cardiac arrhythmias.e
I
C
Recommendations on biomarker measurements for prognostic stratiﬁcation
Beyond its diagnostic role, it is recommended to measure hs-cTn serially for the estimation of prognosis.12,13,119,120
I
B
The measurement of additional biomarkers, such as mid-regional pro-A-type natriuretic peptide, high-sensitivity C-reactive protein,
mid-regional pro-adrenomedullin, GDF-15, copeptin, and h-FABP is not recommended for routine risk or prognosis assessment.50,127,129
III
B
Recommendations for antithrombotic treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention
Antiplatelet treatment
Aspirin is recommended for all patients without contraindications at an initial oral LD of 150300 mg (or 75250 mg i.v.), and at a
MD of 75100 mg o.d. for long-term treatment.179181
I
A
A P2Y12 receptor inhibitor is recommended in addition to aspirin, and maintained over 12 months unless there are contraindications or an excessive risk of bleeding.170,171,182
Options are:
I
A
 Prasugrel in P2Y12 receptor inhibitor-naı¨ve patients proceeding to PCI (60 mg LD, 10 mg/d as standard dose, 5 mg/d for patients aged >_75 years or with a body weight <60 kg).171
I
B
 Ticagrelor irrespective of the planned treatment strategy (invasive or conservative) (180 mg LD, 90 mg b.i.d.).170
I
B
 Clopidogrel (300600 mg LD, 75 mg daily dose), only when prasugrel or ticagrelor are not available, cannot be tolerated, or are contraindicated.182,183
I
C
Treatment with GP IIb/IIIa antagonists in patients in whom coronary anatomy is not known and is not recommended.188,189
III
A
It is not recommended to administer routine pre-treatment with a P2Y12 receptor inhibitor in patients in whom coronary anatomy is not known and an early invasive management is planned.174,177,190,191
III
A
Peri-interventional anticoagulant treatment
Parenteral anticoagulation is recommended for all patients, in addition to antiplatelet treatment, at the time of diagnosis and, especially, during revascularization procedures according to both ischaemic and bleeding risks.192,193
I
A
UFH (weight-adjusted i.v. bolus during PCI of 70100 IU/kg, or 5070 IU/kg in combination with a GP IIb/IIIa inhibitor; activated clotting time target range of 250350 s, or 200250 s if a GP IIb/IIIa inhibitor is given) is recommended in patients undergoing PCI.
I
A
In cases of medical treatment or logistical constraints for transferring the patient to PCI within the required time frame, fondaparinux is recommended and, in such cases, a single bolus of UFH is recommended at the time of PCI.183
I
B
Continued


<!-- PAGE 57 -->

### Page 57

It is recommended to select anticoagulation according to both ischaemic and bleeding risks, and according to the efﬁcacysafety proﬁle of the chosen agent.
I
C
Crossover of UFH and LMWH is not recommended.196
III
B
Recommendations for post-interventional and maintenance treatment in patients with non-ST-segment elevation acute coronary syndrome
In patients with NSTE-ACS treated with coronary stent implantation, DAPT with a P2Y12 receptor inhibitor on top of aspirin is recommended for 12 months unless there are contraindications such as excessive risk of bleeding.170,171,225
I
A
Recommendations for anti-ischaemic drugs in the acute phase of non-ST-segment elevation acute coronary syndrome
Sublingual or i.v. nitrates and early initiation of beta-blocker treatment are recommended in patients with ongoing ischaemic symptoms and without contraindications.
I
C
It is recommended to continue chronic beta-blocker therapy unless the patient is in overt heart failure.
I
C
i.v. nitrates are recommended in patients with uncontrolled hypertension or signs of heart failure.
I
C
Recommendations for combining antiplatelet agents and anticoagulants in non-ST-segment elevation acute coronary syndrome patients requiring chronic oral anticoagulation
Stroke prevention should be offered to AF patients with >_1 non-sex CHA2DS2-VASc stroke risk factors (score of >_1 in males or >_2
in females). For patients with >_2 non-sex stroke risk factors, OAC is recommended.255259
I
A
Patients undergoing coronary stenting
Anticoagulation
During PCI, additional parenteral anticoagulation is recommended, irrespective of the timing of the last dose of all NOACs and if INR
is <2.5 in VKA-treated patients.
I
C
Antiplatelet treatment
In patients with AF and CHA2DS2-VASc score >_1 in men and >_2 in women, after a short period of TAT (up to 1 week from the acute event), DAT is recommended as the default strategy using a NOAC at the recommended dose for stroke prevention and a single oral antiplatelet agent (preferably clopidogrel).238241,244,245
I
A
Periprocedural DAPT administration consisting of aspirin and clopidogrel up to 1 week is recommended.238241,244,245
I
A
Discontinuation of antiplatelet treatment in patients treated with an OAC is recommended after 12 months.236239,246
I
B
The use of ticagrelor or prasugrel as part of TAT is not recommended.
III
C
Recommendations for coronary revascularization
Timing of invasive strategy
An immediate invasive strategy (<2 h) is recommended in patients with at least one of the following very high-risk criteria:
• Haemodynamic instability or CS.
• Recurrent or refractory chest pain despite medical treatment.
• Life-threatening arrhythmias.
• Mechanical complications of MI.
• Heart failure clearly related to NSTE-ACS.
• Presence of ST-segment depression >1 mm in >_6 leads additional to ST-segment elevation in aVR and/or V1.
I
C
An early invasive strategy within 24 h is recommended in patients with any of the following high-risk criteria:
• Diagnosis of NSTEMI suggested by the diagnostic algorithm recommended in section 3.
• Dynamic or presumably new contiguous ST/T-segment changes suggesting ongoing ischaemia.
• Transient ST-segment elevation.273,362
• GRACE risk score >140.271,272,277
I
A
A selective invasive strategy after appropriate ischaemia testing or detection of obstructive CAD by CCTA is recommended in patients considered at low risk.267,268,363
I
A
Technical aspects
Radial access is recommended as the standard approach, unless there are overriding procedural considerations.336,337
I
A
DES are recommended over bare-metal stents for any PCI irrespective of:
• Clinical presentation.
• Lesion type.
• Planned non-cardiac surgery.
• Anticipated duration of DAPT.
• Concomitant anticoagulant therapy.354,365,366
I
A
Continued
ESC Guidelines
1345


<!-- PAGE 58 -->

### Page 58

It is recommended to base the revascularization strategy (ad hoc culprit lesion PCI/multivessel PCI/CABG) on the patient’s clinical status and comorbidities, as well as their disease severity [i.e. the distribution and angiographic lesion characteristics (e.g. SYNTAX
score)], according to the principles for stable CAD.350 However, the decision on immediate PCI of the culprit stenosis does not require Heart Team consultation.
I
B
Recommendations for myocardial infarction with non-obstructive coronary arteries
In all patients with an initial working diagnosis of MINOCA, it is recommended to follow a diagnostic algorithm to differentiate true
MINOCA from alternative diagnoses.
I
C
It is recommended to perform CMR in all MINOCA patients without an obvious underlying cause.370
I
B
It is recommended to manage patients with an initial diagnosis of MINOCA and a ﬁnal established underlying cause according to the disease-speciﬁc guidelines.
I
C
Recommendations for non-ST-segment elevation acute coronary syndrome patients with heart failure or cardiogenic shock
Emergency coronary angiography is recommended in patients with CS complicating ACS.205,416,417
I
B
Emergency PCI of the culprit lesion is recommended for patients with CS due to NSTE-ACS, independent of the time delay from symptom onset, if the coronary anatomy is amenable to PCI.205,417
I
B
Emergency CABG is recommended for patients with CS if the coronary anatomy is not amenable to PCI.205,417
I
B
It is recommended to perform emergency echocardiography without delay to assess LV and valvular function and exclude mechanical complications.
I
C
In cases of haemodynamic instability, emergency surgical or catheter-based repair of mechanical complications of ACS is recommended, as decided by the Heart Team.
I
C
Routine use of IABP in patients with CS and no mechanical complications due to ACS is not recommended.413,414,415
III
B
Routine immediate revascularization of non-culprit lesions in NSTE-ACS patients with multivessel disease presenting with CS is not recommended.346,408
III
B
Recommendations for diabetes mellitus in non-ST-segment elevation acute coronary syndrome patients
It is recommended to screen all patients with NSTE-ACS for diabetes and to monitor blood glucose levels frequently in patients with known diabetes or admission hyperglycaemia.
I
C
Avoidance of hypoglycaemia is recommended.424427
I
B
Recommendations for patients with chronic kidney disease and non-ST-segment elevation acute coronary syndrome
Risk stratiﬁcation in CKD
It is recommended to apply the same diagnostic and therapeutic strategies in patients with CKD (dose adjustment may be necessary)
as for patients with normal renal function.
I
C
It is recommended to assess kidney function by eGFR in all patients.
I
C
Myocardial revascularization in patients with CKD
Use of low- or iso-osmolar contrast media (at lowest possible volume) are recommended in invasive strategies.205,441,442,445,446
I
A
Recommendations for older persons with non-ST-segment elevation acute coronary syndrome
It is recommended to apply the same diagnostic strategies in older patients as for younger patients.458
I
B
It is recommended to apply the same interventional strategies in older patients as for younger patients.463,467
I
B
The choice of antithrombotic agent and dosage, as well as secondary preventions, should be adapted to renal function, as well as speciﬁc contraindications.461
I
B
Recommendations for lifestyle managements after non-ST-segment elevation acute coronary syndrome
Improvement of lifestyle factors in addition to appropriate pharmacological management is recommended in order to reduce allcause and cardiovascular mortality and morbidity and improve health-related quality of life.487497
I
A
Cognitive behavioural interventions are recommended to help individuals achieve a healthy lifestyle.498500
I
A
Multidisciplinary exercise-based cardiac rehabilitation is recommended as an effective means for patients with CAD to achieve a healthy lifestyle and manage risk factors in order to reduce all-cause and cardiovascular mortality and morbidity, and improve healthrelated quality of life.487,497,501
I
A
Involvement of multidisciplinary healthcare professionals (cardiologists, general practitioners, nurses, dieticians, physiotherapists, psychologists, pharmacists) is recommended in order to reduce all-cause and cardiovascular mortality and morbidity, and improve health-related quality of life.492,499,502,503
I
A
Psychological interventions are recommended to improve symptoms of depression in patients with CAD in order to improve healthrelated quality of life.504,505
I
B
Annual inﬂuenza vaccination is recommended for patients with CAD, especially in the older person, in order to improve morbidity.505511
I
B
Continued


<!-- PAGE 59 -->

### Page 59

...................................................
15 Supplementary data
Supplementary Data with additional Supplementary Figures, Tables,
and text complementing the full text are available on the European
Heart Journal website and via the ESC website at www.escardio.org/
guidelines.
16 Appendix
Author/Task
Force
Member
Affiliations:
Emanuele
Barbato, Advanced Biomedical Sciences, University Federico II,
Napoli, Italy; Olivier Barthe´le´my, Sorbonne Universite´, ACTION
Study Group, Institut de Cardiologie, Hoˆpital Pitie´-Salp^eetrie`re
(Assistance Publique- Hoˆpitaux de Paris) (AP-HP), Paris, France;
Johann Bauersachs, Department of Cardiology and Angiology,
Hannover Medical School, Hannover, Germany; Deepak L. Bhatt,
Brigham and Women’s Hospital and Harvard Medical School,
Boston, United States of America; Paul Dendale, Faculty of
Medicine and Life Sciences, Hasselt University, Hasselt, Belgium;
Maria Dorobantu, Cardiology, "Carol Davila" University of
Medicine and Pharmacy, Bucharest, Romania; Thor Edvardsen,
Cardiology, Oslo University Hospital, Oslo, Norway; Thierry
Folliguet,
UPEC,
Cardiac surgery,
Hoˆpital
Henri
Mondor
(Assistance Publique Hoˆpitaux de Paris), Cre´teil, France; Chris P.
Gale, Leeds Institute of Cardiovascular and Metabolic Medicine,
University of Leeds, Leeds, United Kingdom; Martine Gilard,
Cardiology, CHU La Cavale Blanche, Brest, France; Alexander
Jobs, Department of Internal Medicine/Cardiology, Heart Center
Leipzig at University of Leipzig, Leipzig, Germany; Peter Ju¨ni, Li Ka
Shing Knowledge Institute of St. Michael’s Hospital, Toronto, Canada;
Ekaterini Lambrinou, Department of Nursing, School of Health
Sciences, Cyprus University of Technology, Limassol, Cyprus; Basil
S. Lewis, Cardiovascular Clinical Trials Institute, Lady Davis Carmel
Medical Center and the Ruth and Bruce Rappaport School of
Recommendations for pharmacological long-term management after non-ST-segment elevation acute coronary syndrome (excluding antithrombotic treatments)
Lipid-lowering drugs
Statins are recommended in all NSTE-ACS patients. The aim is to reduce LDL-C by >_50% from baseline and/or to achieve LDL-C
<1.4 mmol/L (<55 mg/dL).533,534
I
A
If the LDL-C goalf is not achieved after 46 weeks with the maximally tolerated statin dose, combination with ezetimibe is recommended.514,535
I
B
If the LDL-C goalf is not achieved after 46 weeks despite maximally tolerated statin therapy and ezetimibe, the addition of a PCSK9
inhibitor is recommended.520,535
I
B
ACE inhibitors or ARBs
ACE inhibitors (or ARBs in cases of intolerance to ACE inhibitors) are recommended in patients with heart failure with reduced
LVEF (<40%), diabetes, or CKD unless contraindicated (e.g. severe renal impairment, hyperkalaemia, etc.) in order to reduce all-cause and cardiovascular mortality and cardiovascular morbidity.536538
I
A
Beta-blockers
Beta-blockers are recommended in patients with systolic LV dysfunction or heart failure with reduced LVEF (<40%).539541
I
A
MRAs
MRAs are recommended in patients with heart failure with reduced LVEF (<40%) in order to reduce all-cause and cardiovascular mortality and cardiovascular morbidity.548,549
I
A
Proton pump inhibitors
Concomitant use of a proton pump inhibitor is recommended in patients receiving aspirin monotherapy, DAPT, DAT, TAT, or OAC
monotherapy who are at high risk of gastrointestinal bleeding in order to reduce the risk of gastric bleeds.169
I
A
ACE = angiotensin-converting enzyme; ACS = acute coronary syndromes; AF = atrial ﬁbrillation; ARB = angiotensin receptor blocker; b.i.d. = bis in die (twice a day); CABG =
coronary artery bypass graft(ing); CAD = coronary artery disease; CCTA = coronary computed tomography angiography; CHA2DS2-VASc = Congestive heart failure,
Hypertension, Age >_75 years (2 points), Diabetes, Stroke (2 points)_Vascular disease, Age 65_74, Sex category (female); CKD = chronic kidney disease; CMR = cardiac magnetic resonance; CS = cardiogenic shock; DAPT = dual antiplatelet therapy; DAT = dual antithrombotic therapy; DES = drug-eluting stent; ECG = electrocardiogram/electrocardiography; eGFR = estimated glomerular ﬁltration rate; ESC = European Society of Cardiology; FFR = fractional ﬂow reserve; GDF-15 = growth differentiation factor 15;
GP = glycoprotein; GRACE = Global Registry of Acute Coronary Events; h-FABP = heart-type fatty acid-binding protein; hs-cTn = high-sensitivity cardiac troponin; IABP =
intra-aortic balloon pump; ICA = invasive coronary angiography; INR = international normalized ratio; i.v. = intravenous; LD = loading dose; LDL-C = low-density lipoprotein cholesterol; LMWH = low-molecular-weight heparin; LV = left ventricular; LVEF = left ventricular ejection fraction; MD = maintenance dose; MI = myocardial infarction;
MINOCA = myocardial infarction with non-obstructive coronary arteries; MRA = mineralocorticoid receptor antagonist; NOAC = non-vitamin K antagonist oral anticoagulant;
NSTEMI = non-ST-segment elevation myocardial infarction; NSTE-ACS = non-ST-segment elevation acute coronary syndrome; OAC = oral anticoagulation/anticoagulant;
o.d. = once daily; PCI = percutaneous coronary intervention; PCSK9 = proprotein convertase subtilisin kexin 9; TAT = triple antithrombotic therapy; UFH = unfractionated heparin; VKA = vitamin K antagonist.
aClass of recommendation.
bLevel of evidence.
cDoes not apply to patients discharged the same day in whom NSTEMI has been ruled out dIf none of the following criteria: haemodynamically unstable, major arrhythmias, LVEF <40%, failed reperfusion, additional critical coronary stenoses of major vessels, complications related to percutaneous revascularization, or GRACE risk score >140 if assessed.
eIf one or more of the above criteria are present.
fFor patients at very high cardiovascular risk (such as patients with ACS), an LDL-C reduction of at least 50% from baseline and an LDL-C goal <1.4 mmol/L (<55 mg/dL) are recommended.512
ESC Guidelines
1347


<!-- PAGE 60 -->

### Page 60

.............................................................................................................................................................................
Medicine, Haifa, Israel; Julinda Mehilli, Munich University Clinic,
Ludwig-Maximilians
University,
Munich,
Germany;
Emanuele
Meliga, Interventional Cardiology, AO Mauriziano Umberto I, Turin,
Italy; Be´la Merkely, Heart and Vascular Center, Semmelweis
University, Budapest, Hungary; Christian Mueller, Cardiovascular
Research Institute Basel (CRIB) and Cardiology, University Hospital
Basel, University of Basel, Basel, Switzerland; Marco Roffi, Geneva
University Hospitals, Geneva, Switzerland; Frans H. Rutten,
General Practice, Julius Center for Health Sciences and Primary Care,
University Medical Center Utrecht, Utrecht University, Utrecht,
Netherlands; Dirk Sibbing, Privatklinik Lauterbacher Mu¨hle am
Ostersee, Munich, Germany; and Ludwig-Maximilians Universit€at
Mu¨nchen, Munich, Germany; George C.M. Siontis, Department of
Cardiology, University Hospital of Bern, Inselspital, Bern, Switzerland.
ESC Committee for Practice Guidelines (CPG): Stephan
Windecker (Chairperson) (Switzerland), Victor Aboyans (France),
Colin Baigent (United Kingdom), Jean-Philippe Collet (France),
Veronica Dean (France), Victoria Delgado (Netherlands), Donna
Fitzsimons (United Kingdom), Chris P. Gale (United Kingdom),
Diederick E. Grobbee (Netherlands), Sigrun Halvorsen (Norway),
Gerhard Hindricks (Germany), Bernard Iung (France), Peter Ju¨ni
(Canada), Hugo A. Katus (Germany), Ulf Landmesser (Germany),
Christophe Leclercq (France), Maddalena Lettino (Italy), Basil S.
Lewis
(Israel),
Be´la
Merkely
(Hungary),
Christian
Mueller
(Switzerland), Steffen E. Petersen (United Kingdom), Anna Sonia
Petronio
(Italy),
Dimitrios
J.
Richter
(Greece),
Marco
Roffi
(Switzerland), Evgeny Shlyakhto (Russian Federation), Iain A.
Simpson (United Kingdom), Miguel Sousa-Uva (Portugal), Rhian M.
Touyz (United Kingdom).
ESC National Cardiac Societies actively involved in the review process of the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent STsegment elevation.
Algeria: Algerian Society of Cardiology, Mohammed Chettibi;
Armenia:
Armenian
Cardiologists
Association,
Hamlet
G.
Hayrapetyan; Austria: Austrian Society of Cardiology, Bernhard
Metzler; Azerbaijan: Azerbaijan Society of Cardiology, Ruslan
Najafov; Belarus: Belorussian Scientific Society of Cardiologists,
Valeriy I. Stelmashok; Belgium: Belgian Society of Cardiology, Marc
Claeys; Bosnia and Herzegovina: Association of Cardiologists of
Bosnia and Herzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian
Society of Cardiology, Plamen Marinov Gatzov; Croatia: Croatian
Cardiac Society, Bosko
Skoric; Cyprus: Cyprus
Society of
Cardiology, Georgios Panayi; Czech Republic: Czech Society of
Cardiology, Martin Mates; Denmark: Danish Society of Cardiology,
Rikke Sorensen; Egypt: Egyptian Society of Cardiology, Khaled
Shokry; Estonia: Estonian Society of Cardiology, Toomas Marandi;
Finland: Finnish Cardiac Society, Olli A. Kajander; France: French
Society of Cardiology, Philippe Commeau; Georgia: Georgian
Society of Cardiology, Alexander Aladashvili; Germany: German
Cardiac Society, Steffen Massberg; Greece: Hellenic Society of
Cardiology, Dimitrios Nikas; Hungary: Hungarian Society of
Cardiology, David Becker; Iceland: Icelandic Society of Cardiology,
Ingibjo¨rg J. Guðmundsdottir; Ireland: Irish Cardiac Society, Aaron J.
Peace; Israel: Israel Heart Society, Roy Beigel; Italy: Italian
Federation of Cardiology, Ciro Indolfi; Kazakhstan: Association of
Cardiologists of
Kazakhstan,
Nazipa
Aidargaliyeva;
Kosovo
(Republic of): Kosovo Society of Cardiology, Shpend Elezi;
Kyrgyzstan: Kyrgyz Society of Cardiology, Medet Beishenkulov;
Latvia: Latvian Society of Cardiology, Aija Maca; Lithuania:
Lithuanian Society of Cardiology, Olivija Gustiene; Luxembourg:
Luxembourg Society of Cardiology, Philippe Degrell; Malta: Maltese
Cardiac Society, Andrew Cassar Maempel; Moldova (Republic of): Moldavian Society of Cardiology, Victoria Ivanov; Netherlands:
Netherlands
Society of
Cardiology,
Peter
Damman;
North
Macedonia: North Macedonian Society of Cardiology, Sasko
Kedev; Norway: Norwegian Society of Cardiology, Terje K. Steigen;
Poland:
Polish
Cardiac
Society,
Jacek
Legutko;
Portugal:
Portuguese
Society of
Cardiology,
Jo~ao
Morais;
Romania:
Romanian Society of Cardiology, Dragos Vinereanu; Russian
Federation: Russian Society of Cardiology, Dmitry Duplyakov; San
Marino: San Marino Society of Cardiology, Marco Zavatta; Serbia:
Cardiology Society of Serbia, Milan Pavlovic; Slovakia: Slovak
Society of Cardiology, Marek Orban; Slovenia: Slovenian Society of
Cardiology, Matjaz Bunc; Spain: Spanish Society of Cardiology, Borja
Iba~nez; Sweden: Swedish Society of Cardiology, Robin Hofmann;
Switzerland: Swiss Society of Cardiology, Oliver Gaemperli;
Syrian Arab Republic: Syrian Cardiovascular Association, Yassin
Bani Marjeh; Tunisia: Tunisian Society of Cardiology and CardioVascular Surgery, Faouzi Addad; Turkey: Turkish Society of
Cardiology,
Eralp
Tutar;
Ukraine:
Ukrainian
Association of
Cardiology, Alexander Parkhomenko; United Kingdom of Great
Britain and Northern Ireland: British Cardiovascular Society,
Nina Karia.
